Thomas M. Habermann, M.D.

1. Hematologist
2. Internist

1. Bock AM, Wenzl K, Novak JP, Stokes ME, Hopper MA, Krull JE, Dropik AR, Sarangi V, Ortiz M, Stong N, Huang CC, Maurer MJ, King RL, Farooq U, Wang Y, Witzig TE, Ansell SM, Habermann TM, Cerhan JR, Gandhi AK, Nowakowski G, Novak AJ. Molecular Features of Diffuse Large B-Cell Lymphoma Associated With Primary Treatment Resistance. Hematol Oncol. 2025 Jan; 43 (1):e70006
   View PubMed
2. Atallah-Yunes SA, Rees MJ, Mwangi R, Kuchler RL, Nowakowski GS, Habermann TM, Wang Y, Thompson CA, Feldman AL, Maurer MJ, Cerhan JR, Ansell SM, Witzig TE. Characteristics and outcomes of incidentally diagnosed diffuse large B-cell lymphoma and implications for cancer screening. Am J Hematol 2025 Jan; 100 (1):158-162 Epub 2024 Oct 14
   View PubMed
3. Bommier C, Link BK, Gysbers BJ, Maurer MJ, Larson MC, Khurana A, Wang Y, Thompson CA, Chihara D, Alderuccio JP, Koff JL, Epperla N, Conconi A, Lossos IS, Nowakowski GS, Feldman AL, Habermann TM, King RL, Cerhan JR. Transformation in marginal zone lymphoma: results from a prospective cohort and a meta-analysis of the literature. Blood Adv. 2024 Dec 10; 8 (23):5939-5948
   View PubMed
4. Day JR, Larson MC, Durani U, Koff JL, Wang Y, Habermann TM, Lossos IS, Nastoupil LJ, Strouse CS, Chihara D, Martin P, Leonard JP, Cohen JB, Kahl BS, Ruan J, Burack R, Friedberg JW, Cerhan JR, Flowers CR, Link BL, Maurer MJ, Casulo C. Treatment Patterns and Outcomes in Follicular Lymphoma with POD24: An Analysis from The LEO Consortium. Blood Adv. 2024 Nov 27 [Epub ahead of print]
   View PubMed
5. Abro B, Maurer MJ, Habermann TM, Burack WR, Chapman JR, Cohen JB, Friedberg JW, Inghirami G, Kahl BS, Larson MC, Link BK, Lossos IS, Martin P, McDonnell TJ, Nastoupil LJ, Riska SM, Syrbu S, Vega F, Vij KR, Flowers CR, Cerhan JR, Jaye DL, Feldman AL. Real-world impact of differences in the WHO and ICC classifications of non-Hodgkin lymphoma: a LEO cohort study analysis. Blood. 2024 Nov 7; 144 (19):2063-2066
   View PubMed
6. Chohan KL, Pruthi RK, Zanwar S, Paludo J, Go R, Pardanani A, Ashrani A, Cook JM, Thompson CA, Chanan-Khan A, Ailawadhi S, Habermann TM, Witzig TE, Gertz MA, Dingli D, Buadi FK, Dispenzieri A, Leung N, Kumar SK, Rajkumar V, Nichols WL, Kyle RA, Ansell SM, Kapoor P, Sridharan M, Abeykoon JP. The clinical impact of acquired von Willebrand syndrome secondary to Waldenstrom macroglobulinemia: an underrecognized source of major bleeding events. Leukemia. 2024 Nov; 38 (11):2497-2500 Epub 2024 Aug 28
   View PubMed
7. Atallah-Yunes SA, Rees MJ, Witzig TE, Habermann TM, Munoz J, Iqbal M, McPhail ED, Nowakowski GS. CODOX-M/IVAC-R versus DA-EPOCH-R in double hit/triple hit lymphoma patients aged 60 years or under. Haematologica. 2024 Oct 10 [Epub ahead of print]
   View PubMed
8. Hopper MA, Dropik AR, Walker JS, Novak JP, Laverty MS, Manske MK, Wu X, Wenzl K, Krull JE, Sarangi V, Maurer MJ, Yang ZZ, Del Busso MD, Habermann TM, Link BK, Rimsza LM, Witzig TE, Ansell SM, Cerhan JR, Jevremovic D, Novak AJ. DEK regulates B-cell proliferative capacity and is associated with aggressive disease in low-grade B-cell lymphomas. Blood Cancer J. 2024 Oct 9; 14 (1):172 Epub 2024 Oct 09
   View PubMed
9. Tun AM, Wang Y, Maliske S, Micallef I, Inwards DJ, Habermann TM, Porrata L, Paludo J, Bisneto JV, Rosenthal A, Kharfan-Dabaja MA, Ansell SM, Nowakowski GS, Farooq U, Johnston PB. Autologous Stem Cell Transplant in Fit Patients With Late Relapsed Diffuse Large B-Cell Lymphoma That Responded to Salvage Chemotherapy. Transplant Cell Ther. 2024 Oct; 30 (10):1001.e1-1001.e12 Epub 2024 July 10
   View PubMed
10. Skolka MP, Suanprasert N, Martinez-Thompson JM, King RL, Macon WR, Mauermann ML, Klein CJ, Habermann TM, Johnston PB, Micallef IN, Khurana A, Amrami K, Spinner RJ, Mandrekar J, Dyck PJ, Dyck PJB. Neurologic Clinical, Electrophysiologic, and Pathologic Characteristics of Primary vs Secondary Neurolymphomatosis. Neurology. 2024 Sep 24; 103 (6):e209777 Epub 2024 Sept 03
    View PubMed
11. Moalem KN, Alderuccio JP, Bommier C, Habermann T, Link BK, Cerhan JR, Florindez J, Lossos IS. Transformation of marginal zone lymphoma to Hodgkin lymphoma. Blood Adv. 2024 Sep 10; 8 (17):4559-4562
    View PubMed
12. Stokes ME, Wenzl K, Huang CC, Ortiz M, Hsu CC, Maurer MJ, Stong N, Nakayama Y, Wu L, Chiu H, Polonskaia A, Danziger SA, Towfic F, Parker J, King RL, Link BK, Slager SL, Sarangi V, Asmann YW, Novak JP, Sudhindra A, Ansell SM, Habermann TM, Hagner PR, Nowakowski GS, Cerhan JR, Novak AJ, Gandhi AK. Transcriptomic classification of diffuse large B-cell lymphoma identifies a high-risk activated B-cell-like subpopulation with targetable MYC dysregulation. Nat Commun. 2024 Aug 8; 15 (1):6790 Epub 2024 Aug 08
    View PubMed
13. Okcu I, Wang Y, Bock AM, Zhou J, Moustafa MA, Tun HW, Rosenthal AC, Johnston PB, Baidoun F, Khurana A, Kabat BF, King RL, Habermann TM, Nowakowski GS. Incidence of Central Nervous System Relapse in Primary Mediastinal Large B-Cell Lymphoma: Implications for Central Nervous System Prophylaxis. Clin Lymphoma Myeloma Leuk. 2024 Aug 2 Epub 2024 Aug 02
    View PubMed
14. Laoruangroj C, Habermann TM, Wang Y, King RL, Lester SC, Thompson CA, Witzig TE. Should All Patients With Stage IE Gastric Mucosa-Associated Lymphoid Tissue Lymphoma Receive Antibiotic Eradication Therapy for Helicobacter pylori? JCO Oncol Pract. 2024 Aug; 20 (8):1103-1108 Epub 2024 May 07
    View PubMed
15. Bock AM, Mwangi R, Wang Y, Khurana A, Maurer MJ, Ayers A, Kahl BS, Martin P, Cohen JB, Casulo C, Lossos IS, Farooq U, Ayyappan S, Reicks T, Habermann TM, Witzig TE, Flowers CR, Cerhan JR, Nastoupil LJ, Nowakowski GS. Defining primary refractory large B-cell lymphoma. Blood Adv. 2024 Jul 9; 8 (13):3402-3415
    View PubMed
16. Maurer MJ, Casulo C, Larson MC, Habermann TM, Lossos IS, Wang Y, Nastoupil LJ, Strouse C, Chihara D, Martin P, Cohen JB, Kahl BS, Burack WR, Koff JL, Mun Y, Masaquel A, Wu M, Wei MC, Shewade A, Li J, Cerhan JR, Link BK, Flowers CR. Matching-adjusted indirect comparison from the Lymphoma Epidemiology of Outcomes Consortium for Real World Evidence (LEO CReWE) study to a clinical trial of mosunetuzumab in relapsed or refractory follicular lymphoma. Haematologica. 2024 Jul 1; 109 (7):2177-2185 Epub 2024 July 01
    View PubMed
17. Tun AM, Wang Y, Maliske S, Micallef I, Inwards DJ, Habermann TM, Porrata L, Paludo J, Bisneto JV, Rosenthal A, Kharfan-Dabaja MA, Ansell SM, Nowakowski GS, Farooq U, Johnston PB. Autologous stem cell transplant in fit patients with refractory or early relapsed diffuse large B-cell lymphoma that responded to salvage chemotherapy. Haematologica. 2024 Jul 1; 109 (7):2186-2195 Epub 2024 July 01
    View PubMed
18. Wenzl K, Stokes ME, Novak JP, Bock AM, Khan S, Hopper MA, Krull JE, Dropik AR, Walker JS, Sarangi V, Mwangi R, Ortiz M, Stong N, Huang CC, Maurer MJ, Rimsza L, Link BK, Slager SL, Asmann Y, Mondello P, Morin R, Ansell SM, Habermann TM, Witzig TE, Feldman AL, King RL, Nowakowski G, Cerhan JR, Gandhi AK, Novak AJ. Multiomic analysis identifies a high-risk signature that predicts early clinical failure in DLBCL. Blood Cancer J. 2024 Jun 20; 14 (1):100 Epub 2024 June 20
    View PubMed
19. Atallah-Yunes SA, Habermann TM, Khurana A. Targeted therapy in Burkitt lymphoma: Small molecule inhibitors under investigation. Br J Haematol. 2024 Jun; 204(6):2165-2172. Epub 2024 Apr 05.
    View PubMed
20. Arcaini L, Bommier C, Alderuccio JP, Merli M, Fabbri N, Nizzoli ME, Maurer MJ, Tarantino V, Ferrero S, Rattotti S, Talami A, Murru R, Khurana A, Mwangi R, Deodato M, Cencini E, Re F, Visco C, Feldman AL, Link BK, Delamain MT, Spina M, Annibali O, Pulsoni A, Ferreri AJM, Stelitano CC, Pennese E, Habermann TM, Marcheselli L, Han S, Reis IM, Paulli M, Lossos IS, Cerhan JR, Luminari S. Marginal zone lymphoma international prognostic index: a unifying prognostic index for marginal zone lymphomas requiring systemic treatment. EClinicalMedicine. 2024 Jun; 72:102592 Epub 2024 Apr 11
    View PubMed
21. Bantilan KS, Smith AN, Maurer MJ, Teruya-Feldstein J, Matasar MJ, Moskowitz AJ, Straus DJ, Noy A, Palomba ML, Horwitz SM, Hamlin PA, Portlock CS, Cerhan JR, Habermann TM, Salles GA, Nowakowski GS, Moskowitz CH, Zelenetz AD. Matched control analysis suggests that R-CHOP followed by (R)-ICE may improve outcome in non-GCB DLBCL compared with R-CHOP. Blood Adv. 2024 May 14; 8 (9):2172-2181
    View PubMed
22. Krull JE, Wenzl K, Hopper MA, Manske MK, Sarangi V, Maurer MJ, Larson MC, Mondello P, Yang Z, Novak JP, Serres M, Whitaker KR, Villasboas Bisneto JC, Habermann TM, Witzig TE, Link BK, Rimsza LM, King RL, Ansell SM, Cerhan JR, Novak AJ. Follicular lymphoma B cells exhibit heterogeneous transcriptional states with associated somatic alterations and tumor microenvironments. Cell Rep Med. 2024 Mar 19; 5 (3):101443 Epub 2024 Feb 29
    View PubMed
23. Burlile JF, Frechette KM, Breen WG, Hwang SR, Higgins AS, Nedved AN, Harmsen WS, Pulsipher SD, Witzig TE, Micallef IN, Hoppe BS, Habermann TM, Thanarajasingam G, Johnston PB, Inwards DJ, Bennani NN, Peterson JL, Stish BJ, Rule WG, Ansell SM, Lester SC. Patterns of progression after immune checkpoint inhibitors for Hodgkin lymphoma: implications for radiation therapy. Blood Adv. 2024 Mar 12; 8 (5):1250-1257
    View PubMed
24. Kahl BS, Jegede OA, Peterson C, Swinnen LJ, Habermann TM, Schuster SJ, Weiss M, Fishkin PA, Fenske TS, Williams ME. Long-Term Follow-Up of the RESORT Study (E4402): A Randomized Phase III Comparison of Two Different Rituximab Dosing Strategies for Low-Tumor Burden Follicular Lymphoma. J Clin Oncol. 2024 Mar 1; 42 (7):774-778 Epub 2024 Jan 09
    View PubMed
25. Cerhan JR, Maurer MJ, Link BK, Feldman AL, Habermann TM, Jaye DL, Burack WR, McDonnell TJ, Vega F, Chapman JR, Syrbu S, Vij KR, Inghirami G, Leonard JP, Bernal-Mizrachi L, Farooq U, Witzig TE, Weiner GJ, Wang Y, Alderuccio JP, Slager SL, Larson MC, Riska SM, Gysbers BJ, Lunde JJ, Reicks TW, Ayers AA, O'Leary CB, Yost KJ, Liu H, Nowakowski GS, Ruan J, Chihara D, Koff JL, Casulo C, Thompson CA, Cohen JB, Kahl BS, Nastoupil LJ, Lossos IS, Friedberg JW, Martin P, Flowers CR. The Lymphoma Epidemiology of Outcomes cohort study: Design, baseline characteristics, and early outcomes. Am J Hematol. 2024 Mar; 99 (3):408-421 Epub 2024 Jan 13
    View PubMed
26. Ramsower CA, Rosenthal A, Robetorye RS, Mwangi R, Maurer M, Villa D, McDonnell T, Feldman A, Cohen JB, Habermann T, Campo E, Clot G, Buhler MM, Kulis M, Martin-Subero JI, Gine E, Cook JR, Hill B, Raess PW, Beiske KH, Reichart A, Hartmann S, Holte H, Scott D, Rimsza L. Evaluation of clinical parameters and biomarkers in older, untreated mantle cell lymphoma patients receiving bendamustine-rituximab. Br J Haematol. 2024 Jan; 204 (1):160-170 Epub 2023 Oct 25
    View PubMed
27. Steiner RE, Hwang SR, Khurana A, Habermann TM, Epperla N, Annunzio K, Allen PB, Baird K, Paulino D, Alderuccio JP, Lossos IS, David K, Evens AM, Pandya K, Bair SM, Kamdar M, Ba Aqeel S, Torka P, Lynch R, Smith S, Feng L, Noorani M, Ahmed S, Nair R, Vega F, Wu S, Fang P, Pinnix CC, Gunther JR, Dabaja BS, Lee HJ. Impact of cumulative dose of brentuximab vedotin on outcomes of frontline therapy for advanced-stage Hodgkin lymphoma. Blood Adv. 2023 Dec 26; 7 (24):7485-7493
    View PubMed
28. Bock AM, Gile JJ, Larson MC, Poonsombudlert K, Tawfiq RK, Maliske S, Maurer MJ, Kabat BF, Paludo J, Inwards DJ, Ayyappan S, Link BK, Ansell SM, Habermann TM, Witzig TE, Nowakowski GS, Cerhan JR, Farooq U, Wang Y. Evolving treatment patterns and improved outcomes in relapsed/refractory mantle cell lymphoma: a prospective cohort study. Blood Cancer J. 2023 Nov 13; 13 (1):169
    View PubMed
29. Pophali PA, Morton LM, Parsons SK, Hodgson D, Thanarajasingam G, Thompson C, Habermann TM, Savage KJ. Critical gaps in understanding treatment outcomes in adolescents and young adults with lymphoma: A review of current data. EJHaem. 2023 Nov; 4 (4):927-933 Epub 2023 Aug 25
    View PubMed
30. Zelenetz AD, Gordon LI, Abramson JS, Advani RH, Andreadis B, Bartlett NL, Budde LE, Caimi PF, Chang JE, Christian B, DeVos S, Dholaria B, Fayad LE, Habermann TM, Hamid MS, Hernandez-Ilizaliturri F, Hu B, Kaminski MS, Karimi Y, Kelsey CR, King R, Krivacic S, LaCasce AS, Lim M, Messmer M, Narkhede M, Rabinovitch R, Ramakrishnan P, Reid E, Roberts KB, Saeed H, Smith SD, Svoboda J, Swinnen LJ, Tuscano J, Vose JM, Dwyer MA, Sundar H. NCCN Guidelines(R) Insights: B-Cell Lymphomas, Version 6.2023. J Natl Compr Canc Netw. 2023 Nov; 21 (11):1118-1131
    View PubMed
31. Berndt SI, Vijai J, Benavente Y, Camp NJ, Nieters A, Wang Z, Smedby KE, Kleinstern G, Hjalgrim H, Besson C, Skibola CF, Morton LM, Brooks-Wilson AR, Teras LR, Breeze C, Arias J, Adami HO, Albanes D, Anderson KC, Ansell SM, Bassig B, Becker N, Bhatti P, Birmann BM, Boffetta P, Bracci PM, Brennan P, Brown EE, Burdett L, Cannon-Albright LA, Chang ET, Chiu BCH, Chung CC, Clavel J, Cocco P, Colditz G, Conde L, Conti DV, Cox DG, Curtin K, Casabonne D, De Vivo I, Diepstra A, Diver WR, Dogan A, Edlund CK, Foretova L, Fraumeni JF Jr, Gabbas A, Ghesquieres H, Giles GG, Glaser S, Glenn M, Glimelius B, Gu J, Habermann TM, Haiman CA, Haioun C, Hofmann JN, Holford TR, Holly EA, Hutchinson A, Izhar A, Jackson RD, Jarrett RF, Kaaks R, Kane E, Kolonel LN, Kong Y, Kraft P, Kricker A, Lake A, Lan Q, Lawrence C, Li D, Liebow M, Link BK, Magnani C, Maynadie M, McKay J, Melbye M, Miligi L, Milne RL, Molina TJ, Monnereau A, Montalvan R, North KE, Novak AJ, Onel K, Purdue MP, Rand KA, Riboli E, Riby J, Roman E, Salles G, Sborov DW, Severson RK, Shanafelt TD, Smith MT, Smith A, Song KW, Song L, Southey MC, Spinelli JJ, Staines A, Stephens D, Sutherland HJ, Tkachuk K, Thompson CA, Tilly H, Tinker LF, Travis RC, Turner J, Vachon CM, Vajdic CM, Van Den Berg A, Van Den Berg DJ, Vermeulen RCH, Vineis P, Wang SS, Weiderpass E, Weiner GJ, Weinstein S, Doo NW, Ye Y, Yeager M, Yu K, Zeleniuch-Jacquotte A, Zhang Y, Zheng T, Ziv E, Sampson J, Chatterjee N, Offit K, Cozen W, Wu X, Cerhan JR, Chanock SJ, Slager SL, Rothman N. Correction: Distinct germline genetic susceptibility profiles identified for common non-Hodgkin lymphoma subtypes. Leukemia. 2023 Oct; 37 (10):2142
    View PubMed
32. Hopper MA, Wenzl K, Hartert KT, Krull JE, Dropik AR, Novak JP, Manske MK, Serres MR, Sarangi V, Larson MC, Maurer MJ, Yang ZZ, Paludo J, McPhail ED, Habermann TM, Link BK, Rimsza LM, Ansell SM, Cerhan JR, Jevremovic D, Novak AJ. Molecular classification and identification of an aggressive signature in low-grade B-cell lymphomas. Hematol Oncol. 2023 Oct; 41 (4):644-654 Epub 2023 May 30
    View PubMed
33. Zanwar S, Abeykoon JP, Ansell SM, Gertz MA, Mauermann M, Witzig TE, Johnston P, Kyle RA, King RL, Habermann TM, Kumar S, Kapoor P. Central nervous system involvement (Bing-Neel Syndrome) in patients with Waldenstrom macroglobulinemia. Leuk Lymphoma 2023 Jul-Aug; 64 (8):1490-1493 Epub 2023 June 10
    View PubMed
34. Epperla N, Switchenko J, Bachanova V, Gerson JN, Barta SK, Gordon MJ, Danilov AV, Grover NS, Mathews S, Burkart M, Karmali R, Sawalha Y, Hill BT, Ghosh N, Park SI, Bond DA, Hamadani M, Fenske TS, Martin P, Malecek MK, Kahl BS, Flowers CR, Link BK, Kaplan LD, Inwards DJ, Feldman AL, Hsi ED, Maddocks K, Blum KA, Bartlett NL, Cerhan JR, Leonard JP, Habermann TM, Maurer MJ, Cohen JB. Impact of diagnosis to treatment interval in patients with newly diagnosed mantle cell lymphoma. Blood Adv. 2023 Jun 13; 7 (11):2287-2296
    View PubMed
35. Chohan KL, Young JR, Lester S, Moustafa MA, Rosenthal A, Tun HW, Hoppe BS, Johnston PB, Micallef IN, Habermann TM, Ansell SM. End-of-treatment PET in early-stage Hodgkin lymphoma: valuable in addition to interim PET. Haematologica 2023 Jun 1; 108 (6):1697-1701 Epub 2023 June 01
    View PubMed
36. Wang Y, Larson MC, Ekberg S, Smedby KE, Zhao EJ, Gerrie AS, Farooq U, Maurer MJ, Paludo J, Nowakowski GS, Habermann TM, Albertsson-Lindblad A, Glimelius I, Link BK, Diego V, Jerkeman M, Cerhan JR. 17th International Conference on Malignant Lymphoma, Palazzo dei Congressi, Lugano, Switzerland, 13 - 17 June, 2023. Hematol Oncol. 2023 Jun; 41 Suppl 2:472-474
    View PubMed
37. Bock AM, Mwangi R, Wang Y, Khurana A, Maurer MJ, Ayers A, Kahl B, Martin P, Cohen J, Casulo C, Lossos I, Farooq U, Ayyappan S, Reicks T, Habermann TM, Flowers CR, Cerhan JR, Nastoupil LJ, Nowakowski GS. 17th International Conference on Malignant Lymphoma, Palazzo dei Congressi, Lugano, Switzerland, 13 - 17 June, 2023. Hematol Oncol. 2023 Jun; 41 Suppl 2:430-432
    View PubMed
38. Shreve JT, Hazim AZ, Bock AM, Pritchett JC, Maurer MJ, Shah MV, Binder M, Witzig TE, Wang Y, Nowakowski GS, Novak AJ, Young JR, Cerhan JR, Habermann TM, Ansell SM, Paludo J. 17th International Conference on Malignant Lymphoma, Palazzo dei Congressi, Lugano, Switzerland, 13 - 17 June, 2023. Hematol Oncol. 2023 Jun; 41 Suppl 2:341-342
    View PubMed
39. Bock AM, Mwangi R, Ataei F, Thorpe M, Shreve JT, Pritchett JC, Maurer MJ, Paludo J, Cerhan JR, Khurana A, Witzig TE, Habermann TM, Wang Y, Nowakowski GS, Young JR. 17th International Conference on Malignant Lymphoma, Palazzo dei Congressi, Lugano, Switzerland, 13 - 17 June, 2023. Hematol Oncol. 2023 Jun; 41 Suppl 2:344-345
    View PubMed
40. Luminari S, Bommier C, Fabbri N, Nizzoli ME, Maurer MJ, Tarantino V, Ferrero S, Rattotti S, Merli M, Ferrari A, Murru R, Khurana A, Mwangi R, Deodato M, Del Giudice I, Cencini E, Re F, Visco C, Feldman AL, Link BK, Delamain MT, Spina M, Ombretta A, Pulsoni A, Mannina D, Boccomini C, Ferreri A, Habermann TM, Marcheselli L, Cerhan JR, Arcaini L. 17th International Conference on Malignant Lymphoma, Palazzo dei Congressi, Lugano, Switzerland, 13 - 17 June, 2023. Hematol Oncol. 2023 Jun; 41 Suppl 2:102-103
    View PubMed
41. Bezerra ED, Iqbal M, Munoz J, Khurana A, Wang Y, Maurer MJ, Bansal R, Hathcock MA, Bennani N, Murthy HS, Rosenthal AC, Paludo J, Villasboas JC, Johnston PB, Habermann TM, Ansell SM, Castro JE, Witzig TE, Kharfan-Dabaja MA, Nowakowski GS, Lin Y. Barriers to enrollment in clinical trials of patients with aggressive B-cell NHL that progressed after CAR T-cell therapy. Blood Adv. 2023 Apr 25; 7 (8):1572-1576
    View PubMed
42. Alderuccio JP, Reis IM, Koff JL, Larson MC, Chihara D, Zhao W, Haddadi S, Habermann TM, Martin P, Chapman J, Strouse C, Kahl BS, Cohen JB, Friedberg JW, Cerhan JR, Flowers CR, Lossos IS. Predictive value of staging PET/CT to detect bone marrow involvement and early outcomes in marginal zone lymphoma. Blood. 2023 Apr 13; 141 (15):1888-1893
    View PubMed
43. Tun AM, Wang Y, Matin A, Inwards DJ, Habermann TM, Micallef I, Johnston PB, Porrata L, Paludo J, Bisneto JV, Rosenthal A, Tun HW, Cerhan JR, Witzig TE, Nowakowski GS, Ansell SM. Outcomes of Patients With Classic Hodgkin Lymphoma Who Relapsed After Autologous Stem Cell Transplant. Hemasphere. 2023 Apr; 7 (4):e869 Epub 2023 Apr 04
    View PubMed
44. Desai SH, Mwangi R, Smith AN, Maurer MJ, Farooq U, King RL, Cerhan JR, Feldman AL, Habermann TM, Thompson CA, Wang Y, Ansell SM, Witzig TE, Nowakowski GS. Cell of origin is not associated with outcomes of relapsed or refractory diffuse large B cell lymphoma. Hematol Oncol. 2023 Feb; 41 (1):39-49 Epub 2022 Nov 07
    View PubMed
45. Boyle T, Kleinstern G, Bracci PM, Cerhan JR, Benavente Y, Casabonne D, Chiu BC, Habermann TM, Holly EA, Liebow M, Norman A, Paltiel O, Robinson D, Rothman N, Abu Seir R, Slager SL, Villeneuve PJ, Wang SS, Weisenburger DD, Spinelli JJ. Physical activity and the risk of non-Hodgkin lymphoma subtypes: A pooled analysis. Int J Cancer. 2023 Feb 1; 152 (3):396-407 Epub 2022 Sept 08
    View PubMed
46. McLaughlin N, Wang Y, Witzig T, Villasboas J, Habermann T, Inwards D, Bennani N, Thanarajasingam G, Nowakowski G, Porrata L, Thompson C, Micallef I, Johnston P, Ansell S, Paludo J. Central nervous system involvement by mantle cell lymphoma. Leuk Lymphoma. 2023 Feb; 64 (2):371-377 Epub 2022 Nov 23
    View PubMed
47. Zeremski V, Kropf S, Koehler M, Gebauer N, McPhail ED, Habermann T, Schieppati F, Mougiakakos D. Induction treatment in high-grade B-cell lymphoma with a concurrent MYC and BCL2 and/or BCL6 rearrangement: a systematic review and meta-analysis. Front Oncol. 2023; 13:1188478 Epub 2023 July 20
    View PubMed
48. Desai SH, Mwangi R, Ng WL, King RL, Maurer MJ, Cerhan JR, Feldman AL, Farooq U, Mou E, Habermann TM, Thompson CA, Wang Y, Witzig TE, Nowakowski GS. Increasing tissue requirements in lymphoma trials may exclude patients with high-risk disease or worse prognosis. Blood Adv. 2022 Dec 27; 6 (24):6180-6186
    View PubMed
49. Chohan KL, Abeykoon JP, Ansell SM, Gertz MA, Kapoor P, Paulus A, Ailawadhi S, Reeder CB, Witzig TE, Habermann TM, Lacy MQ, Kyle RA, Go RS, Paludo J. Insurance-based disparities impact survival outcomes in Waldenstrom macroglobulinemia within the United States. Leuk Lymphoma. 2022 Dec; 63 (12):2879-2888 Epub 2022 July 23
    View PubMed
50. O'Donoghue DF, Truong HL, Finnes HD, McDonald JS, May HP, Ansell SM, Bennani NN, Habermann TM, Inwards DJ, Johnston PB, Khurana A, Lin Y, Micallef IN, Nowakowski GS, Paludo J, Porrata LF, Thanarajasingam G, Thompson CA, Villasboas JC, Wang Y, Witzig TE, Leung N. High-Dose Methotrexate in Patients With Lymphoma: Predictors of a Complicated Course. JCO Oncol Pract. 2022 Dec; 18 (12):e1908-e1917 Epub 2022 Oct 14
    View PubMed
51. Berndt SI, Vijai J, Benavente Y, Camp NJ, Nieters A, Wang Z, Smedby KE, Kleinstern G, Hjalgrim H, Besson C, Skibola CF, Morton LM, Brooks-Wilson AR, Teras LR, Breeze C, Arias J, Adami HO, Albanes D, Anderson KC, Ansell SM, Bassig B, Becker N, Bhatti P, Birmann BM, Boffetta P, Bracci PM, Brennan P, Brown EE, Burdett L, Cannon-Albright LA, Chang ET, Chiu BCH, Chung CC, Clavel J, Cocco P, Colditz G, Conde L, Conti DV, Cox DG, Curtin K, Casabonne D, De Vivo I, Diepstra A, Diver WR, Dogan A, Edlund CK, Foretova L, Fraumeni JF Jr, Gabbas A, Ghesquieres H, Giles GG, Glaser S, Glenn M, Glimelius B, Gu J, Habermann TM, Haiman CA, Haioun C, Hofmann JN, Holford TR, Holly EA, Hutchinson A, Izhar A, Jackson RD, Jarrett RF, Kaaks R, Kane E, Kolonel LN, Kong Y, Kraft P, Kricker A, Lake A, Lan Q, Lawrence C, Li D, Liebow M, Link BK, Magnani C, Maynadie M, McKay J, Melbye M, Miligi L, Milne RL, Molina TJ, Monnereau A, Montalvan R, North KE, Novak AJ, Onel K, Purdue MP, Rand KA, Riboli E, Riby J, Roman E, Salles G, Sborov DW, Severson RK, Shanafelt TD, Smith MT, Smith A, Song KW, Song L, Southey MC, Spinelli JJ, Staines A, Stephens D, Sutherland HJ, Tkachuk K, Thompson CA, Tilly H, Tinker LF, Travis RC, Turner J, Vachon CM, Vajdic CM, Van Den Berg A, Van Den Berg DJ, Vermeulen RCH, Vineis P, Wang SS, Weiderpass E, Weiner GJ, Weinstein S, Doo NW, Ye Y, Yeager M, Yu K, Zeleniuch-Jacquotte A, Zhang Y, Zheng T, Ziv E, Sampson J, Chatterjee N, Offit K, Cozen W, Wu X, Cerhan JR, Chanock SJ, Slager SL, Rothman N. Distinct germline genetic susceptibility profiles identified for common non-Hodgkin lymphoma subtypes. Leukemia. 2022 Dec; 36 (12):2835-2844 Epub 2022 Oct 22
    View PubMed
52. Alderuccio JP, Reis IM, Habermann TM, Link BK, Thieblemont C, Conconi A, Larson MC, Cascione L, Zhao W, Cerhan JR, Zucca E, Lossos IS. Revised MALT-IPI: A new predictive model that identifies high-risk patients with extranodal marginal zone lymphoma. Am J Hematol. 2022 Dec; 97 (12):1529-1537 Epub 2022 Sept 19
    View PubMed
53. Alderuccio JP, Habermann T, Kuker R, Moskowitz CH, Zelenetz AD, Lossos IS. A roadmap for clinical trial design in marginal zone lymphoma. Am J Hematol. 2022 Nov; 97 (11):1398-1403 Epub 2022 Sept 12
    View PubMed
54. Wang Y, Larson MC, Maurer MJ, Link BK, Farooq U, Witzig TE, Habermann TM, Cerhan JR, Nowakowski GS. MCL-027 Prognostic Role of Event-free Survival at 24 Months (EFS24) in Newly Diagnosed Mantle Cell Lymphoma (MCL). Clin Lymphoma Myeloma Leuk. 2022 Oct; 22 Suppl 2:S394
    View PubMed
55. Tun AM, Khurana A, Mwangi R, Link BK, Wang Y, Feldman AL, Thompson CA, Novak AJ, Villasboas JC, Thanarajasingam G, Farooq U, Syrbu S, Nowakowski GS, Witzig TE, Ansell SM, Rimsza LM, Cerhan JR, Habermann TM, Maurer MJ. Causes of death in low-grade B-cell lymphomas in the rituximab era: a prospective cohort study. Blood Adv. 2022 Sep 13; 6 (17):5210-5221
    View PubMed
56. Tun AM, Maliske S, Wang Y, Inwards DJ, Habermann TM, Micallef I, Porrata L, Paludo J, Bisneto JV, Rosenthal A, Kharfan-Dabaja MA, Ansell SM, Nowakowski GS, Farooq U, Johnston PB. Progression-Free Survival at 24 Months as A Landmark After Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B-cell Lymphoma. Transplant Cell Ther. 2022 Sep; 28 (9):610-617 Epub 2022 June 22
    View PubMed
57. Seegobin K, Li Z, Alhaj Moustafa M, Majeed U, Wang J, Jiang L, Kuhlman J, Menke D, Li K, Kharfan-Dabaja MA, Ayala E, Iqbal M, Nowakowski GS, Habermann TM, Witzig TE, Johnston P, Thompson C, Ansell S, Tun HW. Clinical characteristics, prognostic indicators, and survival outcomes in intravascular lymphoma: Mayo Clinic experience (2003-2018). Am J Hematol. 2022 Sep; 97 (9):1150-1158 Epub 2022 July 06
    View PubMed
58. Sidana S, Allmer C, Larson MC, Dueck A, Yost K, Warsame R, Thanarajasingam G, Cerhan JR, Paludo J, Rajkumar SV, Habermann TM, Nowakowski GS, Lin Y, Gertz MA, Witzig T, Dispenzieri A, Gonsalves WI, Ansell SM, Thompson CA, Kumar SK. Patient Experience in Clinical Trials: Quality of Life, Financial Burden, and Perception of Care in Patients With Multiple Myeloma or Lymphoma Enrolled on Clinical Trials Compared With Standard Care. JCO Oncol Pract. 2022 Aug; 18 (8):e1320-e1333 Epub 2022 May 17
    View PubMed
59. Kuhlman JJ, Moustafa MA, Jiang L, Iqbal M, Seegobin K, Wolcott Z, Ayala E, Ansell S, Rosenthal A, Paludo J, Micallef I, Johnston P, Inwards D, Habermann T, Kharfan-Dabaja M, Witzig TE, Nowakowski GS, Tun HW. Leukemic High Grade B Cell Lymphoma is Associated With MYC Translocation, Double Hit/Triple Hit Status, Transformation, and CNS Disease Risk: The Mayo Clinic Experience. Clin Lymphoma Myeloma Leuk. 2022 Aug; 22 (8):e815-e825 Epub 2022 Apr 14
    View PubMed
60. Chohan KL, Young JR, Lester S, Alhaj Moustafa M, Rosenthal A, Tun HW, Hoppe BS, Johnston PB, Micallef IN, Habermann TM, Ansell SM. A real-world study of combined modality therapy for early-stage Hodgkin lymphoma: too little treatment impacts outcome. Blood Adv. 2022 Jul 26; 6 (14):4241-4250
    View PubMed
61. Desai SH, Pederson L, LaPlant B, Mwangi R, Maurer M, Young JR, Macon WR, King RL, Wang Y, Cerhan JR, Feldman A, Inwards DJ, Micallef I, Johnston P, Porrata LF, Ansell SM, Habermann TM, Witzig TE, Nowakowski GS. PET2 response associated with survival in newly diagnosed diffuse large B-cell lymphoma: results of two independent prospective cohorts. Blood Cancer J. 2022 May 3; 12 (5):78 Epub 2022 May 03
    View PubMed
62. Thanarajasingam G, Minasian LM, Bhatnagar V, Cavalli F, De Claro RA, Dueck AC, El-Galaly TC, Everest N, Geissler J, Gisselbrecht C, Gormley N, Gribben J, Horowitz M, Ivy SP, Jacobson CA, Keating A, Kluetz PG, Kwong YL, Little RF, Matasar MJ, Mateos MV, McCullough K, Miller RS, Mohty M, Moreau P, Morton LM, Nagai S, Nair A, Nastoupil L, Robertson K, Sidana S, Smedby KE, Sonneveld P, Tzogani K, van Leeuwen FE, Velikova G, Villa D, Wingard JR, Seymour JF, Habermann TM. Reaching beyond maximum grade: progress and future directions for modernising the assessment and reporting of adverse events in haematological malignancies. Lancet Haematol. 2022 May; 9 (5):e374-e384
    View PubMed
63. Casulo C, Larson MC, Lunde JJ, Habermann TM, Lossos IS, Wang Y, Nastoupil LJ, Strouse C, Chihara D, Martin P, Cohen JB, Kahl BS, Burack WR, Koff JL, Mun Y, Masaquel A, Wu M, Wei MC, Shewade A, Li J, Cerhan J, Flowers CR, Link BK, Maurer MJ. Treatment patterns and outcomes of patients with relapsed or refractory follicular lymphoma receiving three or more lines of systemic therapy (LEO CReWE): a multicentre cohort study. Lancet Haematol. 2022 Apr; 9 (4):e289-e300
    View PubMed
64. Abdallah NH, Habermann T, Buadi FK, Gertz MA, Lacy MQ, Rajkumar SV, Dingli D, Go RS, Hayman SR, Kumar SK, Kourelis T, Warsame R, Kapoor P, Muchtar E, Hwa YL, Fonder AL, Hobbs MA, Lin Y, Leung N, Binder M, Siddiqui MA, Kyle RA, Witzig TE, Dispenzieri A. Multicentric Castleman disease: A single center experience of treatment with a focus on autologous stem cell transplantation. Am J Hematol. 2022 Apr; 97(4):401-410. Epub 2022 Jan 19.
    View PubMed
65. Herrmann J, McCullough KB, Habermann TM. How I treat cardiovascular complications in patients with lymphoid malignancies. Blood. 2022 Mar 10; 139 (10):1501-1516
    View PubMed
66. Castellino A, Wang Y, Larson MC, Maurer MJ, Link BK, Farooq U, Feldman AL, Syrbu SI, Habermann TM, Paludo J, Inwards DJ, Witzig TE, Ansell SM, Allmer C, Slager SL, Cohen JB, Martin P, Cerhan JR, Nowakowski GS. Evolving frontline immunochemotherapy for mantle cell lymphoma and the impact on survival outcomes. Blood Adv. 2022 Feb 22; 6 (4):1350-1360
    View PubMed
67. Kleinstern G, Larson MC, Ansell SM, Thompson CA, Nowakowski GS, Call TG, Robinson DP, Maurer MJ, Mwangi R, Feldman AL, Kay NE, Novak AJ, Habermann TM, Slager SL, Cerhan JR. Vaccination History and Risk of Lymphoma and Its Major Subtypes. Cancer Epidemiol Biomarkers Prev 2022 Feb; 31 (2):461-470 Epub 2021 Nov 15
    View PubMed
68. King RL, Gupta A, Kurtin PJ, Ding W, Call TG, Rabe KG, Kenderian SS, Leis JF, Wang Y, Schwager SM, Slager SL, Kay NE, Koehler A, Ansell SM, Inwards DJ, Habermann TM, Shi M, Hanson CA, Howard MT, Parikh SA. Chronic lymphocytic leukemia (CLL) with Reed-Sternberg-like cells vs Classic Hodgkin lymphoma transformation of CLL: does this distinction matter? Blood Cancer J. 2022 Jan 28; 12 (1):18
    View PubMed
69. Wang Y, Zhou S, Qi X, Yang F, Maurer MJ, Habermann TM, Witzig TE, Wang ML, Nowakowski GS. Efficacy of front-line immunochemotherapy for follicular lymphoma: a network meta-analysis of randomized controlled trials. Blood Cancer J. 2022 Jan 5; 12 (1):1 Epub 2022 Jan 05
    View PubMed
70. Ho M, Zanwar S, Duggan P, Carr R, Habermann T, Navin PJ, Salama ME, Parikh SA. Hiding in (not so) plain sight: Spontaneous tumor Lysis syndrome due to intravascular large B cell lymphoma. Am J Hematol. 2022 Jan 01; 97(1):151-159. Epub 2021 Nov 01.
    View PubMed
71. Asleh R, Alnsasra H, Habermann TM, Briasoulis A, Kushwaha SS. Post-transplant Lymphoproliferative Disorder Following Cardiac Transplantation. Front Cardiovasc Med. 2022; 9:787975 Epub 2022 Feb 23
    View PubMed
72. Cheah CY, Zucca E, Rossi D, Habermann TM. Marginal zone lymphoma: present status and future perspectives. Haematologica. 2022 Jan 1; 107 (1):35-43 Epub 2022 Jan 01
    View PubMed
73. Kraft RM, Ansell SM, Villasboas JC, Bennani NN, Wang Y, Habermann TM, Thanarajasingam G, Lester SC, Macon W, Inwards DJ, Porrata LF, Micallef IN, Witzig TE, Thompson CA, Johnston PB, Nowakowski GS, Lin Y, Paludo J. Outcomes in primary cutaneous diffuse large B-cell lymphoma, leg type. Hematol Oncol. 2021 Dec; 39(5):658-663. Epub 2021 Aug 28.
    View PubMed
74. May HP, Mara KC, Barreto EF, Leung N, Habermann TM. Relationship between uric acid and kidney function in adults at risk for tumor lysis syndrome. Leuk Lymphoma. 2021 Dec; 62 (13):3152-3159 Epub 2021 June 25
    View PubMed
75. Zelenetz AD, Gordon LI, Chang JE, Christian B, Abramson JS, Advani RH, Bartlett NL, Budde LE, Caimi PF, De Vos S, Dholaria B, Fakhri B, Fayad LE, Glenn MJ, Habermann TM, Hernandez-Ilizaliturri F, Hsi E, Hu B, Kaminski MS, Kelsey CR, Khan N, Krivacic S, LaCasce AS, Lim M, Narkhede M, Rabinovitch R, Ramakrishnan P, Reid E, Roberts KB, Saeed H, Smith SD, Svoboda J, Swinnen LJ, Tuscano J, Vose JM, Dwyer MA, Sundar H. NCCN Guidelines® Insights: B-Cell Lymphomas, Version 5.2021. J Natl Compr Canc Netw. 2021 Nov; 19(11):1218-1230.
    View PubMed
76. Chihara D, Larson MC, Robinson DP, Thompson CA, Maurer MJ, Casulo C, Pophali P, Link BK, Habermann TM, Feldman AL, Flowers CR, Cerhan JR, Morton LM. Body mass index and survival of patients with lymphoma. Leuk Lymphoma. 2021 Nov; 62 (11):2671-2678 Epub 2021 June 14
    View PubMed
77. Zanwar S, Abeykoon JP, Ansell SM, Gertz MA, Colby C, Larson D, Paludo J, He R, Warsame R, Greipp PT, King RL, Thompson CA, Witzig TE, Lacy MQ, Gonsalves W, Nowakowski GS, Dingli D, Go RS, Habermann TM, Vincent Rajkumar S, Kyle RA, Kumar S, Kapoor P. Disease outcomes and biomarkers of progression in smouldering Waldenstrom macroglobulinaemia. Br J Haematol. 2021 Oct; 195 (2):210-216 Epub 2021 Aug 02
    View PubMed
78. King RL, Khurana A, Mwangi R, Fama A, Ristow KM, Maurer MJ, Macon WR, Ansell SM, Bennani NN, Kudva YC, Walker RC, Watt KD, Schwab TR, Kushwaha SS, Cerhan JR, Habermann TM. Clinicopathologic Characteristics, Treatment, and Outcomes of Post-transplant Lymphoproliferative Disorders: A Single-institution Experience Using 2017 WHO Diagnostic Criteria. Hemasphere. 2021 Oct; 5 (10):e640 Epub 2021 Sept 06
    View PubMed
79. Desai SH, LaPlant B, Macon WR, King RL, Wang Y, Inwards DJ, Micallef I, Johnston PB, Porrata LF, Ansell SM, Habermann TM, Witzig TE, Nowakowski GS. Lenalidomide in combination with R-CHOP produces high response rates and progression-free survival in new, untreated diffuse large B-cell lymphoma transformed from follicular lymphoma: results from the Phase 2 MC078E study. Blood Cancer J. 2021 Sep 25; 11 (9):160 Epub 2021 Sept 25
    View PubMed
80. Sanchez-Valledor LF, Habermann TM, Murrieta-Alvarez I, Cordova-Ramirez AC, Rivera-Alvarez M, Leon-Pena A, Cantero-Fortiz Y, Olivares-Gazca JC, Ruiz-Delgado GJ, Ruiz-Arguelles GJ. Long-term results of the treatment of Hodgkin's lymphoma in a resource-constrained setting: Real-world data from a single center. World J Clin Oncol. 2021 Sep 24; 12 (9):800-807
    View PubMed
81. D'Costa MR, King RL, Alexander MP, Zhang P, Issa N, Dingli D, Amer H, Singh D, Leung N, Sukov WR, Dean PG, Habermann TM, Kukla A. Epstein Barr Virus-Negative Lymphoplasmacytic Proliferation Limited to the Renal Allograft: A Unique Presentation of a Rare Disease. Kidney Int Rep. 2021 Aug; 6 (8):2223-2227 Epub 2021 May 27
    View PubMed
82. Liebow M, Larson MC, Thompson CA, Nowakowski GS, Call TG, Macon WR, Kay NE, Habermann TM, Slager SL, Cerhan JR. Aspirin and other nonsteroidal anti-inflammatory drugs, statins and risk of non-Hodgkin lymphoma. Int J Cancer. 2021 Aug 1; 149 (3):535-545 Epub 2021 Mar 08
    View PubMed
83. Abeykoon JP, Hampel PJ, King RL, Wood AJ, Larson MC, Nowakowski KE, Zanwar SS, Dasari S, Ruan GJ, Ravindran A, Wellik LE, Paludo J, Link BK, Cerhan JR, Ansell SM, Nowakowski GS, Thompson CA, Maurer MJ, Wenzl K, Novak AJ, Wu X, Habermann TM, Witzig TE. The significance of gradient expression of chromosome region maintenance protein 1 (exportin1) in large cell lymphoma. Haematologica. 2021 Aug 1; 106 (8):2261-2264 Epub 2021 Aug 01
    View PubMed
84. Abeykoon JP, Zanwar S, Ansell SM, Muchtar E, He R, Greipp PT, King RL, Ailawadhi S, Paludo J, Larsen JT, Habermann TM, Inwards D, Go RS, Thanarajasingam G, Buadi F, Dispenzieri A, Thompson CA, Witzig TE, Lacy M, Gonsalves W, Nowakowski GS, Dingli D, Rajkumar SV, Kyle RA, Sher T, Roy V, Rosenthal A, Chanan-Khan AA, Reeder C, Gertz MA, Kumar S, Kapoor P. Assessment of fixed-duration therapies for treatment-naive Waldenstrom macroglobulinemia. Am J Hematol. 2021 Aug 1; 96 (8):945-953 Epub 2021 May 22
    View PubMed
85. Boddicker NJ, Larson MC, Castellino A, Herrmann J, Inwards DJ, Thanarajasingam G, Maurer MJ, Allmer C, Witzig TE, Nowakowski GS, Habermann TM, Villarraga HR, Slager SL, Cerhan JR, Thompson CA. Anthracycline treatment, cardiovascular risk factors and the cumulative incidence of cardiovascular disease in a cohort of newly diagnosed lymphoma patients from the modern treatment era. Am J Hematol. 2021 Aug 1; 96 (8):979-988 Epub 2021 May 27
    View PubMed
86. Arushi Khurana Khurana, Mwangi R, Ansell SM, Habermann TM, Cerhan JR, Strouse C, Link BK, Wang Y, King RL, Macon WR, Villasboas JC, Witzig TE, Maurer MJ, Nowakowski GS. Patterns of therapy initiation during the first decade for patients with follicular lymphoma who were observed at diagnosis in the rituximab era. Blood Cancer J. 2021 Jul 17; 11 (7):133 Epub 2021 July 17
    View PubMed
87. Mondello P, Fama A, Larson MC, Feldman AL, Villasboas JC, Yang ZZ, Galkin I, Svelolkin V, Postovalova E, Bagaev A, Ovcharov P, Varlamova A, Huet S, Tesson B, McGrath KR, Slager S, Link BK, Syrbu S, Novak AJ, Habermann TM, Witzig TE, Nowakowski GS, Salles G, Cerhan JR, Ansell SM. Lack of intrafollicular memory CD4 + T cells is predictive of early clinical failure in newly diagnosed follicular lymphoma. Blood Cancer J. 2021 Jul 15; 11 (7):130 Epub 2021 July 15
    View PubMed
88. Khurana A, Mwangi R, Nowakowski GS, Habermann TM, Ansell SM, LaPlant BR, Link BK, Cerhan JR, Maurer MJ, Witzig TE. Impact of Organ Function-Based Clinical Trial Eligibility Criteria in Patients With Diffuse Large B-Cell Lymphoma: Who Gets Left Behind? J Clin Oncol. 2021 May 20; 39 (15):1641-1649 Epub 2021 Feb 02
    View PubMed
89. Maurer MJ, Jakobsen LH, Mwangi R, Schmitz N, Farooq U, Flowers CR, de Nully Brown P, Thompson CA, Frederiksen H, Cunningham D, Jorgensen J, Poeschel V, Nowakowski G, Seymour JF, Merli F, Haioun C, Ghesquieres H, Ziepert M, Tilly H, Salles G, Shi Q, El-Galaly TC, Habermann TM. Relapsed/Refractory International Prognostic Index (R/R-IPI): An international prognostic calculator for relapsed/refractory diffuse large B-cell lymphoma. Am J Hematol. 2021 May 1; 96 (5):599-605 Epub 2021 Mar 18
    View PubMed
90. Nowakowski GS, Hong F, Scott DW, Macon WR, King RL, Habermann TM, Wagner-Johnston N, Casulo C, Wade JL, Nagargoje GG, Reynolds CM, Cohen JB, Khan N, Amengual JE, Richards KL, Little RF, Leonard JP, Friedberg JW, Kostakoglu L, Kahl BS, Witzig TE. Addition of Lenalidomide to R-CHOP Improves Outcomes in Newly Diagnosed Diffuse Large B-Cell Lymphoma in a Randomized Phase II US Intergroup Study ECOG-ACRIN E1412. J Clin Oncol. 2021 Apr 20; 39 (12):1329-1338 Epub 2021 Feb 08
    View PubMed
91. Ruan GJ, Gandhi S, Abeykoon JP, Schram S, Habermann TM, Sandefur BJ, Witzig TE. Elevated Serum Lactate in Patients With Lymphoma: It Is Not Always Infection. Mayo Clin Proc Innov Qual Outcomes. 2021 Apr; 5 (2):423-430 Epub 2021 Apr 08
    View PubMed
92. May HP, Barreto EF, Mara KC, McCullough KB, Patnaik MS, Leung N, Habermann TM. Risk for Significant Kidney Function Decline After Acute Kidney Injury in Adults With Hematologic Malignancy. Kidney Int Rep. 2021 Apr; 6 (4):1050-1057 Epub 2021 Jan 28
    View PubMed
93. Khurana A, Novo M, Nowakowski GS, Ristow KM, Spinner RJ, Hunt CH, King RL, Lachance DH, Habermann TM, Micallef IN, Johnston PB. Clinical manifestations of, diagnostic approach to, and treatment of neurolymphomatosis in the rituximab era. Blood Adv. 2021 Mar 9; 5 (5):1379-1387
    View PubMed
94. Higgins A, Kim H, Harper L, Habermann TM, Nowakowski GS, Thompson CA, Johnston P, Witzig TE, Allmer C, Maurer MJ, Cerhan JR, Young JR, Thanarajasingam G. Testicular FDG-PET/CT uptake threshold in aggressive lymphomas. Am J Hematol 2021 Mar 1; 96 (3):E81-E83 Epub 2021 Jan 18
    View PubMed
95. Cerhan JR, Habermann TM. Epidemiology of Marginal Zone Lymphoma. Ann Lymphoma. 2021 Mar; 5 Epub 2021 Mar 30
    View PubMed
96. Hartert KT, Wenzl K, Krull JE, Manske M, Sarangi V, Asmann Y, Larson MC, Maurer MJ, Slager S, Macon WR, King RL, Feldman AL, Gandhi AK, Link BK, Habermann TM, Yang ZZ, Ansell SM, Cerhan JR, Witzig TE, Nowakowski GS, Novak AJ. Targeting of inflammatory pathways with R2CHOP in high-risk DLBCL. Leukemia. 2021 Feb; 35 (2):522-533 Epub 2020 Mar 05
    View PubMed
97. Gunaratne MDSK, Sahakian AJ, Abeykoon JP, Ansell SM, Gertz MA, Kapoor P, Paulus A, Ailawadhi S, Reeder CB, Witzig TE, Habermann TM, Novak AJ, Lacy MQ, Kyle RA, Go RS, Paludo J. Treatment facility volume and patient outcomes in Waldenstrom macroglobulinemia. Leuk Lymphoma. 2021 Feb; 62(2):308-315. Epub 2020 Oct 15.
    View PubMed
98. Pophali PA, Larson MC, Rosenthal AC, Robinson D, Habermann TM, Thanarajasingam G, Call T, Allmer C, Farooq U, Maurer MJ, Yost KJ, Cerhan JR, Thompson CA. The association of health behaviors with quality of life in lymphoma survivors. Leuk Lymphoma. 2021 Feb; 62 (2):271-280 Epub 2020 Oct 13
    View PubMed
99. Al-Adra DP, Hammel L, Roberts J, Woodle ES, Levine D, Mandelbrot D, Verna E, Locke J, D'Cunha J, Farr M, Sawinski D, Agarwal PK, Plichta J, Pruthi S, Farr D, Carvajal R, Walker J, Zwald F, Habermann T, Gertz M, Bierman P, Dizon DS, Langstraat C, Al-Qaoud T, Eggener S, Richgels JP, Chang GJ, Geltzeiler C, Sapisochin G, Ricciardi R, Krupnick AS, Kennedy C, Mohindra N, Foley DP, Watt KD. Pretransplant solid organ malignancy and organ transplant candidacy: A consensus expert opinion statement. Am J Transplant. 2021 Feb; 21 (2):460-474 Epub 2020 Oct 23
    View PubMed
100. Al-Adra DP, Hammel L, Roberts J, Woodle ES, Levine D, Mandelbrot D, Verna E, Locke J, D'Cunha J, Farr M, Sawinski D, Agarwal PK, Plichta J, Pruthi S, Farr D, Carvajal R, Walker J, Zwald F, Habermann T, Gertz M, Bierman P, Dizon DS, Langstraat C, Al-Qaoud T, Eggener S, Richgels JP, Chang GJ, Geltzeiler C, Sapisochin G, Ricciardi R, Krupnick AS, Kennedy C, Mohindra N, Foley DP, Watt KD. Preexisting melanoma and hematological malignancies, prognosis, and timing to solid organ transplantation: A consensus expert opinion statement. Am J Transplant. 2021 Feb; 21 (2):475-483 Epub 2020 Oct 10
     View PubMed
101. Castellino A, Tun AM, Wang Y, Habermann TM, King RL, Ristow KM, Cerhan JR, Inwards DJ, Paludo J, Ansell SM, Witzig TE, Nowakowski GS. Clinical characteristics and outcomes of primary versus secondary gastrointestinal mantle cell lymphoma. Blood Cancer J. 2021 Jan 7; 11 (1):8 Epub 2021 Jan 07
     View PubMed
102. Moore A, Machiela MJ, Machado M, Wang SS, Kane E, Slager SL, Zhou W, Carrington M, Lan Q, Milne RL, Birmann BM, Adami HO, Albanes D, Arslan AA, Becker N, Benavente Y, Bisanzi S, Boffetta P, Bracci PM, Brennan P, Brooks-Wilson AR, Canzian F, Caporaso N, Clavel J, Cocco P, Conde L, Cox DG, Cozen W, Curtin K, De Vivo I, de Sanjose S, Foretova L, Gapstur SM, Ghesquieres H, Giles GG, Glenn M, Glimelius B, Gao C, Habermann TM, Hjalgrim H, Jackson RD, Liebow M, Link BK, Maynadie M, McKay J, Melbye M, Miligi L, Molina TJ, Monnereau A, Nieters A, North KE, Offit K, Patel AV, Piro S, Ravichandran V, Riboli E, Salles G, Severson RK, Skibola CF, Smedby KE, Southey MC, Spinelli JJ, Staines A, Stewart C, Teras LR, Tinker LF, Travis RC, Vajdic CM, Vermeulen RCH, Vijai J, Weiderpass E, Weinstein S, Doo NW, Zhang Y, Zheng T, Chanock SJ, Rothman N, Cerhan JR, Dean M, Camp NJ, Yeager M, Berndt SI. Genome-wide homozygosity and risk of four non-Hodgkin lymphoma subtypes. J Transl Genet Genom. 2021; 5:200-217 Epub 2021 June 17
     View PubMed
103. Report from the Lymphoma Research Foundation Adolescent and Young Adult (AYA) Lymphoma Scientific Workshop, May 2019 Annals of Lymphoma. 2020; 4(11).
     
104. Khurana A, Micallef IN, LaPlant BR, Patrick O'Neill B, Habermann TM, Ansell SM, Inwards DJ, Porrata LF, Paludo J, Bisneto JCV, Johnston PB. Outcomes of Autologous Stem Cell Transplant Consolidation in Primary Central Nervous System Lymphoma: A Mayo Clinic Experience. Biol Blood Marrow Transplant. 2020 Dec; 26(12):2217-2222. Epub 2020 Aug 18.
     View PubMed
105. Habermann TM, Khurana A, Lentz R, Schmitz JJ, von Bormann AG, Young JR, Hunt CH, Christofferson SN, Nowakowski GS, McCullough KB, Horna P, Wood AJ, Macon WR, Kurtin PJ, Lester SC, Stafford SL, Chamarthy U, Khan F, Ansell SM, King RL. Analysis and impact of a multidisciplinary lymphoma virtual tumor board. Leuk Lymphoma. 2020 Dec; 61 (14):3351-3359 Epub 2020 Sept 23
     View PubMed
106. Krull JE, Wenzl K, Hartert KT, Manske MK, Sarangi V, Maurer MJ, Larson MC, Nowakowski GS, Ansell SM, McPhail E, Habermann TM, Link BK, King RL, Cerhan JR, Novak AJ. Somatic copy number gains in MYC, BCL2, and BCL6 identifies a subset of aggressive alternative-DH/TH DLBCL patients. Blood Cancer J. 2020 Nov 9; 10 (11):117 Epub 2020 Nov 09
     View PubMed
107. St-Pierre F, Broski SM, LaPlant BR, Ristow K, Macon WR, Habermann TM, Witzig TE. Bone involvement on PET/CT predicts event-free survival in follicular lymphoma Grade 3B. Br J Haematol 2020 Oct; 191 (2):e41-e43 Epub 2020 July 23
     View PubMed
108. Evens AM, Hong F, Habermann TM, Advani RH, Gascoyne RD, Witzig TE, Quon A, Ranheim EA, Ansell SM, Cheema PS, Dy PA, O'Brien TE, Winter JN, Cescon TP, Chang JE, Kahl BS. A Three-Arm Randomized Phase II Study of Bendamustine/Rituximab with Bortezomib Induction or Lenalidomide Continuation in Untreated Follicular Lymphoma: ECOG-ACRIN E2408. Clin Cancer Res. 2020 Sep 1; 26 (17):4468-4477 Epub 2020 June 12
     View PubMed
109. Fama A, Larson MC, Link BK, Habermann TM, Feldman AL, Call TG, Ansell SM, Liebow M, Xiang J, Maurer MJ, Slager SL, Nowakowski GS, Stapleton JT, Cerhan JR. Human Pegivirus Infection and Lymphoma Risk: A Systematic Review and Meta-analysis. Clin Infect Dis. 2020 Aug 22; 71 (5):1221-1228
     View PubMed
110. St-Pierre F, Broski SM, LaPlant BR, Maurer MJ, Ristow K, Thanarajasingam G, Macon WR, Habermann TM, Witzig TE. Fluorodeoxyglucose-Positron Emission Tomography Predicts Bone Marrow Involvement in the Staging of Follicular Lymphoma. Oncologist. 2020 Aug; 25 (8):689-695 Epub 2020 Apr 28
     View PubMed
111. Thanarajasingam G, Leonard JP, Witzig TE, Habermann TM, Blum KA, Bartlett NL, Flowers CR, Pitcher BN, Jung SH, Atherton PJ, Tan A, Novotny PJ, Dueck AC. Longitudinal Toxicity over Time (ToxT) analysis to evaluate tolerability: a case study of lenalidomide in the CALGB 50401 (Alliance) trial. Lancet Haematol. 2020 Jun; 7 (6):e490-e497
     View PubMed
112. Jakobsen LH, Ellin F, Smeland KB, Wasterlid T, Christensen JH, Jorgensen JM, Josefsson PL, Ovlisen AK, Holte H, Blaker YN, Grauslund JH, Bjorn J, Molin D, Lagerlof I, Smedby KE, Colvin K, Thanarajasingam G, Maurer MJ, Habermann TM, Song KW, Zhu KY, Gerrie AS, Cheah CY, El-Galaly TC. Minimal relapse risk and early normalization of survival for patients with Burkitt lymphoma treated with intensive immunochemotherapy: an international study of 264 real-world patients. Br J Haematol. 2020 May; 189 (4):661-671 Epub 2020 Feb 04
     View PubMed
113. Zanwar S, Abeykoon JP, Durot E, King R, Perez Burbano GE, Kumar S, Gertz MA, Quinquenel A, Delmer A, Gonsalves W, Cornillet-Lefebvre P, He R, Warsame R, Buadi FK, Novak AJ, Greipp PT, Inwards D, Habermann TM, Micallef I, Go R, Muchtar E, Kourelis T, Dispenzieri A, Lacy MQ, Dingli D, Nowakowski G, Thompson CA, Johnston P, Thanarajasingam G, Bennani NN, Witzig TE, Villasboas J, Leung N, Lin Y, Kyle RA, Rajkumar SV, Ansell SM, Le-Rademacher JG, Kapoor P. Impact of MYD88L265P mutation status on histological transformation of Waldenström Macroglobulinemia. Am J Hematol. 2020 Mar; 95(3):274-281. Epub 2019 Dec 31.
     View PubMed
114. Abeykoon JP, Zanwar S, Ansell SM, Gertz MA, Kumar S, Manske M, Novak AJ, King R, Greipp P, Go R, Inwards D, Muchtar E, Habermann T, Witzig TE, Thompson CA, Dingli D, Lacy MQ, Leung N, Dispenzieri A, Gonsalves W, Warsame R, Kyle RA, Rajkumar V, Parikh SA, Kapoor P. Ibrutinib monotherapy outside of clinical trial setting in Waldenstrom macroglobulinaemia: practice patterns, toxicities and outcomes. Br J Haematol. 2020 Feb; 188 (3):394-403 Epub 2019 Aug 29
     View PubMed
115. Novo M, Nowakowski GS, Habermann TM, Witzig TE, Micallef IN, Johnston PB, Inwards DJ, Botto B, Ristow KM, Young JR, Vitolo U, Ansell SM. Persistent mediastinal FDG uptake on PET-CT after frontline therapy for Hodgkin lymphoma: biopsy, treat or observe? Leuk Lymphoma. 2020 Feb; 61 (2):318-327 Epub 2019 Sept 26
     View PubMed
116. Taparra K, Liu H, Polley MY, Ristow K, Habermann TM, Ansell SM. Bleomycin use in the treatment of Hodgkin lymphoma (HL): toxicity and outcomes in the modern era. Leuk Lymphoma. 2020 Feb; 61 (2):298-308 Epub 2019 Sept 13
     View PubMed
117. Pophali PA, Marinelli LM, Ketterling RP, Meyer RG, McPhail ED, Kurtin PJ, Mwangi R, Maurer MJ, Habermann T, King RL. High level MYC amplification in B-cell lymphomas: is it a marker of aggressive disease? Blood Cancer J. 2020 Jan 13; 10 (1):5
     View PubMed
118. Goyal G, Ravindran A, Young JR, Shah MV, Bennani NN, Patnaik MM, Nowakowski GS, Thanarajasingam G, Habermann TM, Vassallo R, Sher T, Parikh SA, Rech KL, Go RS, Mayo Clinic Histiocytosis Working Group. Clinicopathological features, treatment approaches, and outcomes in Rosai-Dorfman disease. Haematologica. 2020; 105 (2):348-357 Epub 2020 Jan 31
     View PubMed
119. Wang Y, Link BK, Witzig TE, Maurer MJ, Allmer C, King RL, Feldman AL, Habermann TM, Ansell SM, Slager SL, Cerhan JR, Nowakowski GS. Impact of concurrent indolent lymphoma on the clinical outcome of newly diagnosed diffuse large B-cell lymphoma. Blood. 2019 Oct 17; 134 (16):1289-1297
     View PubMed
120. Personett HA, Barreto EF, McCullough KB, Dierkhising R, Leung N, Habermann TM. Impact of early rasburicase on incidence of clinical tumor lysis syndrome in lymphoma. Leuk Lymphoma. 2019 Sep; 60 (9):2271-2277 Epub 2019 June 21
     View PubMed
121. Wang Y, Maurer MJ, Larson MC, Allmer C, Feldman AL, Bennani NN, Thompson CA, Porrata LF, Habermann TM, Witzig TE, Ansell SM, Slager SL, Nowakowski GS, Cerhan JR. Impact of metformin use on the outcomes of newly diagnosed diffuse large B-cell lymphoma and follicular lymphoma. Br J Haematol. 2019 Sep; 186 (6):820-828 Epub 2019 May 28
     View PubMed
122. Wang Y, Wenzl K, Manske MK, Asmann YW, Sarangi V, Greipp PT, Krull JE, Hartert K, He R, Feldman AL, Maurer MJ, Slager SL, Nowakowski GS, Habermann TM, Witzig TE, Link BK, Ansell SM, Cerhan JR, Novak AJ. Amplification of 9p24.1 in diffuse large B-cell lymphoma identifies a unique subset of cases that resemble primary mediastinal large B-cell lymphoma. Blood Cancer J. 2019 Aug 30; 9 (9):73
     View PubMed
123. Wang Y, Farooq U, Link BK, Larson MC, King RL, Maurer MJ, Allmer C, Hefazi M, Thompson CA, Micallef IN, Johnston PB, Habermann TM, Witzig TE, Ansell SM, Cerhan JR, Nowakowski GS. Late Relapses in Patients With Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy. J Clin Oncol. 2019 Jul 20; 37 (21):1819-1827 Epub 2019 June 06
     View PubMed
124. St-Pierre F, Broski SM, LaPlant BR, Ristow K, Maurer MJ, Macon WR, Habermann TM, Ansell SM, Thompson CA, Micallef INM, Nowakowski GS, Witzig TE. Detection of extranodal and spleen involvement by FDG-PET imaging predicts adverse survival in untreated follicular lymphoma. Am J Hematol. 2019 Jul; 94 (7):786-793 Epub 2019 May 16
     View PubMed
125. Asleh R, Clavell AL, Pereira NL, Smith B, Briasoulis A, Alnsasra H, Kremers WK, Habermann TM, Otley CC, Li X, Edwards BS, Stulak JM, Daly RC, Kushwaha SS. Incidence of Malignancies in Patients Treated With Sirolimus Following Heart Transplantation. J Am Coll Cardiol. 2019 Jun 4; 73 (21):2676-2688
     View PubMed
126. Viscuse P, Yost KJ, Jenkins S, Lackore K, Habermann T, Thanarajasingam G, Thompson C. Impact of lymphoma survivorship clinic visit on patient-centered outcomes. J Cancer Surviv. 2019 Jun; 13 (3):344-352 Epub 2019 Apr 26
     View PubMed
127. Tracy SI, Larson MC, Feldman AL, Maurer MJ, Novak AJ, Slager SL, Villasboas JC, Allmer C, Habermann TM, Farooq U, Syrbu S, Cerhan JR, Link BK. The utility of prognostic indices, early events, and histological subtypes on predicting outcomes in non-follicular indolent B-cell lymphomas. Am J Hematol. 2019 Jun; 94 (6):658-666 Epub 2019 Apr 10
     View PubMed
128. Zelenetz AD, Gordon LI, Abramson JS, Advani RH, Bartlett NL, Caimi PF, Chang JE, Chavez JC, Christian B, Fayad LE, Glenn MJ, Habermann TM, Harris NL, Hernandez-Ilizaliturri F, Kaminski MS, Kelsey CR, Khan N, Krivacic S, LaCasce AS, Mehta A, Nademanee A, Rabinovitch R, Reddy N, Reid E, Roberts KB, Smith SD, Snyder ED, Swinnen LJ, Vose JM, Dwyer MA, Sundar H. B-cell lymphomas, version 3.2019 featured updates to the NCCN guidelines Journal Of The National Comprehensive Cancer Network. 2019 Jun; 17 (6):651-61
     
129. Wang Y, Habermann TM, Wang SS, Maurer MJ, Sarangi V, Link BK, Feldman AL, Inwards DJ, Witzig TE, Cozen W, Rothman N, Asmann Y, Slager SL, Cerhan JR. Host genetic variation in tumor necrosis factor and nuclear factor-kappaB pathways and overall survival in mantle cell lymphoma: A discovery and replication study. Am J Hematol 2019 Jun; 94 (6):E153-E155 Epub 2019 Mar 15
     View PubMed
130. Zelenetz AD, Gordon LI, Abramson JS, Advani RH, Bartlett NL, Caimi PF, Chang JE, Chavez JC, Christian B, Fayad LE, Glenn MJ, Habermann TM, Lee Harris N, Hernandez-Ilizaliturri F, Kaminski MS, Kelsey CR, Khan N, Krivacic S, LaCasce AS, Mehta A, Nademanee A, Rabinovitch R, Reddy N, Reid E, Roberts KB, Smith SD, Snyder ED, Swinnen LJ, Vose JM, Dwyer MA, Sundar H. NCCN Guidelines Insights: B-Cell Lymphomas, Version 3.2019. J Natl Compr Canc Netw. 2019 Jun 1; 17 (6):650-661
     View PubMed
131. Dioverti MV, Parikh SA, Osmon DR, Habermann TM, Tande AJ. Cryptococcus neoformans infections in patients with lymphoproliferative neoplasms. Leuk Lymphoma. 2019 Apr; 60 (4):920-926 Epub 2018 Sept 06
     View PubMed
132. Zanwar S, Abeykoon JP, Ansell SM, Gertz MA, Dispenzieri A, Muchtar E, Sidana S, Tandon N, Rajkumar SV, Dingli D, Go R, Lacy MQ, Kourelis T, Witzig TE, Inwards D, Buadi F, Gonsalves W, Habermann T, Johnston P, Nowakowski G, Kyle RA, Kumar S, Kapoor P. Primary systemic amyloidosis in patients with Waldenstrom macroglobulinemia. Leukemia. 2019 Mar; 33 (3):790-794 Epub 2018 Oct 12
     View PubMed
133. Castellino A, Pulido JS, Johnston PB, Ristow KM, Nora Bennani N, Inwards DJ, Macon WR, Micallef INM, King RL, Salomao DR, Witzig TE, Habermann TM, Nowakowski GS. Role of systemic high-dose methotrexate and combined approaches in the management of vitreoretinal lymphoma: A single center experience 1990-2018. Am J Hematol. 2019 Mar; 94 (3):291-298 Epub 2018 Dec 05
     View PubMed
134. Hill BT, Nastoupil L, Winter AM, Becnel MR, Cerhan JR, Habermann TM, Link BK, Maurer MJ, Fakhri B, Reddy P, Smith SD, Mukhija D, Jagadeesh D, Desai A, Alderuccio JP, Lossos IS, Mehra P, Portell CA, Goldman ML, Calzada O, Cohen JB, Hussain MJ, Ghosh N, Caimi P, Tiutan T, Martin P, Kodali A, Evens AM, Kahl BS. Maintenance rituximab or observation after frontline treatment with bendamustine-rituximab for follicular lymphoma. Br J Haematol. 2019 Feb; 184 (4):524-535 Epub 2018 Dec 21
     View PubMed
135. Mackrides N, Chapman J, Chapman J, Ramos JC, Larson MC, Ramos JC, Toomey N, Lin P, Maurer MJ, Rafaelle M, Tan Y, Ikpatt O, Syrbu S, Ansell SM, Habermann TM, Link BK, Feldman AL, Lossos IS, Cerhan JR, Vega F. Prevalence, clinical characteristics and prognosis of EBV-positive follicular lymphoma. Am J Hematol 2019 Feb; 94 (2):E62-E64 Epub 2018 Dec 05
     View PubMed
136. Park JY, Guo W, Al-Hijji M, El Sabbagh A, Begna KH, Habermann TM, Witzig TE, Lewis BR, Lerman A, Herrmann J. Acute coronary syndromes in patients with active hematologic malignancies - Incidence, management, and outcomes. Int J Cardiol. 2019 Jan 15; 275:6-12 Epub 2018 Oct 05
     View PubMed
137. Sarkozy C, Maurer MJ, Link BK, Ghesquieres H, Nicolas E, Thompson CA, Traverse-Glehen A, Feldman AL, Allmer C, Slager SL, Ansell SM, Habermann TM, Bachy E, Cerhan JR, Salles G. Cause of Death in Follicular Lymphoma in the First Decade of the Rituximab Era: A Pooled Analysis of French and US Cohorts. J Clin Oncol. 2019 Jan 10; 37 (2):144-152 Epub 2018 Nov 27
     View PubMed
138. Moore A, Kane E, Wang Z, Panagiotou OA, Teras LR, Monnereau A, Wong Doo N, Machiela MJ, Skibola CF, Slager SL, Salles G, Camp NJ, Bracci PM, Nieters A, Vermeulen RCH, Vijai J, Smedby KE, Zhang Y, Vajdic CM, Cozen W, Spinelli JJ, Hjalgrim H, Giles GG, Link BK, Clavel J, Arslan AA, Purdue MP, Tinker LF, Albanes D, Ferri GM, Habermann TM, Adami HO, Becker N, Benavente Y, Bisanzi S, Boffetta P, Brennan P, Brooks-Wilson AR, Canzian F, Conde L, Cox DG, Curtin K, Foretova L, Gapstur SM, Ghesquieres H, Glenn M, Glimelius B, Jackson RD, Lan Q, Liebow M, Maynadie M, McKay J, Melbye M, Miligi L, Milne RL, Molina TJ, Morton LM, North KE, Offit K, Padoan M, Patel AV, Piro S, Ravichandran V, Riboli E, de Sanjose S, Severson RK, Southey MC, Staines A, Stewart C, Travis RC, Weiderpass E, Weinstein S, Zheng T, Chanock SJ, Chatterjee N, Rothman N, Birmann BM, Cerhan JR, Berndt SI. Genetically Determined Height and Risk of Non-hodgkin Lymphoma. Front Oncol. 2019; 9:1539 Epub 2020 Jan 28
     View PubMed
139. Pophali PA, Ip A, Larson MC, Rosenthal AC, Maurer MJ, Flowers CR, Link BK, Farooq U, Feldman AL, Allmer C, Slager SL, Witzig TE, Habermann TM, Cohen JB, Cerhan JR, Thompson CA. The association of physical activity before and after lymphoma diagnosis with survival outcomes. Am J Hematol. 2018 Dec; 93 (12):1543-1550 Epub 2018 Oct 17
     View PubMed
140. Thompson CA, Yost KJ, Maurer MJ, Allmer C, Farooq U, Habermann TM, Inwards DJ, Macon WR, Link BK, Rosenthal AC, Cerhan JR. Quality of life at diagnosis predicts overall survival in patients with aggressive lymphoma. Hematol Oncol. 2018 Dec; 36 (5):749-756 Epub 2018 June 03
     View PubMed
141. Castellino A, Chiappella A, LaPlant BR, Pederson LD, Gaidano G, Macon WR, Inghirami G, Reeder CB, Tucci A, King RL, Congiu A, Foran JM, Pavone V, Rivera CE, Spina M, Ansell SM, Cavallo F, Molinari AL, Ciccone G, Habermann TM, Witzig TE, Vitolo U, Nowakowski GS. Lenalidomide plus R-CHOP21 in newly diagnosed diffuse large B-cell lymphoma (DLBCL): long-term follow-up results from a combined analysis from two phase 2 trials. Blood Cancer J. 2018 Nov 8; 8 (11):108 Epub 2018 Nov 08
     View PubMed
142. Abeykoon JP, Zanwar S, Ansell SM, Winters J, Gertz MA, King RL, Murray D, Habermann T, Dingli D, Muchtar E, Go RS, Leung N, Inwards DJ, Buadi FK, Dispenzieri A, Lacy MQ, Lin Y, Gonsalves WI, Kourelis T, Witzig TE, Thompson C, Vincent Rajkumar S, Kyle RA, Kumar S, Kapoor P. Predictors of symptomatic hyperviscosity in Waldenstrom macroglobulinemia. Am J Hematol. 2018 Nov; 93 (11):1384-1393 Epub 2018 Oct 02
     View PubMed
143. McPhail ED, Maurer MJ, Macon WR, Feldman AL, Kurtin PJ, Ketterling RP, Vaidya R, Cerhan JR, Ansell SM, Porrata LF, Nowakowski GS, Witzig TE, Habermann TM. Inferior survival in high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements is not associated with MYC/IG gene rearrangements. Haematologica. 2018 Nov; 103 (11):1899-1907 Epub 2018 June 14
     View PubMed
144. Thanarajasingam G, Minasian LM, Baron F, Cavalli F, De Claro RA, Dueck AC, El-Galaly TC, Everest N, Geissler J, Gisselbrecht C, Gribben J, Horowitz M, Ivy SP, Jacobson CA, Keating A, Kluetz PG, Krauss A, Kwong YL, Little RF, Mahon FX, Matasar MJ, Mateos MV, McCullough K, Miller RS, Mohty M, Moreau P, Morton LM, Nagai S, Rule S, Sloan J, Sonneveld P, Thompson CA, Tzogani K, van Leeuwen FE, Velikova G, Villa D, Wingard JR, Wintrich S, Seymour JF, Habermann TM. Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignancies. Lancet Haematol. 2018 Nov; 5 (11):e563-e598 Epub 2018 June 18
     View PubMed
145. Thanarajasingam G, Maurer MJ, Habermann TM, Nowakowski GS, Bennani NN, Thompson CA, Cerhan JR, Witzig TE. Low Plasma Omega-3 Fatty Acid Levels May Predict Inferior Prognosis in Untreated Diffuse Large B-Cell Lymphoma: A New Modifiable Dietary Biomarker? Nutr Cancer. 2018 Oct; 70 (7):1088-1090 Epub 2018 Sept 20
     View PubMed
146. Padrnos L, Ernst B, Dueck AC, Kosiorek HE, Ginos BF, Toro A, Johnston PB, Habermann TM, Leis JF, Mikhael JR, Nowakowski GS, Colgan J, Porrata L, Ansell SM, Witzig TE, Reeder C. A Novel Combination of the mTORC1 Inhibitor Everolimus and the Immunomodulatory Drug Lenalidomide Produces Durable Responses in Patients With Heavily Pretreated Relapsed Lymphoma. Clin Lymphoma Myeloma Leuk. 2018 Oct; 18 (10):664-672.e2 Epub 2018 June 15
     View PubMed
147. Thanarajasingam G, Maurer MJ, Farooq U, Johnston PB, Thompson CA, Bennani NN, Ansell SM, Porrata LF, Macon WR, Syrbu SI, Cerhan JR, Habermann TM, Link BK, Witzig TE, Nowakowski GS. Event-free survival at 24 months captures central nervous system relapse of systemic diffuse large B-cell lymphoma in the immunochemotherapy era. Br J Haematol 2018 Oct; 183 (1):149-152 Epub 2017 Sept 29
     View PubMed
148. Shi Q, Schmitz N, Ou FS, Dixon JG, Cunningham D, Pfreundschuh M, Seymour JF, Jaeger U, Habermann TM, Haioun C, Tilly H, Ghesquieres H, Merli F, Ziepert M, Herbrecht R, Flament J, Fu T, Coiffier B, Flowers CR. Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Diffuse Large B-Cell Lymphoma: An Individual Patient-Level Analysis of Multiple Randomized Trials (SEAL). J Clin Oncol. 2018 Sep 1; 36 (25):2593-2602 Epub 2018 July 05
     View PubMed
149. Sonbol MB, Hilal T, Dueck AC, Rosenthal AC, Conley CR, Kosiorek HE, Ginos BF, Gano KM, Nichols CS, Leis JF, Johnston PB, Habermann TM, Northfelt DW, Bergsagel PL, Inwards DJ, Witzig TE, Ansell SM, Reeder CB. A phase 2 study of rituximab, cyclophosphamide, bortezomib and dexamethasone (R-CyBorD) in relapsed low grade and mantle cell lymphoma. Leuk Lymphoma. 2018 Sep; 59(9):2128-2134. Epub 2018 Jan 10.
     View PubMed
150. Fama A, Xiang J, Link BK, Allmer C, Klinzman D, Feldman AL, Nowakowski GS, Liebow M, Larson MC, Maurer MJ, Ansell SM, Novak AJ, Asmann YW, Slager SL, Call TG, Habermann TM, Cerhan JR, Stapleton JT. Human Pegivirus infection and lymphoma risk and prognosis: a North American study. Br J Haematol. 2018 Sep; 182(5):644-653. Epub 2018 May 29.
     View PubMed
151. Kleinstern G, Maurer MJ, Liebow M, Habermann TM, Koff JL, Allmer C, Witzig TE, Nowakowski GS, Micallef IN, Johnston PB, Inwards DJ, Thompson CA, Feldman AL, Link BK, Flowers C, Slager SL, Cerhan JR. History of autoimmune conditions and lymphoma prognosis. Blood Cancer J. 2018 Aug 1; 8 (8):73 Epub 2018 Aug 01
     View PubMed
152. Chapuy B, Stewart C, Dunford AJ, Kim J, Kamburov A, Redd RA, Lawrence MS, Roemer MGM, Li AJ, Ziepert M, Staiger AM, Wala JA, Ducar MD, Leshchiner I, Rheinbay E, Taylor-Weiner A, Coughlin CA, Hess JM, Pedamallu CS, Livitz D, Rosebrock D, Rosenberg M, Tracy AA, Horn H, van Hummelen P, Feldman AL, Link BK, Novak AJ, Cerhan JR, Habermann TM, Siebert R, Rosenwald A, Thorner AR, Meyerson ML, Golub TR, Beroukhim R, Wulf GG, Ott G, Rodig SJ, Monti S, Neuberg DS, Loeffler M, Pfreundschuh M, Trumper L, Getz G, Shipp MA. Publisher Correction: Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med. 2018 Aug; 24 (8):1292
     View PubMed
153. Chapuy B, Stewart C, Dunford AJ, Kim J, Kamburov A, Redd RA, Lawrence MS, Roemer MGM, Li AJ, Ziepert M, Staiger AM, Wala JA, Ducar MD, Leshchiner I, Rheinbay E, Taylor-Weiner A, Coughlin CA, Hess JM, Pedamallu CS, Livitz D, Rosebrock D, Rosenberg M, Tracy AA, Horn H, van Hummelen P, Feldman AL, Link BK, Novak AJ, Cerhan JR, Habermann TM, Siebert R, Rosenwald A, Thorner AR, Meyerson ML, Golub TR, Beroukhim R, Wulf GG, Ott G, Rodig SJ, Monti S, Neuberg DS, Loeffler M, Pfreundschuh M, Trumper L, Getz G, Shipp MA. Author Correction: Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med. 2018 Aug; 24 (8):1290-1291
     View PubMed
154. Paludo J, Abeykoon JP, Shreders A, Ansell SM, Kumar S, Ailawadhi S, King RL, Koehler AB, Reeder CB, Buadi FK, Dispenzieri A, Lacy MQ, Dingli D, Witzig TE, Go RS, Gonsalves WI, Kourelis T, Warsame R, Leung N, Habermann TM, Hayman S, Lin Y, Kyle RA, Rajkumar SV, Gertz MA, Kapoor P. Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with Waldenstrom macroglobulinemia. Ann Hematol. 2018 Aug; 97 (8):1417-1425 Epub 2018 Apr 03
     View PubMed
155. Maurer MJ, Habermann TM, Shi Q, Schmitz N, Cunningham D, Pfreundschuh M, Seymour JF, Jaeger U, Haioun C, Tilly H, Ghesquieres H, Merli F, Ziepert M, Herbrecht R, Flament J, Fu T, Flowers CR, Coiffier B. Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) enrolled on randomized clinical trials. Ann Oncol. 2018 Aug 1; 29 (8):1822-1827
     View PubMed
156. Bachy E, Maurer MJ, Habermann TM, Gelas-Dore B, Maucort-Boulch D, Estell JA, Van den Neste E, Bouabdallah R, Gyan E, Feldman AL, Bargay J, Delmer A, Slager SL, Gomes da Silva M, Fitoussi O, Belada D, Maisonneuve H, Intragumtornchai T, Ansell SM, Lamy T, Dartigues P, Link BK, Seymour JF, Cerhan JR, Salles G. A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy. Blood. 2018 Jul 5; 132 (1):49-58 Epub 2018 Apr 17
     View PubMed
157. Maurer MJ, Ghesquieres H, Link BK, Jais JP, Habermann TM, Thompson CA, Haioun C, Allmer C, Johnston PB, Delarue R, Micallef IN, Peyrade F, Inwards DJ, Ketterer N, Farooq U, Fitoussi O, Macon WR, Molina TJ, Syrbu S, Feldman AL, Slager SL, Weiner GJ, Ansell SM, Cerhan JR, Salles GA, Witzig TE, Tilly H, Nowakowski GS. Diagnosis-to-Treatment Interval Is an Important Clinical Factor in Newly Diagnosed Diffuse Large B-Cell Lymphoma and Has Implication for Bias in Clinical Trials. J Clin Oncol. 2018 Jun 1; 36 (16):1603-1610 Epub 2018 Apr 19
     View PubMed
158. Tolcher A, Flaherty K, Shapiro GI, Berlin J, Witzig T, Habermann T, Bullock A, Rock E, Elekes A, Lin C, Kostic D, Ohi N, Rasco D, Papadopoulos KP, Patnaik A, Smith L, Cote GM. A First-in-Human Phase I Study of OPB-111077, a Small-Molecule STAT3 and Oxidative Phosphorylation Inhibitor, in Patients with Advanced Cancers. Oncologist. 2018 Jun; 23 (6):658-e72 Epub 2018 Mar 06
     View PubMed
159. Chapuy B, Stewart C, Dunford AJ, Kim J, Kamburov A, Redd RA, Lawrence MS, Roemer MGM, Li AJ, Ziepert M, Staiger AM, Wala JA, Ducar MD, Leshchiner I, Rheinbay E, Taylor-Weiner A, Coughlin CA, Hess JM, Pedamallu CS, Livitz D, Rosebrock D, Rosenberg M, Tracy AA, Horn H, van Hummelen P, Feldman AL, Link BK, Novak AJ, Cerhan JR, Habermann TM, Siebert R, Rosenwald A, Thorner AR, Meyerson ML, Golub TR, Beroukhim R, Wulf GG, Ott G, Rodig SJ, Monti S, Neuberg DS, Loeffler M, Pfreundschuh M, Trumper L, Getz G, Shipp MA. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med. 2018 May; 24 (5):679-690 Epub 2018 Apr 30
     View PubMed
160. Dierickx D, Habermann TM. Post-Transplantation Lymphoproliferative Disorders in Adults. N Engl J Med. 2018 Feb 8; 378 (6):549-562
     View PubMed
161. Tracy SI, Habermann TM, Feldman AL, Maurer MJ, Dogan A, Perepu US, Syrbu S, Ansell SM, Thompson CA, Weiner GJ, Nowakowski GS, Allmer C, Slager SL, Witzig TE, Cerhan JR, Link BK. Outcomes among North American patients with diffuse large B-cell lymphoma are independent of tumor Epstein-Barr virus positivity or immunosuppression. Haematologica. 2018 Feb; 103 (2):297-303 Epub 2017 Nov 23
     View PubMed
162. Abeykoon JP, Paludo J, King RL, Ansell SM, Gertz MA, LaPlant BR, Halvorson AE, Gonsalves WI, Dingli D, Fang H, Rajkumar SV, Lacy MQ, He R, Kourelis T, Reeder CB, Novak AJ, McPhail ED, Viswanatha DS, Witzig TE, Go RS, Habermann TM, Buadi FK, Dispenzieri A, Leung N, Lin Y, Thompson CA, Hayman SR, Kyle RA, Kumar SK, Kapoor P. MYD88 mutation status does not impact overall survival in Waldenstrom macroglobulinemia. Am J Hematol. 2018 Feb; 93 (2):187-194 Epub 2017 Nov 17
     View PubMed
163. Ghesquieres H, Larrabee BR, Casasnovas O, Maurer MJ, McKay JD, Ansell SM, Montgomery D, Asmann YW, Farrell K, Verney A, Slager SL, Allmer C, Perrot A, Delarue R, Habermann TM, Dupuis J, Link BK, Canioni D, Dogan A, Cozen W, Jarrett RF, Cerhan JR, Salles G. A susceptibility locus for classical Hodgkin lymphoma at 8q24 near MYC/PVT1 predicts patient outcome in two independent cohorts. Br J Haematol 2018 Jan; 180 (2):286-290 Epub 2016 Sept 09
     View PubMed
164. Ghesquieres H, Larrabee BR, Haioun C, Link BK, Verney A, Slager SL, Ketterer N, Ansell SM, Delarue R, Maurer MJ, Fitoussi O, Habermann TM, Peyrade F, Dogan A, Molina TJ, Novak AJ, Tilly H, Cerhan JR, Salles G. FCGR3A/2A polymorphisms and diffuse large B-cell lymphoma outcome treated with immunochemotherapy: a meta-analysis on 1134 patients from two prospective cohorts. Hematol Oncol. 2017 Dec; 35 (4):447-455 Epub 2016 June 10
     View PubMed
165. Cerhan JR, Link BK, Habermann TM, Maurer MJ, Feldman AL, Syrbu SI, Thompson CA, Farooq U, Novak AJ, Slager SL, Allmer C, Lunde JJ, Macon WR, Inwards DJ, Johnston PB, Micallef INM, Nowakowski GS, Ansell SM, Kay NE, Weiner GJ, Witzig TE. Cohort Profile: The Lymphoma Specialized Program of Research Excellence (SPORE) Molecular Epidemiology Resource (MER) Cohort Study. Int J Epidemiol. 2017 Dec 1; 46 (6):1753-1754i
     View PubMed
166. Sargent DJ, Shi Q, Flowers CR, Schmitz N, Habermann TM, Flament J, Fu T, Coiffier B, SEAL group. The Search for Surrogate Endpoints in Trials in Diffuse Large B-Cell Lymphoma: The Surrogate Endpoints for Aggressive Lymphoma Project. Oncologist. 2017 Dec; 22 (12):1415-1418 Epub 2017 Aug 10
     View PubMed
167. Chang TW, Weaver AL, Shanafelt TD, Habermann TM, Wriston CC, Cerhan JR, Call TG, Brewer JD. Risk of cutaneous T-cell lymphoma in patients with chronic lymphocytic leukemia and other subtypes of non-Hodgkin lymphoma. Int J Dermatol. 2017 Nov; 56 (11):1125-1129 Epub 2017 July 07
     View PubMed
168. Witzig TE, Luigi Zinzani P, Habermann TM, Tuscano JM, Drach J, Ramchandren R, Kalayoglu Besisik S, Takeshita K, Casadebaig Bravo ML, Zhang L, Fu T, Goy A. Long-term analysis of phase II studies of single-agent lenalidomide in relapsed/refractory mantle cell lymphoma. Am J Hematol. 2017 Oct; 92 (10):E575-E583 Epub 2017 Aug 28
     View PubMed
169. Paludo J, Abeykoon JP, Kumar S, Shreders A, Ailawadhi S, Gertz MA, Kourelis T, King RL, Reeder CB, Leung N, Kyle RA, Buadi FK, Habermann TM, Dingli D, Witzig TE, Dispenzieri A, Lacy MQ, Go RS, Lin Y, Gonsalves WI, Warsame R, Lust JA, Rajkumar SV, Ansell SM, Kapoor P. Dexamethasone, rituximab and cyclophosphamide for relapsed and/or refractory and treatment-naive patients with Waldenstrom macroglobulinemia. Br J Haematol. 2017 Oct; 179 (1):98-105 Epub 2017 Aug 08
     View PubMed
170. Farooq U, Maurer MJ, Thompson CA, Thanarajasingam G, Inwards DJ, Micallef I, Macon W, Syrbu S, Lin T, Lin Y, Ansell SM, Nowakowski GS, Habermann TM, Cerhan JR, Link BK. Clinical heterogeneity of diffuse large B cell lymphoma following failure of front-line immunochemotherapy. Br J Haematol. 2017 Oct; 179 (1):50-60 Epub 2017 June 27
     View PubMed
171. Pham AQ, Broski SM, Habermann TM, Jevremovic D, Wiseman GA, Feldman AL, Maurer MJ, Ristow KM, Witzig TE. Accuracy of 18-F FDG PET/CT to detect bone marrow clearance in patients with peripheral T-cell lymphoma - tissue remains the issue. Leuk Lymphoma. 2017 Oct; 58 (10):2342-2348 Epub 2017 Mar 14
     View PubMed
172. Kapoor P, Ansell SM, Fonseca R, Chanan-Khan A, Kyle RA, Kumar SK, Mikhael JR, Witzig TE, Mauermann M, Dispenzieri A, Ailawadhi S, Stewart AK, Lacy MQ, Thompson CA, Buadi FK, Dingli D, Morice WG, Go RS, Jevremovic D, Sher T, King RL, Braggio E, Novak A, Roy V, Ketterling RP, Greipp PT, Grogan M, Micallef IN, Bergsagel PL, Colgan JP, Leung N, Gonsalves WI, Lin Y, Inwards DJ, Hayman SR, Nowakowski GS, Johnston PB, Russell SJ, Markovic SN, Zeldenrust SR, Hwa YL, Lust JA, Porrata LF, Habermann TM, Rajkumar SV, Gertz MA, Reeder CB. Diagnosis and Management of Waldenstrom Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines 2016. JAMA Oncol. 2017 Sep 1; 3 (9):1257-1265
     View PubMed
173. Tracy SI, Maurer MJ, Witzig TE, Drake MT, Ansell SM, Nowakowski GS, Thompson CA, Inwards DJ, Johnston PB, Micallef IN, Allmer C, Macon WR, Weiner GJ, Slager SL, Habermann TM, Link BK, Cerhan JR. Vitamin D insufficiency is associated with an increased risk of early clinical failure in follicular lymphoma. Blood Cancer J. 2017 Aug 25; 7 (8):e595
     View PubMed
174. Morrison VA, Weller EA, Habermann TM, Li S, Fisher RI, Cheson BD, Peterson BA. Patterns of growth factor usage and febrile neutropenia among older patients with diffuse large B-cell non-Hodgkin lymphoma treated with CHOP or R-CHOP: the Intergroup experience (CALGB 9793; ECOG-SWOG 4494). Leuk Lymphoma. 2017 Aug; 58 (8):1814-1822 Epub 2016 Dec 14
     View PubMed
175. Epperla N, Pham AQ, Burnette BL, Wiseman GA, Habermann TM, Macon WR, Ansell SM, Inwards DJ, Micallef IN, Johnston PB, Markovic SN, Porrata LF, Colgan JP, Ristow KM, Nowakowski GS, Witzig TE. Risk of histological transformation and therapy-related myelodysplasia/acute myeloid leukaemia in patients receiving radioimmunotherapy for follicular lymphoma. Br J Haematol. 2017 Aug; 178 (3):427-433 Epub 2017 May 03
     View PubMed
176. Larsen JT, Shanafelt TD, Leis JF, LaPlant B, Call T, Pettinger A, Hanson C, Erlichman C, Habermann TM, Reeder C, Nikcevich D, Bowen D, Conte M, Boysen J, Secreto C, Lesnick C, Tschumper R, Jelinek D, Kay NE, Ding W. Akt inhibitor MK-2206 in combination with bendamustine and rituximab in relapsed or refractory chronic lymphocytic leukemia: Results from the N1087 alliance study. Am J Hematol. 2017 Aug; 92 (8):759-763 Epub 2017 June 01
     View PubMed
177. Shenoy N, Bhagat T, Nieves E, Stenson M, Lawson J, Choudhary GS, Habermann T, Nowakowski G, Singh R, Wu X, Verma A, Witzig TE. Upregulation of TET activity with ascorbic acid induces epigenetic modulation of lymphoma cells. Blood Cancer J. 2017 Jul 21; 7 (7):e587 Epub 2017 July 21
     View PubMed
178. Ding W, LaPlant BR, Call TG, Parikh SA, Leis JF, He R, Shanafelt TD, Sinha S, Le-Rademacher J, Feldman AL, Habermann TM, Witzig TE, Wiseman GA, Lin Y, Asmus E, Nowakowski GS, Conte MJ, Bowen DA, Aitken CN, Van Dyke DL, Greipp PT, Liu X, Wu X, Zhang H, Secreto CR, Tian S, Braggio E, Wellik LE, Micallef I, Viswanatha DS, Yan H, Chanan-Khan AA, Kay NE, Dong H, Ansell SM. Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL. Blood. 2017 Jun 29; 129 (26):3419-3427 Epub 2017 Apr 19
     View PubMed
179. Witzig TE, LaPlant B, Habermann TM, McPhail E, Inwards DJ, Micallef IN, Colgan JP, Nowakowski GS, Ansell SM, Johnston PB. High rate of event-free survival at 24 months with everolimus/RCHOP for untreated diffuse large B-cell lymphoma: updated results from NCCTG N1085 (Alliance). Blood Cancer J 2017 Jun 23; 7 (6):e576 Epub 2017 June 23
     View PubMed
180. Vidal L, Gafter-Gvili A, Salles G, Bousseta S, Oberman B, Rubin C, van Oers MH, Fortpied C, Ghielmini M, Pettengell R, Witzens-Harig M, Dreger P, Vitolo U, Gomes da Silva M, Evangelista A, Li H, Freedman L, Habermann TM, Shpilberg O. Rituximab maintenance improves overall survival of patients with follicular lymphoma-Individual patient data meta-analysis. Eur J Cancer. 2017 May; 76:216-225 Epub 2017 Mar 21
     View PubMed
181. Bennani NN, LaPlant BR, Ansell SM, Habermann TM, Inwards DJ, Micallef IN, Johnston PB, Porrata LF, Colgan JP, Markovic SN, Nowakowski GS, Macon WR, Reeder CB, Mikhael JR, Northfelt DW, Ghobrial IM, Witzig TE. Efficacy of the oral mTORC1 inhibitor everolimus in relapsed or refractory indolent lymphoma. Am J Hematol. 2017 May; 92 (5):448-453 Epub 2017 Mar 10
     View PubMed
182. Rosenthal A, Dueck AC, Ansell S, Gano K, Conley C, Nowakowski GS, Camoriano J, Leis JF, Mikhael JR, Keith Stewart A, Stewart AK, Inwards D, Dingli D, Kumar S, Noel P, Gertz M, Porrata L, Russell S, Colgan J, Fonseca R, Habermann TM, Kapoor P, Buadi F, Leung N, Tiedemann R, Witzig TE, Reeder C. A phase 2 study of lenalidomide, rituximab, cyclophosphamide, and dexamethasone (LR-CD) for untreated low-grade non-Hodgkin lymphoma requiring therapy. Am J Hematol. 2017 May; 92 (5):467-472 Epub 2017 Mar 22
     View PubMed
183. Rossille D, Azzaoui I, Feldman AL, Maurer MJ, Laboure G, Parrens M, Pangault C, Habermann TM, Ansell SM, Link BK, Tarte K, Witzig TE, Lamy T, Slager SL, Roussel M, Milpied N, Cerhan JR, Fest T. Soluble programmed death-ligand 1 as a prognostic biomarker for overall survival in patients with diffuse large B-cell lymphoma: a replication study and combined analysis of 508 patients. Leukemia. 2017 Apr; 31 (4):988-991 Epub 2017 Jan 27
     View PubMed
184. Wierda WG, Zelenetz AD, Gordon LI, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Byrd JC, Caimi P, Fayad LE, Fisher RI, Glenn MJ, Habermann TM, Harris NL, Hernandez-Ilizaliturri F, Hoppe RT, Horwitz SM, Kaminski MS, Kelsey CR, Kim YH, Krivacic S, LaCasce AS, Martin MG, Nademanee A, Porcu P, Press O, Rabinovitch R, Reddy N, Reid E, Roberts K, Saad AA, Snyder ED, Sokol L, Swinnen LJ, Vose JM, Yahalom J, Dwyer MA, Sundar H. Nccn guidelines (r) insights chronic lymphocytic leukemia/small lymphocytic leukemia, version 1.2017 featured updates to the nccn guidelines Journal Of The National Comprehensive Cancer Network. 2017 Mar 1; 15: (3)293-311.
     
185. Wierda WG, Zelenetz AD, Gordon LI, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Byrd JC, Caimi P, Fayad LE, Fisher RI, Glenn MJ, Habermann TM, Harris NL, Hernandez-Ilizaliturri F, Hoppe RT, Horwitz SM, Kaminski MS, Kelsey CR, Kim YH, Krivacic S, LaCasce AS, Martin MG, Nademanee A, Porcu P, Press O, Rabinovitch R, Reddy N, Reid E, Roberts K, Saad AA, Snyder ED, Sokol L, Swinnen LJ, Vose JM, Yahalom J, Dwyer MA, Sundar H. NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 1.2017. J Natl Compr Canc Netw. 2017 Mar; 15 (3):293-311
     View PubMed
186. Sfeir JG, Drake MT, LaPlant BR, Maurer MJ, Link BK, Berndt TJ, Shanafelt TD, Cerhan JR, Habermann TM, Feldman AL, Witzig T. Validation of a vitamin D replacement strategy in vitamin D-insufficient patients with lymphoma or chronic lymphocytic leukemia. Blood Cancer J. 2017 Feb 3; 7 (2):e526 Epub 2017 Feb 03
     View PubMed
187. Bernatsky S, Velasquez Garcia HA, Spinelli JJ, Gaffney P, Smedby KE, Ramsey-Goldman R, Wang SS, Adami HO, Albanes D, Angelucci E, Ansell SM, Asmann YW, Becker N, Benavente Y, Berndt SI, Bertrand KA, Birmann BM, Boeing H, Boffetta P, Bracci PM, Brennan P, Brooks-Wilson AR, Cerhan JR, Chanock SJ, Clavel J, Conde L, Cotenbader KH, Cox DG, Cozen W, Crouch S, De Roos AJ, de Sanjose S, Di Lollo S, Diver WR, Dogan A, Foretova L, Ghesquieres H, Giles GG, Glimelius B, Habermann TM, Haioun C, Hartge P, Hjalgrim H, Holford TR, Holly EA, Jackson RD, Kaaks R, Kane E, Kelly RS, Klein RJ, Kraft P, Kricker A, Lan Q, Lawrence C, Liebow M, Lightfoot T, Link BK, Maynadie M, McKay J, Melbye M, Molina TJ, Monnereau A, Morton LM, Nieters A, North KE, Novak AJ, Offit K, Purdue MP, Rais M, Riby J, Roman E, Rothman N, Salles G, Severi G, Severson RK, Skibola CF, Slager SL, Smith A, Smith MT, Southey MC, Staines A, Teras LR, Thompson CA, Tilly H, Tinker LF, Tjonneland A, Turner J, Vajdic CM, Vermeulen RCH, Vijai J, Vineis P, Virtamo J, Wang Z, Weinstein S, Witzig TE, Zelenetz A, Zeleniuch-Jacquotte A, Zhang Y, Zheng T, Zucca M, Clarke AE. Lupus-related single nucleotide polymorphisms and risk of diffuse large B-cell lymphoma. Lupus Sci Med. 2017; 4 (1):e000187 Epub 2017 Nov 12
     View PubMed
188. Maurer M, Link Brian, Habermann TM, Thompson CA, Allmer Cristine, Johnston PB, Micallef IN, Inwards DJ, Farooq Umar, Macon WR, Syrbu Sergei, Feldman AL, Slager SL, Weiner George, Ansell SM, Cerhan JR, Witzig TE, Nowakowski GS. Time from Diagnosis to Initiation of Treatment of DLBCL and Implication for Potential Selection Bias in Clinical Trials Blood. December 2016; 128(22):3034.
     
189. Sammassimo S, Pruneri G, Andreola G, Montoro J, Steffanoni S, Nowakowski GS, Gandini S, Negri M, Habermann TM, Raderer M, Li ZM, Zinzani PL, Adam P, Zucca E, Martinelli G. A retrospective international study on primary extranodal marginal zone lymphoma of the lung (BALT lymphoma) on behalf of International Extranodal Lymphoma Study Group (IELSG). Hematol Oncol. 2016 Dec; 34 (4):177-183 Epub 2015 July 07
     View PubMed
190. Maurer MJ, Bachy E, Ghesquieres H, Ansell SM, Nowakowski GS, Thompson CA, Inwards DJ, Allmer C, Chassagne-Clement C, Nicolas-Virelizier E, Sebban C, Lebras L, Sarkozy C, Macon WR, Feldman AL, Syrbu SI, Traverse-Glehan A, Coiffier B, Slager SL, Weiner GJ, Witzig TE, Habermann TM, Salles G, Cerhan JR, Link BK. Early event status informs subsequent outcome in newly diagnosed follicular lymphoma. Am J Hematol. 2016 Nov; 91 (11):1096-1101 Epub 2016 Sept 03
     View PubMed
191. Barta SK, Li H, Hochster HS, Hong F, Weller E, Gascoyne RD, Habermann TM, Gordon LI, Colocci N, Bengtson EM, Horning SJ, Kahl BS. Randomized phase 3 study in low-grade lymphoma comparing maintenance anti-CD20 antibody with observation after induction therapy: A trial of the ECOG-ACRIN Cancer Research Group (E1496). Cancer. 2016 Oct; 122 (19):2996-3004 Epub 2016 June 28
     View PubMed
192. Horwitz SM, Zelenetz AD, Gordon LI, Wierda WG, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Byrd JC, Fayad LE, Fisher RI, Glenn MJ, Habermann TM, Lee Harris N, Hernandez-Ilizaliturri F, Hoppe RT, Kaminski MS, Kelsey CR, Kim YH, Krivacic S, LaCasce AS, Lunning M, Nademanee A, Press O, Rabinovitch R, Reddy N, Reid E, Roberts K, Saad AA, Sokol L, Swinnen LJ, Vose JM, Yahalom J, Zafar N, Dwyer M, Sundar H, Porcu P. NCCN Guidelines Insights: Non-Hodgkin's Lymphomas, Version 3.2016. J Natl Compr Canc Netw. 2016 Sep; 14 (9):1067-79
     View PubMed
193. Horwitz SM, Zelenetz AD, Gordon LI, Wierda WG, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Byrd JC, Fayad LE, Fisher RI, Glenn MJ, Habermann TM, Harris NL, Hernandez-Ilizaliturri F, Hoppe RT, Kaminski MS, Kelsey CR, Kim YH, Krivacic S, LaCasce AS, Lunning M, Nademanee A, Press O, Rabinovitch R, Reddy N, Reid E, Roberts K, Saad AA, Sokol L, Swinnen LJ, Vose JM, Yahalom J, Zafar N, Dwyer M, Sundar H, Porcu P. Non-Hodgkin's lymphomas, version 3.2016 featured updates to the nccn guidelines Journal Of The National Comprehensive Cancer Network. 2016 Sep; 14: (9)1067-79.
     
194. Sharma A, Jasim S, Reading CC, Ristow KM, Villasboas Bisneto JC, Habermann TM, Fatourechi V, Stan M. Clinical Presentation and Diagnostic Challenges of Thyroid Lymphoma: A Cohort Study. Thyroid. 2016 Aug; 26 (8):1061-7 Epub 2016 July 06
     View PubMed
195. Crump M, Leppä S, Fayad L, Lee JJ, Di Rocco A, Ogura M, Hagberg H, Schnell F, Rifkin R, Mackensen A, Offner F, Pinter-Brown L, Smith S, Tobinai K, Yeh SP, Hsi ED, Nguyen T, Shi P, Hahka-Kemppinen M, Thornton D, Lin B, Kahl B, Schmitz N, Savage KJ, Habermann T. Randomized, Double-Blind, Phase III Trial of Enzastaurin Versus Placebo in Patients Achieving Remission After First-Line Therapy for High-Risk Diffuse Large B-Cell Lymphoma. J Clin Oncol. 2016 Jul 20; 34(21):2484-92. Epub 2016 May 23.
     View PubMed
196. Johnston PB, LaPlant B, McPhail E, Habermann TM, Inwards DJ, Micallef IN, Colgan JP, Nowakowski GS, Ansell SM, Witzig TE. Everolimus combined with R-CHOP-21 for new, untreated, diffuse large B-cell lymphoma (NCCTG 1085 [Alliance]): safety and efficacy results of a phase 1 and feasibility trial. Lancet Haematol. 2016 Jul; 3 (7):e309-16 Epub 2016 June 05
     View PubMed
197. Williams ME, Hong F, Gascoyne RD, Wagner LI, Krauss JC, Habermann TM, Swinnen LJ, Schuster SJ, Peterson CG, Sborov MD, Martin SE, Weiss M, Ehmann WC, Horning SJ, Kahl BS. Rituximab extended schedule or retreatment trial for low tumour burden non-follicular indolent B-cell non-Hodgkin lymphomas: Eastern Cooperative Oncology Group Protocol E4402. Br J Haematol. 2016 Jun; 173 (6):867-75 Epub 2016 Mar 11
     View PubMed
198. Kenderian SS, Habermann TM, Macon WR, Ristow KM, Ansell SM, Colgan JP, Johnston PB, Inwards DJ, Markovic SN, Micallef IN, Thompson CA, Porrata LF, Martenson JA, Witzig TE, Nowakowski GS. Large B-cell transformation in nodular lymphocyte-predominant Hodgkin lymphoma: 40-year experience from a single institution. Blood. 2016 Apr 21; 127 (16):1960-6 Epub 2016 Feb 02
     View PubMed
199. Machiela MJ, Lan Q, Slager SL, Vermeulen RC, Teras LR, Camp NJ, Cerhan JR, Spinelli JJ, Wang SS, Nieters A, Vijai J, Yeager M, Wang Z, Ghesquieres H, McKay J, Conde L, de Bakker PI, Cox DG, Burdett L, Monnereau A, Flowers CR, De Roos AJ, Brooks-Wilson AR, Giles GG, Melbye M, Gu J, Jackson RD, Kane E, Purdue MP, Vajdic CM, Albanes D, Kelly RS, Zucca M, Bertrand KA, Zeleniuch-Jacquotte A, Lawrence C, Hutchinson A, Zhi D, Habermann TM, Link BK, Novak AJ, Dogan A, Asmann YW, Liebow M, Thompson CA, Ansell SM, Witzig TE, Tilly H, Haioun C, Molina TJ, Hjalgrim H, Glimelius B, Adami HO, Roos G, Bracci PM, Riby J, Smith MT, Holly EA, Cozen W, Hartge P, Morton LM, Severson RK, Tinker LF, North KE, Becker N, Benavente Y, Boffetta P, Brennan P, Foretova L, Maynadie M, Staines A, Lightfoot T, Crouch S, Smith A, Roman E, Diver WR, Offit K, Zelenetz A, Klein RJ, Villano DJ, Zheng T, Zhang Y, Holford TR, Turner J, Southey MC, Clavel J, Virtamo J, Weinstein S, Riboli E, Vineis P, Kaaks R, Boeing H, Tjonneland A, Angelucci E, Di Lollo S, Rais M, De Vivo I, Giovannucci E, Kraft P, Huang J, Ma B, Ye Y, Chiu BC, Liang L, Park JH, Chung CC, Weisenburger DD, Fraumeni JF Jr, Salles G, Glenn M, Cannon-Albright L, Curtin K, Wu X, Smedby KE, de Sanjose S, Skibola CF, Berndt SI, Birmann BM, Chanock SJ, Rothman N. Genetically predicted longer telomere length is associated with increased risk of B-cell lymphoma subtypes. Hum Mol Genet. 2016 Apr 15; 25 (8):1663-76 Epub 2016 Feb 09
     View PubMed
200. Zelenetz AD, Gordon LI, Wierda WG, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Byrd JC, Fayad LE, Fisher RI, Glenn MJ, Habermann TM, Harris NL, Lee Harris N, Hernandez-Ilizaliturri F, Hoppe RT, Horwitz SM, Kaminski MS, Kelsey CR, Kim YH, Krivacic S, LaCasce AS, Lunning M, Nademanee A, Porcu P, Press O, Rabinovitch R, Reddy N, Reid E, Roberts K, Saad AA, Sokol L, Swinnen LJ, Vose JM, Yahalom J, Zafar N, Dwyer M, Sundar H. Diffuse Large B-Cell Lymphoma Version 1.2016. J Natl Compr Canc Netw. 2016 Feb; 14: (2)196-231.
     View PubMed
201. Maurer MJ, Jais JP, Ghesquieres H, Witzig TE, Hong F, Haioun C, Thompson CA, Thieblemont C, Micallef IN, Porrata LF, Ribrag V, Nowakowski GS, Casasnovas O, Bologna S, Morschhauser F, Morrison VA, Peterson BA, Macon WR, Copie-Bergman C, Feldman AL, Syrbu SI, Kurtin PJ, Gascoyne RD, Li H, Allmer C, Kahl BS, Ansell SM, Slager SL, Link BK, Salles G, Habermann TM, Tilly H, Cerhan JR. Personalized risk prediction for event-free survival at 24 months in patients with diffuse large B-cell lymphoma. Am J Hematol. 2016 Feb; 91 (2):179-84 Epub 2015 Nov 26
     View PubMed
202. Leal AD, Thompson CA, Wang AH, Vierkant RA, Habermann TM, Ross JA, Mesa RA, Virnig BA, Cerhan JR. Hormonal and Reproductive Factors and Risk of Myeloproliferative Neoplasms in Postmenopausal Women. Cancer Epidemiol Biomarkers Prev. 2016 Jan; 25 (1):151-7 Epub 2015 Nov 12
     View PubMed
203. Gupta M, Stenson M, O'Byrne M, Maurer MJ, Habermann T, Cerhan JR, Weiner GW, Witzig TE. Comprehensive serum cytokine analysis identifies IL-1RA and soluble IL-2Ralpha as predictors of event-free survival in T-cell lymphoma. Ann Oncol. 2016 Jan; 27 (1):165-72 Epub 2015 Oct 20
     View PubMed
204. Batchelor TT, Thye LS, Habermann TM. Current Management Concepts: Primary Central Nervous System Lymphoma, Natural Killer T-Cell Lymphoma Nasal Type, and Post-transplant Lymphoproliferative Disorder. Am Soc Clin Oncol Educ Book. 2016; 35:e354-66
     View PubMed
205. Sampson JN, Wheeler WA, Yeager M, Panagiotou O, Wang Z, Berndt SI, Lan Q, Abnet CC, Amundadottir LT, Figueroa JD, Landi MT, Mirabello L, Savage SA, Taylor PR, De Vivo I, McGlynn KA, Purdue MP, Rajaraman P, Adami HO, Ahlbom A, Albanes D, Amary MF, An SJ, Andersson U, Andriole G Jr, Andrulis IL, Angelucci E, Ansell SM, Arici C, Armstrong BK, Arslan AA, Austin MA, Baris D, Barkauskas DA, Bassig BA, Becker N, Benavente Y, Benhamou S, Berg C, Van Den Berg D, Bernstein L, Bertrand KA, Birmann BM, Black A, Boeing H, Boffetta P, Boutron-Ruault MC, Bracci PM, Brinton L, Brooks-Wilson AR, Bueno-de-Mesquita HB, Burdett L, Buring J, Butler MA, Cai Q, Cancel-Tassin G, Canzian F, Carrato A, Carreon T, Carta A, Chan JK, Chang ET, Chang GC, Chang IS, Chang J, Chang-Claude J, Chen CJ, Chen CY, Chen C, Chen CH, Chen C, Chen H, Chen K, Chen KY, Chen KC, Chen Y, Chen YH, Chen YS, Chen YM, Chien LH, Chirlaque MD, Choi JE, Choi YY, Chow WH, Chung CC, Clavel J, Clavel-Chapelon F, Cocco P, Colt JS, Comperat E, Conde L, Connors JM, Conti D, Cortessis VK, Cotterchio M, Cozen W, Crouch S, Crous-Bou M, Cussenot O, Davis FG, Ding T, Diver WR, Dorronsoro M, Dossus L, Duell EJ, Ennas MG, Erickson RL, Feychting M, Flanagan AM, Foretova L, Fraumeni JF Jr, Freedman ND, Beane Freeman LE, Fuchs C, Gago-Dominguez M, Gallinger S, Gao YT, Gapstur SM, Garcia-Closas M, Garcia-Closas R, Gascoyne RD, Gastier-Foster J, Gaudet MM, Gaziano JM, Giffen C, Giles GG, Giovannucci E, Glimelius B, Goggins M, Gokgoz N, Goldstein AM, Gorlick R, Gross M, Grubb R 3rd, Gu J, Guan P, Gunter M, Guo H, Habermann TM, Haiman CA, Halai D, Hallmans G, Hassan M, Hattinger C, He Q, He X, Helzlsouer K, Henderson B, Henriksson R, Hjalgrim H, Hoffman-Bolton J, Hohensee C, Holford TR, Holly EA, Hong YC, Hoover RN, Horn-Ross PL, Hosain GM, Hosgood HD 3rd, Hsiao CF, Hu N, Hu W, Hu Z, Huang MS, Huerta JM, Hung JY, Hutchinson A, Inskip PD, Jackson RD, Jacobs EJ, Jenab M, Jeon HS, Ji BT, Jin G, Jin L, Johansen C, Johnson A, Jung YJ, Kaaks R, Kamineni A, Kane E, Kang CH, Karagas MR, Kelly RS, Khaw KT, Kim C, Kim HN, Kim JH, Kim JS, Kim YH, Kim YT, Kim YC, Kitahara CM, Klein AP, Klein RJ, Kogevinas M, Kohno T, Kolonel LN, Kooperberg C, Kricker A, Krogh V, Kunitoh H, Kurtz RC, Kweon SS, LaCroix A, Lawrence C, Lecanda F, Lee VH, Li D, Li H, Li J, Li YJ, Li Y, Liao LM, Liebow M, Lightfoot T, Lim WY, Lin CC, Lin D, Lindstrom S, Linet MS, Link BK, Liu C, Liu J, Liu L, Ljungberg B, Lloreta J, Di Lollo S, Lu D, Lund E, Malats N, Mannisto S, Le Marchand L, Marina N, Novak AJ, Oberg AL, et al, Park JY, Park KH, Petersen GM, Shanafelt TD, Shen H, Su J, Thompson CA, Wang C, Witzig TE, Wu G, Wu J, Yin Z, Yu H, Zhao X, Zhou B, Cerhan JR, Slager SL. Analysis of Heritability and Shared Heritability Based on Genome-Wide Association Studies for Thirteen Cancer Types. J Natl Cancer Inst. 2015 Dec; 107 (12):djv279 Epub 2015 Oct 12
     View PubMed
206. Ghesquieres H, Slager SL, Jardin F, Veron AS, Asmann YW, Maurer MJ, Fest T, Habermann TM, Bene MC, Novak AJ, Mareschal S, Haioun C, Lamy T, Ansell SM, Tilly H, Witzig TE, Weiner GJ, Feldman AL, Dogan A, Cunningham JM, Olswold CL, Molina TJ, Link BK, Milpied N, Cox DG, Salles GA, Cerhan JR. Genome-Wide Association Study of Event-Free Survival in Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy. J Clin Oncol. 2015 Nov 20; 33 (33):3930-7 Epub 2015 Oct 12
     View PubMed
207. Diefenbach CS, Li H, Hong F, Gordon LI, Fisher RI, Bartlett NL, Crump M, Gascoyne RD, Wagner H Jr, Stiff PJ, Cheson BD, Stewart DA, Kahl BS, Friedberg JW, Blum KA, Habermann TM, Tuscano JM, Hoppe RT, Horning SJ, Advani RH. Evaluation of the International Prognostic Score (IPS-7) and a Simpler Prognostic Score (IPS-3) for advanced Hodgkin lymphoma in the modern era. Br J Haematol. 2015 Nov; 171 (4):530-8 Epub 2015 Sept 07
     View PubMed
208. Jackson AE, Mian M, Kalpadakis C, Pangalis GA, Stathis A, Porro E, Conconi A, Cortelazzo S, Gaidano G, Lopez Guillermo A, Johnson PW, Martelli M, Martinelli G, Thieblemont C, McPhail ED, Copie-Bergman C, Pileri SA, Jack A, Campo E, Mazzucchelli L, Ristow K, Habermann TM, Cavalli F, Nowakowski GS, Zucca E. Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue of the Salivary Glands: A Multicenter, International Experience of 248 Patients (IELSG 41). Oncologist. 2015 Oct; 20 (10):1149-53 Epub 2015 Aug 12
     View PubMed
209. Al-Hamadani M, Habermann TM, Cerhan JR, Macon WR, Maurer MJ, Go RS. Non-Hodgkin lymphoma subtype distribution, geodemographic patterns, and survival in the US: A longitudinal analysis of the National Cancer Data Base from 1998 to 2011. Am J Hematol. 2015 Sep; 90 (9):790-5 Epub 2015 July 27
     View PubMed
210. Novak AJ, Asmann YW, Maurer MJ, Wang C, Slager SL, Hodge LS, Manske M, Price-Troska T, Yang ZZ, Zimmermann MT, Nowakowski GS, Ansell SM, Witzig TE, McPhail E, Ketterling R, Feldman AL, Dogan A, Link BK, Habermann TM, Cerhan JR. Whole-exome analysis reveals novel somatic genomic alterations associated with outcome in immunochemotherapy-treated diffuse large B-cell lymphoma. Blood Cancer J. 2015 Aug 28; 5:e346
     View PubMed
211. Wilson WH, Young RM, Schmitz R, Yang Y, Pittaluga S, Wright G, Lih CJ, Williams PM, Shaffer AL, Gerecitano J, de Vos S, Goy A, Kenkre VP, Barr PM, Blum KA, Shustov A, Advani R, Fowler NH, Vose JM, Elstrom RL, Habermann TM, Barrientos JC, McGreivy J, Fardis M, Chang BY, Clow F, Munneke B, Moussa D, Beaupre DM, Staudt LM. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nat Med. 2015 Aug; 21 (8):922-6 Epub 2015 July 20
     View PubMed
212. Witzig TE, Nowakowski GS, Habermann TM, Goy A, Hernandez-Ilizaliturri FJ, Chiappella A, Vitolo U, Fowler N, Czuczman MS. A comprehensive review of lenalidomide therapy for B-cell non-Hodgkin lymphoma. Ann Oncol. 2015 Aug; 26 (8):1667-77 Epub 2015 Feb 23
     View PubMed
213. Witzig TE, Reeder C, Han JJ, LaPlant B, Stenson M, Tun HW, Macon W, Ansell SM, Habermann TM, Inwards DJ, Micallef IN, Johnston PB, Porrata LF, Colgan JP, Markovic S, Nowakowski GS, Gupta M. The mTORC1 inhibitor everolimus has antitumor activity in vitro and produces tumor responses in patients with relapsed T-cell lymphoma. Blood. 2015 Jul 16; 126 (3):328-35 Epub 2015 Apr 28
     View PubMed
214. Swinnen LJ, Li H, Quon A, Gascoyne R, Hong F, Ranheim EA, Habermann TM, Kahl BS, Horning SJ, Advani RH. Response-adapted therapy for aggressive non-Hodgkin's lymphomas based on early [18F] FDG-PET scanning: ECOG-ACRIN Cancer Research Group study (E3404). Br J Haematol. 2015 Jul; 170 (1):56-65 Epub 2015 Mar 30
     View PubMed
215. Advani RH, Hong F, Fisher RI, Bartlett NL, Robinson KS, Gascoyne RD, Wagner H Jr, Stiff PJ, Cheson BD, Stewart DA, Gordon LI, Kahl BS, Friedberg JW, Blum KA, Habermann TM, Tuscano JM, Hoppe RT, Horning SJ. Randomized Phase III Trial Comparing ABVD Plus Radiotherapy With the Stanford V Regimen in Patients With Stages I or II Locally Extensive, Bulky Mediastinal Hodgkin Lymphoma: A Subset Analysis of the North American Intergroup E2496 Trial. J Clin Oncol. 2015 Jun 10; 33 (17):1936-42 Epub 2015 Apr 20
     View PubMed
216. Briski R, Feldman AL, Bailey NG, Lim MS, Ristow K, Habermann TM, Macon WR, Inwards DJ, Colgan JP, Nowakowski GS, Kaminski MS, Witzig TE, Ansell SM, Wilcox RA. Survival in patients with limited-stage peripheral t-cell lymphomas. Leuk Lymphoma. 2015 Jun; 56(6):1665-70.
     View PubMed
217. Balasubramaniam SC, Salomao DR, Davies JB, Ramsay RC, Habermann TM, Chow GK, Boorjian SA, Pulido JS. Paraneoplastic sarcoid-like reactions and the eye. Retina. 2015 Apr; 35 (4):789-97
     View PubMed
218. Parikh SA, Habermann TM, Chaffee KG, Call TG, Ding W, Leis JF, Macon WR, Schwager SM, Ristow KM, Porrata LF, Kay NE, Slager SL, Shanafelt TD. Hodgkin transformation of chronic lymphocytic leukemia: Incidence, outcomes, and comparison to de novo Hodgkin lymphoma. Am J Hematol. 2015 Apr; 90 (4):334-8 Epub 2015 Jan 30
     View PubMed
219. Wagner LI, Zhao F, Hong F, Williams ME, Gascoyne RD, Krauss JC, Advani RH, Go RS, Habermann TM, Leach JW, O'Connor B, Schuster SJ, Cella D, Horning SJ, Kahl BS. Anxiety and health-related quality of life among patients with low-tumor burden non-Hodgkin lymphoma randomly assigned to two different rituximab dosing regimens: results from ECOG trial E4402 (RESORT). J Clin Oncol. 2015 Mar 1; 33 (7):740-8 Epub 2015 Jan 20
     View PubMed
220. Mir MA, Maurer MJ, Ziesmer SC, Slager SL, Habermann T, Macon WR, Link BK, Syrbu S, Witzig T, Friedberg JW, Press O, LeBlanc M, Cerhan JR, Novak A, Ansell SM. Elevated serum levels of IL-2R, IL-1RA, and CXCL9 are associated with a poor prognosis in follicular lymphoma. Blood. 2015 Feb 5; 125 (6):992-8 Epub 2014 Nov 24
     View PubMed
221. Correia C, Schneider PA, Dai H, Dogan A, Maurer MJ, Church AK, Novak AJ, Feldman AL, Wu X, Ding H, Meng XW, Cerhan JR, Slager SL, Macon WR, Habermann TM, Karp JE, Gore SD, Kay NE, Jelinek DF, Witzig TE, Nowakowski GS, Kaufmann SH. BCL2 mutations are associated with increased risk of transformation and shortened survival in follicular lymphoma. Blood. 2015 Jan 22; 125(4):658-67. Epub 2014 Dec 01.
     View PubMed
222. Nowakowski GS, LaPlant B, Macon WR, Reeder CB, Foran JM, Nelson GD, Thompson CA, Rivera CE, Inwards DJ, Micallef IN, Johnston PB, Porrata LF, Ansell SM, Gascoyne RD, Habermann TM, Witzig TE. Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-Cell lymphoma: a phase II study. J Clin Oncol. 2015 Jan 20; 33 (3):251-7 Epub 2014 Aug 18
     View PubMed
223. Vijai J, Wang Z, Berndt SI, Skibola CF, Slager SL, de Sanjose S, Melbye M, Glimelius B, Bracci PM, Conde L, Birmann BM, Wang SS, Brooks-Wilson AR, Lan Q, de Bakker PI, Vermeulen RC, Portlock C, Ansell SM, Link BK, Riby J, North KE, Gu J, Hjalgrim H, Cozen W, Becker N, Teras LR, Spinelli JJ, Turner J, Zhang Y, Purdue MP, Giles GG, Kelly RS, Zeleniuch-Jacquotte A, Ennas MG, Monnereau A, Bertrand KA, Albanes D, Lightfoot T, Yeager M, Chung CC, Burdett L, Hutchinson A, Lawrence C, Montalvan R, Liang L, Huang J, Ma B, Villano DJ, Maria A, Corines M, Thomas T, Novak AJ, Dogan A, Liebow M, Thompson CA, Witzig TE, Habermann TM, Weiner GJ, Smith MT, Holly EA, Jackson RD, Tinker LF, Ye Y, Adami HO, Smedby KE, De Roos AJ, Hartge P, Morton LM, Severson RK, Benavente Y, Boffetta P, Brennan P, Foretova L, Maynadie M, McKay J, Staines A, Diver WR, Vajdic CM, Armstrong BK, Kricker A, Zheng T, Holford TR, Severi G, Vineis P, Ferri GM, Ricco R, Miligi L, Clavel J, Giovannucci E, Kraft P, Virtamo J, Smith A, Kane E, Roman E, Chiu BC, Fraumeni JF, Wu X, Cerhan JR, Offit K, Chanock SJ, Rothman N, Nieters A. A genome-wide association study of marginal zone lymphoma shows association to the HLA region. Nat Commun. 2015 Jan 8; 6:5751 Epub 2015 Jan 08
     View PubMed
224. Wudhikarn K, Smith BJ, Button AM, Habermann TM, Thompson CA, Rosenstein LJ, Syrbu SI, Weiner GJ, Cerhan JR, Link BK. Relationships between chemotherapy, chemotherapy dose intensity and outcomes of follicular lymphoma in the immunochemotherapy era: a report from the University of Iowa/Mayo Clinic Lymphoma Specialized Program of Research Excellence Molecular Epidemiology Resource. Leuk Lymphoma. 2015; 56 (8):2365-72 Epub 2015 Feb 09
     View PubMed
225. Zelenetz AD, Gordon LI, Wierda WG, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Byrd JC, Czuczman MS, Fayad LE, Fisher RI, Glenn MJ, Habermann TM, Harris NL, Hoppe RT, Horwitz SM, Kelsey CR, Kim YH, Krivacic S, LaCasce AS, Nademanee A, Porcu P, Press O, Rabinovitch R, Reddy N, Reid E, Saad AA, Sokol L, Swinnen LJ, Tsien C, Vose JM, Wilson L, Yahalom J, Zafar N, Dwyer M, Sundar H. Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 1.2015. J. Natl. Compr. Cancer Netw. 2015; 13(3):326-62.
     
226. Casper C, Teltsch DY, Robinson D Jr, Desrosiers MP, Rotella P, Dispenzieri A, Qi M, Habermann T, Reynolds MW. Clinical characteristics and healthcare utilization of patients with multicentric Castleman disease. Br J Haematol. 2015; 168(1):82-93.
     View PubMed
227. Rausch Osian S, Leal AD, Allmer C, Maurer MJ, Nowakowski G, Inwards DJ, Macon WR, Ehlers SL, Weiner GJ, Habermann TM, Cerhan JR, Thompson CA. Widespread use of complementary and alternative medicine among non-Hodgkin lymphoma survivors. Leuk Lymphoma. 2015; 56(2):434-9.
     View PubMed
228. Witzig TE, Maurer MJ, Habermann TM, Link BK, Micallef IN, Nowakowski GS, Ansell SM, Colgan JP, Inwards DJ, Porrata LF, Markovic SN, Johnston PB, Lin Y, Thompson C, Gupta M, Katzmann JA, Cerhan JR. Elevated monoclonal and polyclonal serum immunoglobulin free light chain as prognostic factors in B- and T-cell non-Hodgkin lymphoma. Am J Hematol. 2014 Dec; 89 (12):1116-20 Epub 2014 Sept 26
     View PubMed
229. Porrata LF, Ristow KM, Habermann TM, Witzig TE, Colgan JP, Inwards DJ, Ansell SM, Micallef IN, Johnston PB, Nowakowski G, Thompson CA, Markovic SN. Peripheral blood absolute lymphocyte/monocyte ratio during rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone treatment cycles predicts clinical outcomes in diffuse large B-cell lymphoma. Leuk Lymphoma. 2014 Dec; 55 (12):2728-38 Epub 2014 Mar 19
     View PubMed
230. Thompson CA, Ghesquieres H, Maurer MJ, Cerhan JR, Biron P, Ansell SM, Chassagne-Clement C, Inwards DJ, Gargi T, Johnston PB, Nicolas-Virelizier E, Macon WR, Peix M, Micallef IN, Sebban C, Nowakowski GS, Porrata LF, Weiner GJ, Witzig TE, Habermann TM, Link BK. Utility of routine post-therapy surveillance imaging in diffuse large B-cell lymphoma. J Clin Oncol. 2014 Nov 1; 32 (31):3506-12 Epub 2014 Sept 29
     View PubMed
231. Cerhan JR, Berndt SI, Vijai J, Ghesquieres H, McKay J, Wang SS, Wang Z, Yeager M, Conde L, de Bakker PI, Nieters A, Cox D, Burdett L, Monnereau A, Flowers CR, De Roos AJ, Brooks-Wilson AR, Lan Q, Severi G, Melbye M, Gu J, Jackson RD, Kane E, Teras LR, Purdue MP, Vajdic CM, Spinelli JJ, Giles GG, Albanes D, Kelly RS, Zucca M, Bertrand KA, Zeleniuch-Jacquotte A, Lawrence C, Hutchinson A, Zhi D, Habermann TM, Link BK, Novak AJ, Dogan A, Asmann YW, Liebow M, Thompson CA, Ansell SM, Witzig TE, Weiner GJ, Veron AS, Zelenika D, Tilly H, Haioun C, Molina TJ, Hjalgrim H, Glimelius B, Adami HO, Bracci PM, Riby J, Smith MT, Holly EA, Cozen W, Hartge P, Morton LM, Severson RK, Tinker LF, North KE, Becker N, Benavente Y, Boffetta P, Brennan P, Foretova L, Maynadie M, Staines A, Lightfoot T, Crouch S, Smith A, Roman E, Diver WR, Offit K, Zelenetz A, Klein RJ, Villano DJ, Zheng T, Zhang Y, Holford TR, Kricker A, Turner J, Southey MC, Clavel J, Virtamo J, Weinstein S, Riboli E, Vineis P, Kaaks R, Trichopoulos D, Vermeulen RC, Boeing H, Tjonneland A, Angelucci E, Di Lollo S, Rais M, Birmann BM, Laden F, Giovannucci E, Kraft P, Huang J, Ma B, Ye Y, Chiu BC, Sampson J, Liang L, Park JH, Chung CC, Weisenburger DD, Chatterjee N, Fraumeni JF Jr, Slager SL, Wu X, de Sanjose S, Smedby KE, Salles G, Skibola CF, Rothman N, Chanock SJ. Genome-wide association study identifies multiple susceptibility loci for diffuse large B cell lymphoma. Nat Genet. 2014 Nov; 46 (11):1233-8 Epub 2014 Sept 28
     View PubMed
232. Asmann YW, Maurer MJ, Wang C, Sarangi V, Ansell SM, Feldman AL, Nowakowski GS, Manske M, Price-Troska T, Yang ZZ, Slager SL, Habermann TM, Cerhan JR, Novak AJ. Genetic diversity of newly diagnosed follicular lymphoma. Blood Cancer J 2014 Oct 31; 4:e256
     View PubMed
233. Skibola CF, Berndt SI, Vijai J, Conde L, Wang Z, Yeager M, de Bakker PI, Birmann BM, Vajdic CM, Foo JN, Bracci PM, Vermeulen RC, Slager SL, de Sanjose S, Wang SS, Linet MS, Salles G, Lan Q, Severi G, Hjalgrim H, Lightfoot T, Melbye M, Gu J, Ghesquieres H, Link BK, Morton LM, Holly EA, Smith A, Tinker LF, Teras LR, Kricker A, Becker N, Purdue MP, Spinelli JJ, Zhang Y, Giles GG, Vineis P, Monnereau A, Bertrand KA, Albanes D, Zeleniuch-Jacquotte A, Gabbas A, Chung CC, Burdett L, Hutchinson A, Lawrence C, Montalvan R, Liang L, Huang J, Ma B, Liu J, Adami HO, Glimelius B, Ye Y, Nowakowski GS, Dogan A, Thompson CA, Habermann TM, Novak AJ, Liebow M, Witzig TE, Weiner GJ, Schenk M, Hartge P, De Roos AJ, Cozen W, Zhi D, Akers NK, Riby J, Smith MT, Lacher M, Villano DJ, Maria A, Roman E, Kane E, Jackson RD, North KE, Diver WR, Turner J, Armstrong BK, Benavente Y, Boffetta P, Brennan P, Foretova L, Maynadie M, Staines A, McKay J, Brooks-Wilson AR, Zheng T, Holford TR, Chamosa S, Kaaks R, Kelly RS, Ohlsson B, Travis RC, Weiderpass E, Clavel J, Giovannucci E, Kraft P, Virtamo J, Mazza P, Cocco P, Ennas MG, Chiu BC, Fraumeni JF Jr, Nieters A, Offit K, Wu X, Cerhan JR, Smedby KE, Chanock SJ, Rothman N. Genome-wide association study identifies five susceptibility loci for follicular lymphoma outside the HLA region. Am J Hum Genet. 2014 Oct 2; 95 (4):462-71
     View PubMed
234. Kahl BS, Hong F, Williams ME, Gascoyne RD, Wagner LI, Krauss JC, Habermann TM, Swinnen LJ, Schuster SJ, Peterson CG, Sborov MD, Martin SE, Weiss M, Ehmann WC, Horning SJ. Rituximab extended schedule or re-treatment trial for low-tumor burden follicular lymphoma: eastern cooperative oncology group protocol e4402. J Clin Oncol. 2014 Oct 1; 32 (28):3096-102 Epub 2014 Aug 25
     View PubMed
235. Jackson AE, Smeltzer JP, Habermann TM, Jones JM, Burnette B, Ristow K, Wiseman GA, Macon WR, Nowakowski GS, Witzig TE. The utility of restaging bone marrow biopsy in PET-negative patients with diffuse large B-cell lymphoma and baseline bone marrow involvement. Am J Hematol. 2014 Sep; 89 (9):865-7 Epub 2014 June 19
     View PubMed
236. Parrilla Castellar ER, Jaffe ES, Said JW, Swerdlow SH, Ketterling RP, Knudson RA, Sidhu JS, Hsi ED, Karikehalli S, Jiang L, Vasmatzis G, Gibson SE, Ondrejka S, Nicolae A, Grogg KL, Allmer C, Ristow KM, Wilson WH, Macon WR, Law ME, Cerhan JR, Habermann TM, Ansell SM, Dogan A, Maurer MJ, Feldman AL. ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes. Blood. 2014 Aug 28; 124(9):1473-80. Epub 2014 Jun 03.
     View PubMed
237. Morton LM, Slager SL, Cerhan JR, Wang SS, Vajdic CM, Skibola CF, Bracci PM, de Sanjose S, Smedby KE, Chiu BC, Zhang Y, Mbulaiteye SM, Monnereau A, Turner JJ, Clavel J, Adami HO, Chang ET, Glimelius B, Hjalgrim H, Melbye M, Crosignani P, di Lollo S, Miligi L, Nanni O, Ramazzotti V, Rodella S, Costantini AS, Stagnaro E, Tumino R, Vindigni C, Vineis P, Becker N, Benavente Y, Boffetta P, Brennan P, Cocco P, Foretova L, Maynadie M, Nieters A, Staines A, Colt JS, Cozen W, Davis S, de Roos AJ, Hartge P, Rothman N, Severson RK, Holly EA, Call TG, Feldman AL, Habermann TM, Liebow M, Blair A, Cantor KP, Kane EV, Lightfoot T, Roman E, Smith A, Brooks-Wilson A, Connors JM, Gascoyne RD, Spinelli JJ, Armstrong BK, Kricker A, Holford TR, Lan Q, Zheng T, Orsi L, Dal Maso L, Franceschi S, La Vecchia C, Negri E, Serraino D, Bernstein L, Levine A, Friedberg JW, Kelly JL, Berndt SI, Birmann BM, Clarke CA, Flowers CR, Foran JM, Kadin ME, Paltiel O, Weisenburger DD, Linet MS, Sampson JN. Etiologic heterogeneity among non-Hodgkin lymphoma subtypes: the InterLymph Non-Hodgkin Lymphoma Subtypes Project. J Natl Cancer Inst Monogr. 2014 Aug; 2014 (48):130-44
     View PubMed
238. Smedby KE, Sampson JN, Turner JJ, Slager SL, Maynadie M, Roman E, Habermann TM, Flowers CR, Berndt SI, Bracci PM, Hjalgrim H, Weisenburger DD, Morton LM. Medical history, lifestyle, family history, and occupational risk factors for mantle cell lymphoma: the InterLymph Non-Hodgkin Lymphoma Subtypes Project. J Natl Cancer Inst Monogr. 2014 Aug; 2014 (48):76-86
     View PubMed
239. Monnereau A, Slager SL, Hughes AM, Smith A, Glimelius B, Habermann TM, Berndt SI, Staines A, Norman AD, Cerhan JR, Sampson JN, Morton LM, Clavel J. Medical history, lifestyle, and occupational risk factors for hairy cell leukemia: the InterLymph Non-Hodgkin Lymphoma Subtypes Project. J Natl Cancer Inst Monogr. 2014 Aug; 2014 (48):115-24
     View PubMed
240. Cozen W, Timofeeva MN, Li D, Diepstra A, Hazelett D, Delahaye-Sourdeix M, Edlund CK, Franke L, Rostgaard K, Van Den Berg DJ, Cortessis VK, Smedby KE, Glaser SL, Westra HJ, Robison LL, Mack TM, Ghesquieres H, Hwang AE, Nieters A, de Sanjose S, Lightfoot T, Becker N, Maynadie M, Foretova L, Roman E, Benavente Y, Rand KA, Nathwani BN, Glimelius B, Staines A, Boffetta P, Link BK, Kiemeney L, Ansell SM, Bhatia S, Strong LC, Galan P, Vatten L, Habermann TM, Duell EJ, Lake A, Veenstra RN, Visser L, Liu Y, Urayama KY, Montgomery D, Gaborieau V, Weiss LM, Byrnes G, Lathrop M, Cocco P, Best T, Skol AD, Adami HO, Melbye M, Cerhan JR, Gallagher A, Taylor GM, Slager SL, Brennan P, Coetzee GA, Conti DV, Onel K, Jarrett RF, Hjalgrim H, van den Berg A, McKay JD. A meta-analysis of Hodgkin lymphoma reveals 19p13.3 TCF3 as a novel susceptibility locus. Nat Commun. 2014 Jun 12; 5:3856 Epub 2014 June 12
     View PubMed
241. Gustafson HL, Yao S, Goldman BH, Lee K, Spier CM, LeBlanc ML, Rimsza LM, Cerhan JR, Habermann TM, Link BK, Maurer MJ, Slager SL, Persky DO, Miller TP, Fisher RI, Ambrosone CB, Briehl MM. Genetic polymorphisms in oxidative stress-related genes are associated with outcomes following treatment for aggressive B-cell non-Hodgkin lymphoma. Am J Hematol. 2014 Jun; 89(6):639-45. Epub 2014 Apr 12.
     View PubMed
242. Briski R, Feldman AL, Bailey NG, Lim MS, Ristow K, Habermann TM, Macon WR, Inwards DJ, Colgan JP, Nowakowski GS, Kaminski MS, Witzig TE, Ansell SM, Wilcox RA. The role of front-line anthracycline-containing chemotherapy regimens in peripheral T-cell lymphomas. Blood Cancer J. 2014 May 30; 4:e214
     View PubMed
243. Wang T, Feldman AL, Wada DA, Lu Y, Polk A, Briski R, Ristow K, Habermann TM, Thomas D, Ziesmer SC, Wellik LE, Lanigan TM, Witzig TE, Pittelkow MR, Bailey NG, Hristov AC, Lim MS, Ansell SM, Wilcox RA. GATA-3 expression identifies a high-risk subset of PTCL, NOS with distinct molecular and clinical features. Blood. 2014 May 8; 123 (19):3007-15 Epub 2014 Feb 04
     View PubMed
244. Maurer MJ, Ghesquieres H, Jais JP, Witzig TE, Haioun C, Thompson CA, Delarue R, Micallef IN, Peyrade F, Macon WR, Jo Molina T, Ketterer N, Syrbu SI, Fitoussi O, Kurtin PJ, Allmer C, Nicolas-Virelizier E, Slager SL, Habermann TM, Link BK, Salles G, Tilly H, Cerhan JR. Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy. J Clin Oncol. 2014 Apr 1; 32 (10):1066-73 Epub 2014 Feb 18
     View PubMed
245. Robinson D Jr, Reynolds M, Casper C, Dispenzieri A, Vermeulen J, Payne K, Schramm J, Ristow K, Desrosiers MP, Yeomans K, Teltsch D, Swain R, Habermann TM, Rotella P, Van de Velde H. Clinical epidemiology and treatment patterns of patients with multicentric castleman disease: results from two us treatment centres. Br J Haematol. 2014 Apr; 165(1):39-48.
     View PubMed
246. Ganjoo K, Hong FX, Horning SJ, Gascoyne RD, Natkunam Y, Swinnen LJ, Habermann TM, Kahl BS, Advani RH. Bevacizumab and cyclosphosphamide, doxorubicin, vincristine and prednisone in combination for patients with peripheral t-cell or natural killer cell neoplasms: an eastern cooperative oncology group study (e2404). Leuk Lymphoma. 2014 Apr; 55(4):768-72.
     View PubMed
247. Leal AD, Thompson CA, Wang AH, Vierkant RA, Habermann TM, Ross JA, Mesa RA, Virnig BA, Cerhan JR. Anthropometric, medical history and lifestyle risk factors for myeloproliferative neoplasms in the Iowa Women's Health Study cohort. Int J Cancer. 2014 Apr 1; 134 (7):1741-50 Epub 2013 Oct 15
     View PubMed
248. Hong F, Habermann TM, Gordon LI, Hochster H, Gascoyne RD, Morrison VA, Fisher RI, Bartlett NL, Stiff PJ, Cheson BD, Crump M, Horning SJ, Kahl BS. The role of body mass index in survival outcome for lymphoma patients: US intergroup experience. Ann Oncol. 2014 Mar; 25 (3):669-674
     View PubMed
249. Brewer JD, Habermann TM, Shanafelt TD. Lymphoma-associated skin cancer: incidence, natural history, and clinical management. Int J Dermatol. 2014 Mar; 53 (3):267-74 Epub 2013 Dec 10
     View PubMed
250. Hong F, Habermann TM, Gordon LI, Hochster H, Gascoyne RD, Morrison VA, Fisher RI, Bartlett NL, Stiff PJ, Cheson BD, Crump M, Horning SJ, Kahl BS. The role of body mass index in survival outcome for lymphoma patients: US intergroup experience. Ann Oncol. 2014 Mar; 25 (3):669-674 Epub 2019 Dec 04
     View PubMed
251. Hosein PJ, Maragulia JC, Salzberg MP, Press OW, Habermann TM, Vose JM, Bast M, Advani RH, Tibshirani R, Evens AM, Islam N, Leonard JP, Martin P, Zelenetz AD, Lossos IS. A multicentre study of primary breast diffuse large B-cell lymphoma in the rituximab era. Br J Haematol. 2014; 165(3):358-63.
     View PubMed
252. Marri PR, Hodge LS, Maurer MJ, Ziesmer SC, Slager SL, Habermann TM, Link BK, Cerhan JR, Novak AJ, Ansell SM. Prognostic significance of pretreatment serum cytokines in classical Hodgkin lymphoma. Clin Cancer Res. 2013 Dec 15; 19 (24):6812-9 Epub 2013 Oct 18
     View PubMed
253. Taner T, Nagorney DM, Tefferi A, Habermann TM, Harmsen WS, Slettedahl SW, Donohue JH. Splenectomy for massive splenomegaly: long-term results and risks for mortality. Ann Surg. 2013 Dec; 258 (6):1034-9
     View PubMed
254. Porrata LF, Ristow Kay, Habermann TM, Witzig TE, Colgan JP, Inwards DJ, Ansell SM, Micallef IN, Johnston PB, Nowakowski GS, Thompson CA, Markovic SN. Peripheral Blood Absolute Lymphocyte/Monocyte Ratio Recovery During RCHOP Treatment Cycles Predicts Clinical Outcomes In Diffuse Large B-Cell Lymphoma Blood. 2013; 122(21):4306.
     
255. Evens AM, Advani R, Press OW, Lossos IS, Vose JM, Hernandez-Ilizaliturri FJ, Robinson BK, Otis S, Nadav Dagan L, Abdallah R, Kroll-Desrosiers A, Yarber JL, Sandoval J, Foyil K, Parker LM, Gordon LI, Blum KA, Flowers CR, Leonard JP, Habermann TM, Bartlett NL. Lymphoma occurring during pregnancy: antenatal therapy, complications, and maternal survival in a multicenter analysis. J Clin Oncol. 2013 Nov 10; 31 (32):4132-9 Epub 2013 Sept 16
     View PubMed
256. Ghesquieres H, Maurer MJ, Casasnovas O, Ansell SM, Larrabee BR, Lech-Maranda E, Novak AJ, Borrel AL, Slager SL, Brice P, Allmer C, Brion A, Ziesmer SC, Morschhauser F, Habermann TM, Gaillard I, Link BK, Stamatoullas A, Ferme C, Dogan A, Macon WR, Audouin J, Cerhan JR, Salles G. Cytokine gene polymorphisms and progression-free survival in classical Hodgkin lymphoma by EBV status: results from two independent cohorts. Cytokine. 2013 Nov; 64 (2):523-31 Epub 2013 Sept 03
     View PubMed
257. Ghesquieres H, Dogan A, Link BK, Maurer MJ, Cunningham JM, Novak AJ, Larrabee BR, Slager SL, Allmer C, Habermann TM, Ansell SM, Cerhan JR. FCGR2A and FCGR3A polymorphisms in classical Hodgkin lymphoma by Epstein-Barr virus status. Leuk Lymphoma 2013 Nov; 54 (11):2571-3 Epub 2013 June 03
     View PubMed
258. Link BK, Maurer MJ, Nowakowski GS, Ansell SM, Macon WR, Syrbu SI, Slager SL, Thompson CA, Inwards DJ, Johnston PB, Colgan JP, Witzig TE, Habermann TM, Cerhan JR. Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era: a report from the University of Iowa/MayoClinic Specialized Program of Research Excellence Molecular Epidemiology Resource. J Clin Oncol. 2013 Sep 10; 31 (26):3272-8 Epub 2013 July 29
     View PubMed
259. Vose JM, Habermann TM, Czuczman MS, Zinzani PL, Reeder CB, Tuscano JM, Lossos IS, Li J, Pietronigro D, Witzig TE. Single-agent lenalidomide is active in patients with relapsed or refractory aggressive non-Hodgkin lymphoma who received prior stem cell transplantation. Br J Haematol. 2013 Sep; 162(5):639-47. Epub 2013 Jul 09.
     View PubMed
260. Charbonneau B, Wang AH, Maurer MJ, Asmann YW, Zent CS, Link BK, Ansell SM, Weiner GJ, Ozsan N, Feldman AL, Witzig TE, Cunningham JM, Dogan A, Habermann TM, Slager SL, Novak AJ, Cerhan JR. CXCR5 polymorphisms in non-Hodgkin lymphoma risk and prognosis. Cancer Immunol Immunother. 2013 Sep; 62 (9):1475-84 Epub 2013 June 28
     View PubMed
261. Parikh SA, Rabe KG, Call TG, Zent CS, Habermann TM, Ding W, Leis JF, Schwager SM, Hanson CA, Macon WR, Kay NE, Slager SL, Shanafelt TD. Diffuse large B-cell lymphoma (Richter syndrome) in patients with chronic lymphocytic leukaemia (CLL): a cohort study of newly diagnosed patients. Br J Haematol. 2013 Sep; 162 (6):774-82 Epub 2013 July 11
     View PubMed
262. Vaidya R, Habermann TM, Donohue JH, Ristow KM, Maurer MJ, Macon WR, Colgan JP, Inwards DJ, Ansell SM, Porrata LF, Micallef IN, Johnston PB, Markovic SN, Thompson CA, Nowakowski GS, Witzig TE. Bowel perforation in intestinal lymphoma: incidence and clinical features. Ann Oncol. 2013 Sep; 24 (9):2439-43 Epub 2013 May 22
     View PubMed
263. Witzig TE, Wiseman GA, Maurer MJ, Habermann TM, Micallef IN, Nowakowski GS, Ansell SM, Colgan JP, Inwards DJ, Porrata LF, Link BK, Zent CS, Johnston PB, Shanafelt TD, Allmer C, Asmann YW, Gupta M, Ballas ZK, Smith BJ, Weiner GJ. A phase I trial of immunostimulatory CpG 7909 oligodeoxynucleotide and 90 yttrium ibritumomab tiuxetan radioimmunotherapy for relapsed B-cell non-Hodgkin lymphoma. Am J Hematol. 2013 Jul; 88 (7):589-93 Epub 2013 June 12
     View PubMed
264. Chen L, Monti S, Juszczynski P, Ouyang J, Chapuy B, Neuberg D, Doench JG, Bogusz AM, Habermann TM, Dogan A, Witzig TE, Kutok JL, Rodig SJ, Golub T, Shipp MA. SYK inhibition modulates distinct PI3K/AKT- dependent survival pathways and cholesterol biosynthesis in diffuse large B cell lymphomas. Cancer Cell. 2013 Jun 10; 23(6):826-38.
     View PubMed
265. Evens AM, Choquet S, Kroll-Desrosiers AR, Jagadeesh D, Smith SM, Morschhauser F, Leblond V, Roy R, Barton B, Gordon LI, Gandhi MK, Dierickx D, Schiff D, Habermann TM, Trappe R. Primary CNS posttransplant lymphoproliferative disease (PTLD): an international report of 84 cases in the modern era. Am J Transplant. 2013 Jun; 13(6):1512-22.
     View PubMed
266. Charbonneau B, O'Connor HM, Wang AH, Liebow M, Thompson CA, Fredericksen ZS, Macon WR, Slager SL, Call TG, Habermann TM, Cerhan JR. Trans fatty acid intake is associated with increased risk and n3 fatty acid intake with reduced risk of non-hodgkin lymphoma. J Nutr. 2013 May; 143 (5):672-81 Epub 2013 Mar 13
     View PubMed
267. Porrata LF, Ristow KM, Habermann TM, Macon WR, Witzig TE, Colgan JP, Inwards DJ, Ansell SM, Micallef IN, Johnston PB, Nowakowski G, Thompson CA, Markovic SN. Peripheral blood absolute lymphocyte/monocyte ratio recovery during ABVD treatment cycles predicts clinical outcomes in classical Hodgkin lymphoma. Blood Cancer J. 2013 Apr 19; 3:e110
     View PubMed
268. Gordon LI, Hong F, Fisher RI, Bartlett NL, Connors JM, Gascoyne RD, Wagner H, Stiff PJ, Cheson BD, Gospodarowicz M, Advani R, Kahl BS, Friedberg JW, Blum KA, Habermann TM, Tuscano JM, Hoppe RT, Horning SJ. Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496). J Clin Oncol. 2013 Feb 20; 31(6):684-91. Epub 2012 Nov 26.
     View PubMed
269. Yost KJ, Thompson CA, Eton DT, Allmer C, Ehlers SL, Habermann TM, Shanafelt TD, Maurer MJ, Slager SL, Link BK, Cerhan JR. The Functional Assessment of Cancer Therapy - General (FACT-G) is valid for monitoring quality of life in patients with non-Hodgkin lymphoma. Leuk Lymphoma. 2013 Feb; 54 (2):290-7 Epub 2012 Sept 06
     View PubMed
270. Iqbal S, DePew ZS, Kurtin PJ, Sykes AM, Johnson GB, Edell ES, Habermann TM, Maldonado F. Endobronchial ultrasound and lymphoproliferative disorders: a retrospective study. Ann Thorac Surg. 2012 Dec; 94: (6)1830-4.
     View PubMed
271. Kelly JL, Fredericksen ZS, Liebow M, Shanafelt TD, Thompson CA, Call TG, Habermann TM, Macon WR, Wang AH, Slager SL, Cerhan JR. The association between early life and adult body mass index and physical activity with risk of non-Hodgkin lymphoma: impact of gender. Ann Epidemiol. 2012 Dec; 22 (12):855-62 Epub 2012 Nov 10
     View PubMed
272. Charbonneau B, Maurer MJ, Ansell SM, Slager SL, Fredericksen ZS, Ziesmer SC, Macon WR, Habermann TM, Witzig TE, Link BK, Cerhan JR, Novak AJ. Pretreatment circulating serum cytokines associated with follicular and diffuse large B-cell lymphoma: a clinic-based case-control study. Cytokine. 2012 Dec; 60 (3):882-9 Epub 2012 Sept 23
     View PubMed
273. Porrata LF, Ristow K, Habermann TM, Ozsan N, Dogan A, Macon W, Colgan JP, Witzig TE, Inwards DJ, Ansell SM, Micallef IN, Johnston PB, Nowakowski GS, Thompson C, Markovic SN. Absolute monocyte/lymphocyte count prognostic score is independent of immunohistochemically determined cell of origin in predicting survival in diffuse large B-cell lymphoma. Leuk Lymphoma. 2012 Nov; 53 (11):2159-65 Epub 2012 May 21
     View PubMed
274. Dispenzieri A, Armitage JO, Loe MJ, Geyer SM, Allred J, Camoriano JK, Menke DM, Weisenburger DD, Ristow K, Dogan A, Habermann TM. The clinical spectrum of Castleman's disease. Am J Hematol. 2012 Nov; 87 (11):997-1002 Epub 2012 July 13
     View PubMed
275. Cerhan JR, Fredericksen ZS, Novak AJ, Ansell SM, Kay NE, Liebow M, Dogan A, Cunningham JM, Wang AH, Witzig TE, Habermann TM, Asmann YW, Slager SL. A two-stage evaluation of genetic variation in immune and inflammation genes with risk of non-Hodgkin lymphoma identifies new susceptibility locus in 6p21.3 region. Cancer Epidemiol Biomarkers Prev. 2012 Oct; 21 (10):1799-806 Epub 2012 Aug 21
     View PubMed
276. Monti S, Chapuy B, Takeyama K, Rodig SJ, Hao Y, Yeda KT, Inguilizian H, Mermel C, Currie T, Dogan A, Kutok JL, Beroukhim R, Neuberg D, Habermann TM, Getz G, Kung AL, Golub TR, Shipp MA. Integrative analysis reveals an outcome-associated and targetable pattern of p53 and cell cycle deregulation in diffuse large B cell lymphoma. Cancer Cell. 2012 Sep 11; 22(3):359-72.
     View PubMed
277. Holtan SG, O'Connor HM, Fredericksen ZS, Liebow M, Thompson CA, Macon WR, Micallef IN, Wang AH, Slager SL, Habermann TM, Call TG, Cerhan JR. Food-frequency questionnaire-based estimates of total antioxidant capacity and risk of non-Hodgkin lymphoma. Int J Cancer. 2012 Sep 1; 131 (5):1158-68 Epub 2011 Nov 30
     View PubMed
278. Ansell SM, Maurer MJ, Ziesmer SC, Slager SL, Habermann TM, Link BK, Witzig TE, Macon WR, Dogan A, Cerhan JR, Novak AJ. Elevated pretreatment serum levels of interferon-inducible protein-10 (CXCL10) predict disease relapse and prognosis in diffuse large B-cell lymphoma patients. Am J Hematol. 2012 Sep; 87 (9):865-9 Epub 2012 June 03
     View PubMed
279. Charbonneau B, Maurer MJ, Fredericksen ZS, Zent CS, Link BK, Novak AJ, Ansell SM, Weiner GJ, Wang AH, Witzig TE, Dogan A, Slager SL, Habermann TM, Cerhan JR. Germline variation in complement genes and event-free survival in follicular and diffuse large B-cell lymphoma. Am J Hematol. 2012 Sep; 87 (9):880-5 Epub 2012 June 20
     View PubMed
280. Smeltzer JP, Viswanatha DS, Habermann TM, Patnaik MM. Secondary Epstein-Barr virus associated lymphoproliferative disorder developing in a patient with angioimmunoblastic T cell lymphoma on vorinostat. Am J Hematol. 2012 Sep; 87 (9):927-8 Epub 2012 June 20
     View PubMed
281. Gibson TM, Wang SS, Cerhan JR, Maurer MJ, Hartge P, Habermann TM, Davis S, Cozen W, Lynch CF, Severson RK, Rothman N, Chanock SJ, Morton LM. Inherited genetic variation and overall survival following follicular lymphoma. Am J Hematol. 2012 Jul; 87(7):724-6. Epub 2012 Mar 31.
     View PubMed
282. Kelly JL, Drake MT, Fredericksen ZS, Asmann YW, Liebow M, Shanafelt TD, Feldman AL, Ansell SM, Macon WR, Herr MM, Wang AH, Nowakowski GS, Call TG, Habermann TM, Slager SL, Witzig TE, Cerhan JR. Early life sun exposure, vitamin D-related gene variants, and risk of non-Hodgkin lymphoma. Cancer Causes Control. 2012 Jul; 23: (7)1017-29.
     View PubMed
283. Wiernik PH, Li H, Weller E, Hochster HS, Horning SJ, Nazeer T, Gordon LI, Habermann TM, Minniti CJ, Shapiro GR, Cassileth PA. Activity of topotecan 21-day infusion in patients with previously treated large cell lymphoma: long-term follow-up of an Eastern Cooperative Oncology Group study (E5493). Leuk Lymphoma. 2012 Jun; 53(6):1137-42. Epub 2012 Jan 11.
     View PubMed
284. Cerhan JR, Natkunam Y, Morton LM, Maurer MJ, Asmann Y, Habermann TM, Vasef MA, Cozen W, Lynch CF, Allmer C, Slager SL, Lossos IS, Chanock SJ, Rothman N, Hartge P, Dogan A, Wang SS. LIM domain only 2 protein expression, LMO2 germline genetic variation, and overall survival in diffuse large B-cell lymphoma in the pre-rituximab era. Leuk Lymphoma. 2012 Jun; 53 (6):1105-12 Epub 2012 Jan 03
     View PubMed
285. Eggers SD, Pittock SJ, Shepard NT, Habermann TM, Neff BA, Klebig RR. Positional periodic alternating vertical nystagmus with PCA-Tr antibodies in Hodgkin lymphoma. Neurology. 2012 May 29; 78 (22):1800-2 Epub 2012 May 16
     View PubMed
286. Kasamon YL, Jacene HA, Gocke CD, Swinnen LJ, Gladstone DE, Perkins B, Link BK, Popplewell LL, Habermann TM, Herman JM, Matsui WH, Jones RJ, Ambinder RF. Phase 2 study of rituximab-ABVD in classical Hodgkin lymphoma. Blood. 2012 May 3; 119(18):4129-32. Epub 2012 Feb 16.
     View PubMed
287. Porrata LF, Ristow K, Habermann TM, Witzig TE, Colgan JP, Inwards DJ, Ansell SM, Micallef IN, Johnston PB, Nowakowski GS, Thompson C, Markovic SN. Peripheral blood lymphocyte/monocyte ratio at diagnosis and survival in nodular lymphocyte-predominant Hodgkin lymphoma. Br J Haematol. 2012 May; 157(3):321-30. Epub 2012 Feb 24.
     View PubMed
288. Flanagan EP, O'Neill BP, Habermann TM, Porter AB, Keegan BM. Secondary intramedullary spinal cord non-Hodgkin's lymphoma. J Neurooncol. 2012 May; 107 (3):575-80 Epub 2011 Dec 22
     View PubMed
289. Habermann TM. New developments in the management of diffuse large B-cell lymphoma. Hematology. 2012 Apr; 17 Suppl 1:S93-7
     View PubMed
290. Wilcox RA, Ristow K, Habermann TM, Inwards DJ, Micallef IN, Johnston PB, Colgan JP, Nowakowski GS, Ansell SM, Witzig TE, Markovic SN, Porrata L. The absolute monocyte count is associated with overall survival in patients newly diagnosed with follicular lymphoma. Leuk Lymphoma. 2012 Apr; 53: (4)575-80.
     View PubMed
291. Lohr JG, Stojanov P, Lawrence MS, Auclair D, Chapuy B, Sougnez C, Cruz-Gordillo P, Knoechel B, Asmann YW, Slager SL, Novak AJ, Dogan A, Ansell SM, Link BK, Zou L, Gould J, Saksena G, Stransky N, Rangel-Escareno C, Fernandez-Lopez JC, Hidalgo-Miranda A, Melendez-Zajgla J, Hernandez-Lemus E, Schwarz-Cruz y, Imaz-Rosshandler I, Ojesina AI, Jung J, Pedamallu CS, Lander ES, Habermann TM, Cerhan JR, Shipp MA, Getz G, Golub TR. Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. Proc Natl Acad Sci U S A. 2012 Mar 6; 109(10):3879-84. Epub 2012 Feb 17.
     View PubMed
292. Porrata LF, Ristow K, Colgan JP, Habermann TM, Witzig TE, Inwards DJ, Ansell SM, Micallef IN, Johnston PB, Nowakowski GS, Thompson C, Markovic SN. Peripheral blood lymphocyte/monocyte ratio at diagnosis and survival in classical Hodgkin's lymphoma. Haematologica. 2012 Feb; 97 (2):262-9 Epub 2011 Oct 11
     View PubMed
293. Cozen W, Li D, Best T, Van Den, Gourraud PA, Cortessis VK, Skol AD, Mack TM, Glaser SL, Weiss LM, Nathwani BN, Bhatia S, Schumacher FR, Edlund CK, Hwang AE, Slager SL, Fredericksen ZS, Strong LC, Habermann TM, Link BK, Cerhan JR, Robison LL, Conti DV, Onel K. A genome-wide meta-analysis of nodular sclerosing Hodgkin lymphoma identifies risk loci at 6p21.32. Blood. 2012 Jan 12; 119(2):469-75. Epub 2011 Nov 15.
     View PubMed
294. Naina HV, Harris S, Dispenzieri A, Cosio FG, Habermann TM, Stegall MD, Dean PG, Prieto M, Kyle RA, Rajkumar SV, Leung N. Long-term follow-up of patients with monoclonal gammopathy of undetermined significance after kidney transplantation. Am J Nephrol. 2012; 35(4):365-71. Epub 2012 Apr 02.
     View PubMed
295. Thompson CA, Maurer MJ, Cerhan JR, Katzmann JA, Ansell SM, Habermann TM, Macon WR, Weiner GJ, Link BK, Witzig TE. Elevated serum free light chains are associated with inferior event free and overall survival in Hodgkin lymphoma. Am J Hematol. 2011 Dec; 86 (12):998-1000 Epub 2011 Oct 17
     View PubMed
296. Nowakowski GS, LaPlant B, Habermann TM, Rivera CE, Macon WR, Inwards DJ, Micallef IN, Johnston PB, Porrata LF, Ansell SM, Klebig RR, Reeder CB, Witzig TE. Lenalidomide can be safely combined with R-CHOP (R2CHOP) in the initial chemotherapy for aggressive B-cell lymphomas: phase I study. Leukemia. 2011 Dec; 25 (12):1877-81 Epub 2011 July 01
     View PubMed
297. Witzig TE, Tang H, Micallef IN, Ansell SM, Link BK, Inwards DJ, Porrata LF, Johnston PB, Colgan JP, Markovic SN, Nowakowski GS, Thompson CA, Allmer C, Maurer MJ, Gupta M, Weiner G, Hohl R, Kurtin PJ, Ding H, Loegering D, Schneider P, Peterson K, Habermann TM, Kaufmann SH. Multi-institutional phase 2 study of the farnesyltransferase inhibitor tipifarnib (R115777) in patients with relapsed and refractory lymphomas. Blood. 2011 Nov 3; 118 (18):4882-9 Epub 2011 July 01
     View PubMed
298. Micallef IN, Maurer MJ, Wiseman GA, Nikcevich DA, Kurtin PJ, Cannon MW, Perez DG, Soori GS, Link BK, Habermann TM, Witzig TE. Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diffuse large B-cell lymphoma. Blood. 2011 Oct 13; 118 (15):4053-61 Epub 2011 June 14
     View PubMed
299. Laack NN, O'Neill BP, Ballman KV, O'Fallon JR, Carrero XW, Kurtin PJ, Scheithauer BW, Brown PD, Habermann TM, Colgan JP, Gilbert MR, Hawkins RB, Morton RF, Windschitl HE, Fitch TR, Pajon ER Jr, North Central Cancer Treatment Group and Mayo Clinic. CHOD/BVAM chemotherapy and whole-brain radiotherapy for newly diagnosed primary central nervous system lymphoma. Int J Radiat Oncol Biol Phys. 2011 Oct 1; 81 (2):476-82 Epub 2010 Aug 26
     View PubMed
300. Wilcox RA, Ristow K, Habermann TM, Inwards DJ, Micallef IN, Johnston PB, Colgan JP, Nowakowski GS, Ansell SM, Witzig TE, Markovic SN, Porrata L. The absolute monocyte and lymphocyte prognostic score predicts survival and identifies high-risk patients in diffuse large-B-cell lymphoma. Leukemia. 2011 Sep; 25 (9):1502-9 Epub 2011 May 24
     View PubMed
301. Habermann TM, Rai K. Historical treatments of in hairy cell leukemia, splenectomy and interferon: past and current uses. Leuk Lymphoma. 2011 Jun; 52 Suppl 2:18-20
     View PubMed
302. Maurer MJ, Micallef IN, Cerhan JR, Katzmann JA, Link BK, Colgan JP, Habermann TM, Inwards DJ, Markovic SN, Ansell SM, Porrata LF, Johnston PB, Nowakowski GS, Thompson CA, Gupta M, Syrbu SI, Kurtin PJ, Macon WR, Nikcevich DA, Witzig TE. Elevated serum free light chains are associated with event-free and overall survival in two independent cohorts of patients with diffuse large B-cell lymphoma. J Clin Oncol. 2011 Apr 20; 29 (12):1620-6 Epub 2011 Mar 07
     View PubMed
303. Smedby KE, Foo JN, Skibola CF, Darabi H, Conde L, Hjalgrim H, Kumar V, Chang ET, Rothman N, Cerhan JR, Brooks-Wilson AR, Rehnberg E, Irwan ID, Ryder LP, Brown PN, Bracci PM, Agana L, Riby J, Cozen W, Davis S, Hartge P, Morton LM, Severson RK, Wang SS, Slager SL, Fredericksen ZS, Novak AJ, Kay NE, Habermann TM, Armstrong B, Kricker A, Milliken S, Purdue MP, Vajdic CM, Boyle P, Lan Q, Zahm SH, Zhang Y, Zheng T, Leach S, Spinelli JJ, Smith MT, Chanock SJ, Padyukov L, Alfredsson L, Klareskog L, Glimelius B, Melbye M, Liu ET, Adami HO, Humphreys K, Liu J. GWAS of follicular lymphoma reveals allelic heterogeneity at 6p21.32 and suggests shared genetic susceptibility with diffuse large B-cell lymphoma. PLoS Genet. 2011 Apr; 7(4):e1001378. Epub 2011 Apr 21.
     View PubMed
304. Witzig TE, Reeder CB, LaPlant BR, Gupta M, Johnston PB, Micallef IN, Porrata LF, Ansell SM, Colgan JP, Jacobsen ED, Ghobrial IM, Habermann TM. A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma. Leukemia. 2011 Feb; 25 (2):341-7 Epub 2010 Dec 07
     View PubMed
305. Cerhan JR, Fredericksen ZS, Wang AH, Habermann TM, Kay NE, Macon WR, Cunningham JM, Shanafelt TD, Ansell SM, Call TG, Witzig TE, Slager SL, Liebow M. Design and validity of a clinic-based case-control study on the molecular epidemiology of lymphoma. Int J Mol Epidemiol Genet. 2011; 2(2):95-113. Epub 2011 Apr 05.
     View PubMed
306. Halfdanarson TR, Rubio-Tapia A, Ristow KM, Habermann TM, Murray JA, Inwards DJ. Patients with celiac disease and B-cell lymphoma have a better prognosis than those with T-cell lymphoma. Clin Gastroenterol Hepatol. 2010 Dec; 8 (12):1042-7 Epub 2010 Sept 17
     View PubMed
307. Kelly JL, Novak AJ, Fredericksen ZS, Liebow M, Ansell SM, Dogan A, Wang AH, Witzig TE, Call TG, Kay NE, Habermann TM, Slager SL, Cerhan JR. Germline variation in apoptosis pathway genes and risk of non-Hodgkin's lymphoma. Cancer Epidemiol Biomarkers Prev. 2010 Nov; 19(11):2847-58. Epub 2010 Sep 20.
     View PubMed
308. Porrata LF, Ristow K, Habermann T, Inwards DJ, Micallef IN, Markovic SN. Predicting survival for diffuse large B-cell lymphoma patients using baseline neutrophil/lymphocyte ratio. Am J Hematol. 2010 Nov; 85 (11):896-9
     View PubMed
309. Advani RH, Chen H, Habermann TM, Morrison VA, Weller EA, Fisher RI, Peterson BA, Gascoyne RD, Horning SJ. Comparison of conventional prognostic indices in patients older than 60 years with diffuse large B-cell lymphoma treated with R-CHOP in the US Intergroup Study (ECOG 4494, CALGB 9793): consideration of age greater than 70 years in an elderly prognostic index (E-IPI). Br J Haematol. 2010 Oct; 151(2):143-51.
     View PubMed
310. Drake MT, Maurer MJ, Link BK, Habermann TM, Ansell SM, Micallef IN, Kelly JL, Macon WR, Nowakowski GS, Inwards DJ, Johnston PB, Singh RJ, Allmer C, Slager SL, Weiner GJ, Witzig TE, Cerhan JR. Vitamin D insufficiency and prognosis in non-Hodgkin's lymphoma. J Clin Oncol. 2010 Sep 20; 28 (27):4191-8 Epub 2010 Aug 16
     View PubMed
311. Ansell SM, Kyle RA, Reeder CB, Fonseca R, Mikhael JR, Morice WG, Bergsagel PL, Buadi FK, Colgan JP, Dingli D, Dispenzieri A, Greipp PR, Habermann TM, Hayman SR, Inwards DJ, Johnston PB, Kumar SK, Lacy MQ, Lust JA, Markovic SN, Micallef IN, Nowakowski GS, Porrata LF, Roy V, Russell SJ, Short KE, Stewart AK, Thompson CA, Witzig TE, Zeldenrust SR, Dalton RJ, Rajkumar SV, Gertz MA. Diagnosis and management of Waldenstrom macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines. Mayo Clin Proc. 2010 Sep; 85 (9):824-33 Epub 2010 Aug 11
     View PubMed
312. Porrata LF, Rsitow K, Inwards DJ, Ansell SM, Micallef IN, Johnston PB, Habermann TM, Witzig TE, Colgan JP, Nowakowski GS, Thompson CA, Markovic SN. Lymphopenia assessed during routine follow-up after immunochemotherapy (R-CHOP) is a risk factor for predicting relapse in patients with diffuse large B-cell lymphoma. Leukemia. 2010 Jul; 24 (7):1343-9 Epub 2010 May 20
     View PubMed
313. Geyer SM, Morton LM, Habermann TM, Allmer C, Davis S, Cozen W, Severson RK, Lynch CF, Wang SS, Maurer MJ, Hartge P, Cerhan JR. Smoking, alcohol use, obesity, and overall survival from non-Hodgkin lymphoma: a population-based study. Cancer. 2010 Jun 15; 116 (12):2993-3000
     View PubMed
314. Zent CS, LaPlant BR, Johnston PB, Call TG, Habermann TM, Micallef IN, Witzig TE. The treatment of recurrent/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL) with everolimus results in clinical responses and mobilization of CLL cells into the circulation. Cancer. 2010 May 1; 116 (9):2201-7
     View PubMed
315. Johnston PB, Inwards DJ, Colgan JP, Laplant BR, Kabat BF, Habermann TM, Micallef IN, Porrata LF, Ansell SM, Reeder CB, Roy V, Witzig TE. A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma. Am J Hematol. 2010 May; 85 (5):320-4
     View PubMed
316. Winter JN, Li S, Aurora V, Variakojis D, Nelson B, Krajewska M, Zhang L, Habermann TM, Fisher RI, Macon WR, Chhanabhai M, Felgar RE, Hsi ED, Medeiros LJ, Weick JK, Weller EA, Melnick A, Reed JC, Horning SJ, Gascoyne RD. Expression of p21 protein predicts clinical outcome in DLBCL patients older than 60 years treated with R-CHOP but not CHOP: a prospective ECOG and Southwest Oncology Group correlative study on E4494. Clin Cancer Res. 2010 Apr 15; 16(8):2435-42. Epub 2010 Apr 06.
     View PubMed
317. Thomas A, Gingrich RD, Smith BJ, Jacobus L, Ristow K, Allmer C, Maurer MJ, Habermann TM, Link BK. 18-Fluoro-deoxyglucose positron emission tomography report interpretation as predictor of outcome in diffuse large B-cell lymphoma including analysis of 'indeterminate' reports. Leuk Lymphoma. 2010 Mar; 51(3):439-46.
     View PubMed
318. Thompson CA, Habermann TM, Wang AH, Vierkant RA, Folsom AR, Ross JA, Cerhan JR. Antioxidant intake from fruits, vegetables and other sources and risk of non-Hodgkin's lymphoma: the Iowa Women's Health Study. Int J Cancer. 2010 Feb 15; 126 (4):992-1003
     View PubMed
319. Nowakowski GS, Maurer MJ, Habermann TM, Ansell SM, Macon WR, Ristow KM, Allmer C, Slager SL, Witzig TE, Cerhan JR. Statin use and prognosis in patients with diffuse large B-cell lymphoma and follicular lymphoma in the rituximab era. J Clin Oncol. 2010 Jan 20; 28 (3):412-7 Epub 2009 Dec 14
     View PubMed
320. Habermann TM, Thompson CA, LaPlant BR, Bauer BA, Janney CA, Clark MM, Rummans TA, Maurer MJ, Sloan JA, Geyer SM, Cerhan JR. Complementary and alternative medicine use among long-term lymphoma survivors: a pilot study. Am J Hematol. 2009 Dec; 84 (12):795-8
     View PubMed
321. Ansell SM, Hurvitz SA, Koenig PA, LaPlant BR, Kabat BF, Fernando D, Habermann TM, Inwards DJ, Verma M, Yamada R, Erlichman C, Lowy I, Timmerman JM. Phase I study of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with relapsed and refractory B-cell non-Hodgkin lymphoma. Clin Cancer Res. 2009 Oct 15; 15 (20):6446-53 Epub 2009 Oct 06
     View PubMed
322. West CP, Tan AD, Habermann TM, Sloan JA, Shanafelt TD. Association of resident fatigue and distress with perceived medical errors. JAMA. 2009 Sep 23; 302 (12):1294-300
     View PubMed
323. Issa N, Amer H, Dean PG, Kremers WK, Kudva YC, Rostambeigi N, Cosio FG, Larson TS, Habermann TM, Stegall MD, Griffin MD. Posttransplant lymphoproliferative disorder following pancreas transplantation. Am J Transplant. 2009 Aug; 9 (8):1894-902 Epub 2009 June 10
     View PubMed
324. Cerhan JR, Novak AJ, Fredericksen ZS, Wang AH, Liebow M, Call TG, Dogan A, Witzig TE, Ansell SM, Habermann TM, Kay NE, Slager SL. Risk of non-Hodgkin lymphoma in association with germline variation in complement genes. Br J Haematol. 2009 Jun; 145 (5):614-23 Epub 2009 Mar 30
     View PubMed
325. Carson KR, Evens AM, Richey EA, Habermann TM, Focosi D, Seymour JF, Laubach J, Bawn SD, Gordon LI, Winter JN, Furman RR, Vose JM, Zelenetz AD, Mamtani R, Raisch DW, Dorshimer GW, Rosen ST, Muro K, Gottardi-Littell NR, Talley RL, Sartor O, Green D, Major EO, Bennett CL. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood. 2009 May 14; 113(20):4834-40. Epub 2009 Mar 05.
     View PubMed
326. Habermann TM, Lossos IS, Justice G, Vose JM, Wiernik PH, McBride K, Wride K, Ervin-Haynes A, Takeshita K, Pietronigro D, Zeldis JB, Tuscano JM. Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma. Br J Haematol. 2009 May; 145 (3):344-9 Epub 2009 Feb 24
     View PubMed
327. Hochster H, Weller E, Gascoyne RD, Habermann TM, Gordon LI, Ryan T, Zhang L, Colocci N, Frankel S, Horning SJ. Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 Study. J Clin Oncol. 2009 Apr 1; 27(10):1607-14. Epub 2009 Mar 02.
     View PubMed
328. Wang SS, Maurer MJ, Morton LM, Habermann TM, Davis S, Cozen W, Lynch CF, Severson RK, Rothman N, Chanock SJ, Hartge P, Cerhan JR. Polymorphisms in DNA repair and one-carbon metabolism genes and overall survival in diffuse large B-cell lymphoma and follicular lymphoma. Leukemia 2009 Mar; 23 (3):596-602 Epub 2008 Oct 02
     View PubMed
329. Porrata LF, Ristow K, Habermann TM, Witzig TE, Inwards DJ, Markovic SN. Absolute lymphocyte count at the time of first relapse predicts survival in patients with diffuse large B-cell lymphoma. Am J Hematol. 2009 Feb; 84(2):93-7.
     View PubMed
330. Kumar N, Sandroni P, Steensma DP, Luthra HS, Habermann TM. Polyradiculopathy due to methotrexate-induced ebv-associated lymphoproliferative disorder. Neurology. 2008 Nov 11; 71(20):1644-5.
     View PubMed
331. Cerhan JR, Liu-Mares W, Fredericksen ZS, Novak AJ, Cunningham JM, Kay NE, Dogan A, Liebow M, Wang AH, Call TG, Habermann TM, Ansell SM, Slager SL. Genetic variation in tumor necrosis factor and the nuclear factor-kappaB canonical pathway and risk of non-Hodgkin's lymphoma. Cancer Epidemiol Biomarkers Prev. 2008 Nov; 17 (11):3161-9
     View PubMed
332. Wiernik PH, Lossos IS, Tuscano JM, Justice G, Vose JM, Cole CE, Lam W, McBride K, Wride K, Pietronigro D, Takeshita K, Ervin-Haynes A, Zeldis JB, Habermann TM. Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma. J Clin Oncol. 2008 Oct 20; 26(30):4952-7. Epub 2008 Jul 07.
     View PubMed
333. Habermann TM, Wang SS, Maurer MJ, Morton LM, Lynch CF, Ansell SM, Hartge P, Severson RK, Rothman N, Davis S, Geyer SM, Cozen W, Chanock SJ, Cerhan JR. Host immune gene polymorphisms in combination with clinical and demographic factors predict late survival in diffuse large B-cell lymphoma patients in the pre-rituximab era. Blood. 2008 Oct 1; 112 (7):2694-702 Epub 2008 July 16
     View PubMed
334. Shaikh A, Habermann TM, Fidler ME, Kumar S, Leung N. Acute renal failure secondary to severe type I cryoglobulinemia following rituximab therapy for Waldenstrom's macroglobulinemia. Clin Exp Nephrol. 2008 Aug; 12 (4):292-295 Epub 2008 Feb 22
     View PubMed
335. Chen L, Monti S, Juszczynski P, Daley J, Chen W, Witzig TE, Habermann TM, Kutok JL, Shipp MA. SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma. Blood. 2008 Feb 15; 111(4):2230-7. Epub 2007 Nov 15.
     View PubMed
336. Habermann TM. Posttransplant lymphoproliferative disorders. Cancer Treat Res. 2008; 142:273-92
     View PubMed
337. Cerhan JR, Ansell SM, Fredericksen ZS, Kay NE, Liebow M, Call TG, Dogan A, Cunningham JM, Wang AH, Liu-Mares W, Macon WR, Jelinek D, Witzig TE, Habermann TM, Slager SL. Genetic variation in 1253 immune and inflammation genes and risk of non-Hodgkin lymphoma. Blood. 2007 Dec 15; 110 (13):4455-63 Epub 2007 Sept 07
     View PubMed
338. Maddocks-Christianson K, Slager SL, Zent CS, Reinalda M, Call TG, Habermann TM, Bowen DA, Hoyer JD, Schwager S, Jelinek DF, Kay NE, Shanafelt TD. Risk factors for development of a second lymphoid malignancy in patients with chronic lymphocytic leukaemia. Br J Haematol. 2007 Nov; 139 (3):398-404
     View PubMed
339. Segovis CM, Mueller PS, Rethlefsen ML, LaRusso NF, Litin SC, Tefferi A, Habermann TM. If you feed them, they will come: a prospective study of the effects of complimentary food on attendance and physician attitudes at medical grand rounds at an academic medical center. BMC Med Educ. 2007 Jul 12; 7:22 Epub 2007 July 12
     View PubMed
340. Simpson L, Ansell SM, Colgan JP, Habermann TM, Inwards DJ, Ristow KM, Johnston PB, Markovic SN, Micallef IN, Porrata LF, Witzig TE. Effectiveness of second line salvage chemotherapy with ifosfamide, carboplatin, and etoposide in patients with relapsed diffuse large B-cell lymphoma not responding to cis-platinum, cytosine arabinoside, and dexamethasone. Leuk Lymphoma. 2007 Jul; 48(7):1332-7.
     View PubMed
341. Cerhan JR, Wang S, Wang S, Maurer MJ, Ansell SM, Geyer SM, Cozen W, Morton LM, Davis S, Severson RK, Rothman N, Lynch CF, Wacholder S, Chanock SJ, Habermann TM, Hartge P. Prognostic significance of host immune gene polymorphisms in follicular lymphoma survival. Blood. 2007 Jun 15; 109 (12):5439-46 Epub 2007 Feb 27
     View PubMed
342. West CP, Huntington JL, Huschka MM, Novotny PJ, Sloan JA, Kolars JC, Habermann TM, Shanafelt TD. A prospective study of the relationship between medical knowledge and professionalism among internal medicine residents. Acad Med. 2007 Jun; 82 (6):587-92
     View PubMed
343. Witzig TE, Inwards DJ, Habermann TM, Dogan A, Kurtin PJ, Gross JB Jr, Ananthamurthy A, Ristow KM, Garity JA. Treatment of benign orbital pseudolymphomas with the monoclonal anti-CD20 antibody rituximab. Mayo Clin Proc. 2007 Jun; 82 (6):692-9
     View PubMed
344. Behl D, Ristow K, Markovic SN, Witzig TE, Habermann TM, Colgan JP, Inwards DJ, White WL, Ansell SM, Micallef IN, Johnston PB, Porrata LF. Absolute lymphocyte count predicts therapeutic efficacy of rituximab therapy in follicular lymphomas. Br J Haematol. 2007 Jun; 137(5):409-15. Epub 2007 Apr 13.
     View PubMed
345. Larsen M, Habermann TM, Bishop AT, Shin AY, Spinner RJ. Epstein-Barr virus infection as a complication of transplantation of a nerve allograft from a living related donor. Case report. J Neurosurg. 2007 May; 106(5):924-8.
     View PubMed
346. Habermann TM. Antibody therapy in aggressive lymphomas. Hematology Am Soc Hematol Educ Program. 2007; 257-64.
     View PubMed
347. Micallef IN, Kahl BS, Maurer MJ, Dogan A, Ansell SM, Colgan JP, Geyer S, Inwards DJ, White WL, Habermann TM. A pilot study of epratuzumab and rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated, diffuse large B-cell lymphoma. Cancer. 2006 Dec 15; 107 (12):2826-32
     View PubMed
348. Habermann TM. Splenectomy, interferon, and treatments of historical interest in hairy cell leukemia. Hematol Oncol Clin North Am. 2006 Oct; 20 (5):1075-86
     View PubMed
349. West CP, Huschka MM, Novotny PJ, Sloan JA, Kolars JC, Habermann TM, Shanafelt TD. Association of perceived medical errors with resident distress and empathy: a prospective longitudinal study. JAMA. 2006 Sep 6; 296 (9):1071-8
     View PubMed
350. Siddiqui M, Ristow K, Markovic SN, Witzig TE, Habermann TM, Colgan JP, Inwards DJ, White WL, Ansell SM, Micallef IN, Johnston PB, Call TG, Porrata LF. Absolute lymphocyte count predicts overall survival in follicular lymphomas. Br J Haematol. 2006 Sep; 134(6):596-601. Epub 2006 Aug 01.
     View PubMed
351. Micallef IN, Remstein ED, Ansell SM, Colgan JP, Inwards DJ, Johnston PB, Lewis JT, Markovic SN, Porrata LF, White WL, Witzig TE, Ristow K, Habermann TM. The International Prognostic Index predicts outcome after histological transformation of low-grade non-Hodgkin lymphoma. Leuk Lymphoma. 2006 Sep; 47 (9):1794-9
     View PubMed
352. Habermann TM, Weller EA, Morrison VA, Gascoyne RD, Cassileth PA, Cohn JB, Dakhil SR, Woda B, Fisher RI, Peterson BA, Horning SJ. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol. 2006 Jul 1; 24 (19):3121-7 Epub 2006 June 05
     View PubMed
353. Winter JN, Weller EA, Horning SJ, Krajewska M, Variakojis D, Habermann TM, Fisher RI, Kurtin PJ, Macon WR, Chhanabhai M, Felgar RE, Hsi ED, Medeiros LJ, Weick JK, Reed JC, Gascoyne RD. Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study. Blood. 2006 Jun 01; 107(11):4207-13. Epub 2006 Jan 31.
     View PubMed
354. Kremers WK, Devarbhavi HC, Wiesner RH, Krom RA, Macon WR, Habermann TM. Post-transplant lymphoproliferative disorders following liver transplantation: incidence, risk factors and survival. Am J Transplant. 2006 May; 6 (5 Pt 1):1017-24
     View PubMed
355. Mikuls TR, Endo JO, Puumala SE, Aoun PA, Black NA, O'Dell JR, Stoner JA, Boilesen EC, Bast MA, Bergman DA, Ristow KM, Ooi M, Armitage JO, Habermann TM. Prospective study of survival outcomes in Non-Hodgkin's lymphoma patients with rheumatoid arthritis. J Clin Oncol. 2006 Apr 1; 24(10):1597-602. Epub 2006 Mar 06.
     View PubMed
356. Mueller PS, Segovis CM, Litin SC, Habermann TM, Parrino TA. Current status of medical grand rounds in departments of medicine at US medical schools. Mayo Clin Proc. 2006 Mar; 81(3):313-21.
     View PubMed
357. Woog JJ, Kim YD, Yeatts RP, Kim S, Esmaeli B, Kikkawa D, Lee HB, Korn BS, Punja K, Habermann TM, Colgan JP, Salomao D, Cameron JD. Natural killer/T-cell lymphoma with ocular and adnexal involvement. Ophthalmology. 2006 Jan; 113 (1):140-7 Epub 2005 Dec 19
     View PubMed
358. McClure RF, Remstein ED, Macon WR, Dewald GW, Habermann TM, Hoering A, Kurtin PJ. Adult B-cell lymphomas with burkitt-like morphology are phenotypically and genotypically heterogeneous with aggressive clinical behavior. Am J Surg Pathol. 2005 Dec; 29 (12):1652-60
     View PubMed
359. Habermann TM. Diffuse large B-cell lymphoma. Clin Adv Hematol Oncol. 2005 Nov; 3(11):suppl 4-5.
     View PubMed
360. Ghobrial IM, Habermann TM, Maurer MJ, Geyer SM, Ristow KM, Larson TS, Walker RC, Ansell SM, Macon WR, Gores GG, Stegall MD, McGregor CG. Prognostic analysis for survival in adult solid organ transplant recipients with post-transplantation lymphoproliferative disorders. J Clin Oncol. 2005 Oct 20; 23 (30):7574-82 Epub 2005 Sept 26
     View PubMed
361. Martin WG, Ristow KM, Habermann TM, Colgan JP, Witzig TE, Ansell SM. Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin's lymphoma. J Clin Oncol. 2005 Oct 20; 23 (30):7614-20 Epub 2005 Sept 26
     View PubMed
362. Vernino S, Salomao DR, Habermann TM, O'Neill BP. Primary CNS lymphoma complicating treatment of myasthenia gravis with mycophenolate mofetil. Neurology. 2005 Aug 23; 65(4):639-41.
     View PubMed
363. Feuerhake F, Kutok JL, Monti S, Chen W, LaCasce AS, Cattoretti G, Kurtin P, Pinkus GS, de Leval L, Harris NL, Savage KJ, Neuberg D, Habermann TM, Dalla-Favera R, Golub TR, Aster JC, Shipp MA. NF kappa B activity, function, and target-gene signatures in primary mediastinal large B-cell lymphoma and diffuse large B-cell lymphoma subtypes. Blood. 2005 Aug 15; 106(4):1392-9.
     View PubMed
364. Shanafelt TD, West C, Zhao X, Novotny P, Kolars J, Habermann T, Sloan J. Relationship between increased personal well-being and enhanced empathy among internal medicine residents. J Gen Intern Med. 2005 Jul; 20 (7):559-64
     View PubMed
365. Monti S, Savage KJ, Kutok JL, Feuerhake F, Kurtin P, Mihm M, Wu BY, Pasqualucci L, Neuberg D, Aguiar RCT, Dal Cin P, Ladd C, Pinkus GS, Salles G, Harris NL, Dalla-Favera R, Habermann TM, Aster JC, Golub TR, Shipp MA. Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. Blood. 2005 Mar 1; 105(5):1851-61.
     View PubMed
366. Witzig TE, Vukov AM, Habermann TM, Geyer S, Kurtin PJ, Friedenberg WR, White WL, Chalchal HI, Flynn PJ, Fitch TR, Welker DA. Rituximab therapy for patients with newly diagnosed, advanced-stage, follicular grade I non-Hodgkin's lymphoma: a phase II trial in the North Central Cancer Treatment Group. J Clin Oncol. 2005 Feb 20; 23 (6):1103-8 Epub 2005 Jan 18
     View PubMed
367. Ghobrial IM, Habermann TM, Ristow KM, Ansell SM, Macon W, Geyer SM, McGregor CG. Prognostic factors in patients with post-transplant lymphoproliferative disorders (PTLD) in the rituximab era. Leuk Lymphoma. 2005 Feb; 46 (2):191-6
     View PubMed
368. Ghobrial IM, Habermann TM, Macon WR, Ristow KM, Larson TS, Walker RC, Ansell SM, Gores GJ, Stegall MD, McGregor CG. Differences between early and late posttransplant lymphoproliferative disorders in solid organ transplant patients: are they two different diseases? Transplantation. 2005 Jan 27; 79 (2):244-7
     View PubMed
369. Pena de la Vega L, Fervenza FC, Lager D, Habermann T, Leung N. Acute granulomatous interstitial nephritis secondary to bisphosphonate alendronate sodium. Ren Fail. 2005; 27 (4):485-9
     View PubMed
370. Novak AJ, Grote DM, Stenson M, Ziesmer SC, Witzig TE, Habermann TM, Harder B, Ristow KM, Bram RJ, Jelinek DF, Gross JA, Ansell SM. Expression of BLyS and its receptors in B-cell non-Hodgkin lymphoma: correlation with disease activity and patient outcome. Blood. 2004 Oct 15; 104 (8):2247-53 Epub 2004 July 13
     View PubMed
371. Horning SJ, Weller E, Kim KM, Earle JD, O'Connell MJ, Habermann TM, Glick JH. Chemotherapy with or without radiotherapy in limited-stage diffuse aggressive non-Hodgkin's lymphoma: Eastern cooperative oncology group study 1484. J Clin Oncol. 2004 Aug 1; 22(15):3032-8.
     View PubMed
372. Vachon CM, Habermann TM, Kurtin PJ, Cerhan JR. Clinical characteristics of familial vs. sporadic non-Hodgkin lymphoma in patients diagnosed at the Mayo Clinic (1986-2000). Leuk Lymphoma. 2004 May; 45 (5):929-35
     View PubMed
373. Ghobrial IM, Wolf RC, Pereira DL, Fonseca R, White WL, Colgan JP, Habermann TM, Inwards DJ, Markovic SN, Ansell SM, Micallef IN, Porrata LF, Witzig TE. Therapeutic options in patients with lymphoma and severe liver dysfunction. Mayo Clin Proc. 2004 Feb; 79(2):169-75.
     View PubMed
374. Habermann TM, Ziemer RE, Lantz JC. Images and reflections from Mayo Clinic heritage. Mayo Clin Proc. 2003 Nov; 78 (11):1324
     View PubMed
375. Cerhan JR, Anderson KE, Janney CA, Vachon CM, Witzig TE, Habermann TM. Association of aspirin and other non-steroidal anti-inflammatory drug use with incidence of non-Hodgkin lymphoma. Int J Cancer. 2003 Sep 20; 106: (5)784-8.
     View PubMed
376. Mueller PS, Litin SC, Sowden ML, Habermann TM, LaRusso NF. Strategies for improving attendance at medical grand rounds at an academic medical center. Mayo Clin Proc. 2003 May; 78(5):549-53.
     View PubMed
377. Shanafelt TD, Sloan JA, Habermann TM. The well-being of physicians. Am J Med. 2003 Apr 15; 114 (6):513-9
     View PubMed
378. Habermann TM, Ziemer RE, Lantz JC. Images and reflections from Mayo Clinic Heritage. Henry S. Plummer. Mayo Clin Proc. 2002 Nov; 77 (11):1182
     View PubMed
379. Cerhan JR, Vachon CM, Habermann TM, Ansell SM, Witzig TE, Kurtin PJ, Janney CA, Zheng W, Potter JD, Sellers TA, Folsom AR. Hormone replacement therapy and risk of non-hodgkin lymphoma and chronic lymphocytic leukemia. Cancer Epidemiol Biomarkers Prev. 2002 Nov; 11 (11):1466-71
     View PubMed
380. Ansell SM, Ristow KM, Habermann TM, Wiseman GA, Witzig TE. Subsequent chemotherapy regimens are well tolerated after radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for non-Hodgkin's lymphoma. J Clin Oncol. 2002 Sep 15; 20: (18)3885-90.
     View PubMed
381. Cerhan JR, Janney CA, Vachon CM, Habermann TM, Kay NE, Potter JD, Sellers TA, Folsom AR. Anthropometric characteristics, physical activity, and risk of non-Hodgkin's lymphoma subtypes and B-cell chronic lymphocytic leukemia: a prospective study. Am J Epidemiol. 2002 Sep 15; 156 (6):527-35
     View PubMed
382. Sparano JA, Weller E, Nazeer T, Habermann T, Traynor AE, Manalo J, Cassileth P. Phase 2 trial of infusional cyclophosphamide, doxorubicin, and etoposide in patients with poor-prognosis, intermediate-grade non-Hodgkin lymphoma: an Eastern Cooperative Oncology Group trial (E3493). Blood. 2002 Sep 1; 100(5):1634-40.
     View PubMed
383. Habermann TM, Ziemer RE, Lantz JC. Images and reflections from Mayo Clinic heritage. Mayo Clin Proc. 2002 Sep; 77 (9):964
     View PubMed
384. Stepanek J, Habermann TM, Ziemer RE, Lantz JC. Images and reflections from Mayo Clinic heritage. Mayo Clin Proc. 2002 Jul; 77 (7):613
     View PubMed
385. Yip CC, Bartley GB, Habermann TM, Garrity JA. Involvement of the lacrimal drainage system by leukemia or lymphoma. Ophthal Plast Reconstr Surg. 2002 Jul; 18(4):242-6.
     View PubMed
386. Bouwhuis SA, el-Azhary RA, McEvoy MT, Gibson LE, Habermann TM, Witzig TE, Pittelkow MR. Treatment of late-stage Sezary syndrome with 2-Chlorodeoxyadenosine. Int J Dermatol. 2002 Jun; 41 (6):352-6
     View PubMed
387. Cerhan JR, Habermann TM, Vachon CM, Putnam SD, Zheng W, Potter JD, Folsom AR. Menstrual and reproductive factors and risk of non-Hodgkin lymphoma: the Iowa women's health study (United States). Cancer Causes Control. 2002 Mar; 13 (2):131-6
     View PubMed
388. Habermann TM, Ziemer RE, Lantz JC. Images and reflections from Mayo Clinic heritage. Mayo Clin Proc. 2002 Feb; 77 (2):188
     View PubMed
389. Ansell SM, Witzig TE, Kurtin PJ, Sloan JA, Jelinek DF, Howell KG, Markovic SN, Habermann TM, Klee GG, Atherton PJ, Erlichman C. Phase 1 study of interleukin-12 in combination with rituximab in patients with B-cell non-Hodgkin lymphoma. Blood. 2002 Jan 1; 99 (1):67-74
     View PubMed
390. Coyne CA, Xu R, Raich P, Plomer K, Dignan M, Wenzel LB, Fairclough D, Habermann TM, Schnell L, Quella S, Chella D. A randomized controlled trial of an easy-to-read informed consent statement for clinical trial participation. JCO. 2002; 21(5):836-842.
     
391. Yoong Y, Kurtin PJ, Allmer C, Geyer S, Habermann TM, Nagorney DM, Witzig TE. Efficacy of splenectomy for patients with mantle cell non-Hodgkin's lymphoma. Leuk Lymphoma. 2001 Nov-Dec; 42 (6):1235-41
     View PubMed
392. Kanelli S, Ansell SM, Habermann TM, Inwards DJ, Tuinstra N, Witzig TE. Rituximab toxicity in patients with peripheral blood malignant B-cell lymphocytosis. Leuk Lymphoma. 2001 Nov-Dec; 42(6):1329-37.
     View PubMed
393. Habermann TM, Ziemer RE, Beck CS. Images and reflections from Mayo Clinic heritage. Mayo Clin Proc. 2001 Oct; 76 (10):1062
     View PubMed
394. Hogan WJ, Edwards WD, Macon WR, Habermann TM. Fulminant hepatic failure secondary to adenovirus following fludarabine-based chemotherapy for non-Hodgkin's lymphoma. Leuk Lymphoma. 2001 Sep-Oct; 42 (5):1145-50
     View PubMed
395. Habermann TM, Ziemer RE, Beck CS. Images and reflections from Mayo Clinic heritage. Mayo Clin Proc. 2001 Aug; 76 (8):768
     View PubMed
396. Habermann TM, Ziemer RE, Beck CS. Images and reflections from Mayo Clinic heritage. Mayo Clin Proc. 2001 Jun; 76 (6):632
     View PubMed
397. Stafford SL, Kozelsky TF, Garrity JA, Kurtin PJ, Leavitt JA, Martenson JA, Habermann TM. Orbital lymphoma: radiotherapy outcome and complications. Radiother Oncol. 2001 May; 59 (2):139-44
     View PubMed
398. Habermann TM, Ziemer RE, Beck CS. Images and reflections from Mayo Clinic heritage. Mayo Clin Proc. 2001 Apr; 76 (4):448
     View PubMed
399. Habermann TM, Ziemer RE, Beck CS. Images and reflections from Mayo Clinic heritage. Mayo Clin Proc. 2001 Mar; 76 (3):345
     View PubMed
400. Ansell SM, Stenson M, Habermann TM, Jelinek DF, Witzig TE. Cd4+ T-cell immune response to large B-cell non-Hodgkin's lymphoma predicts patient outcome. J Clin Oncol. 2001 Feb 01; 19: (3)720-6.
     View PubMed
401. Wiernik P, Leong T, Oken MM, Neiman RS, Habermann TM, Bennett JM, Schuster S, Glick JH. Bleomycin, lomustine, cyclophosphamide, vincristine, procarbazine, and prednisone (BLEO-CCVPP) in patients with Hodgkin's disease who relapsed after radiotherapy alone: A study of the Eastern Cooperative Oncology Group (E381). Leukemia and Lymphoma. 2001; 40(3-4):357-363.
     
402. Montori VM, St Louis EK, Habermann TM. 62-year-old woman with rapidly evolving dementia. Mayo Clin Proc. 2000 Nov; 75 (11):1193-6
     View PubMed
403. Flinn IW, Kopecky KJ, Foucar MK, Head D, Bennett JM, Hutchison R, Corbett W, Cassileth P, Habermann T, Golomb H, Rai K, Eisenhauer E, Appelbaum F, Cheson B, Grever MR. Long-term follow-up of remission duration, mortality, and second malignancies in hairy cell leukemia patients treated with pentostatin. Blood. 2000 Nov 1; 96(9):2981-6.
     View PubMed
404. Habermann TM. Monoclonal antibody therapy for posttransplant lymphoproliferative disorders. Liver Transpl. 2000 Sep; 6(5):657-8.
     View PubMed
405. Loftus EV Jr, Tremaine WJ, Habermann TM, Harmsen WS, Zinsmeister AR, Sandborn WJ. Risk of lymphoma in inflammatory bowel disease. Am J Gastroenterol. 2000 Sep; 95(9):2308-12.
     View PubMed
406. Wolanskyj AP, Schroeder G, Wilson PR, Habermann TM, Inwards DJ, Witzig TE. A randomized, placebo-controlled study of outpatient premedication for bone marrow biopsy in adults with lymphoma. Clin Lymphoma. 2000 Sep; 1 (2):154-7
     View PubMed
407. Habermann TM, Steensma DP. Lymphadenopathy. Mayo Clin Proc. 2000 Jul; 75(7):723-32.
     View PubMed
408. Kucuk O, Young ML, Habermann TM, Wolf BC, Jimeno J, Cassileth PA. Phase II trial of didemnin B in previously treated non-Hodgkin's lymphoma - an Eastern Cooperative Oncology Group (ECoG) study. Am J Clin Oncol. 2000 Jun; 23(3):273-277.
     View PubMed
409. Parker AS, Cerhan JR, Dick F, Kemp J, Habermann TM, Wallace RB, Sellers TA, Folsom AR. Smoking and risk of non-Hodgkin lymphoma subtypes in a cohort of older women. Leuk Lymphoma. 2000 Apr; 37(3-4):341-9.
     View PubMed
410. Fonseca R, Habermann TM, Colgan JP, O'Neill BP, White WL, Witzig TE, Egan KS, Martenson JA, Burgart LJ, Inwards DJ. Testicular lymphoma is associated with a high incidence of extranodal recurrence. Cancer. 2000 Jan 1; 88 (1):154-61
     View PubMed
411. Habermann TM. Non-Hodgkin's lymphoma: present status and future prospects. Hosp Pract (1995). 1999 Dec 15; 34 (13):81-4, 87-8
     View PubMed
412. Hanson CA, Kurtin PJ, Katzmann JA, Hoyer JD, Li CY, Hodnefield JM, Meyers CH, Habermann TM, Witzig TE. Immunophenotypic analysis of peripheral blood and bone marrow in the staging of B-cell malignant lymphoma. Blood. 1999 Dec 1; 94 (11):3889-96
     View PubMed
413. Paya CV, Fung JJ, Nalesnik MA, Kieff E, Green M, Gores G, Gores G, Habermann TM, Wiesner PH, Swinnen JL, Woodle ES, Bromberg JS. Epstein-Barr virus-induced posttransplant lymphoproliferative disorders. ASTS/ASTP EBV-PTLD Task Force and The Mayo Clinic Organized International Consensus Development Meeting. Transplantation. 1999 Nov 27; 68 (10):1517-25
     View PubMed
414. Gordon LI, Young M, Weller E, Habermann TM, Winter JN, Glick J, Ghosh C, Flynn P, Cassileth PA. A phase II trial of 200% ProMACE-CytaBOM in patients with previously untreated aggressive lymphomas: analysis of response, toxicity, and dose intensity. Blood. 1999 Nov 15; 94(10):3307-14.
     View PubMed
415. O'Neill BP, Habermann TM, Witzig TE, Rodriguez M. Prevention of recurrence and prolonged survival in primary central nervous system lymphoma (PCNSL) patients treated with adjuvant high-dose methylprednisolone. Med Oncol. 1999 Sep; 16 (3):211-5
     View PubMed
416. Ansell SM, Kurtin PJ, Stenson M, Habermann TM, Greipp PR, Therneau TM, Witzig TE. Evaluation of the proliferative index as a prognostic factor in diffuse large cell lymphoma: correlation with the International Index. Leuk Lymphoma. 1999 Aug; 34 (5-6):529-37
     View PubMed
417. Tallman MS, Hakimian D, Kopecky KJ, Wheaton S, Wollins E, Foucar K, Cassileth PA, Habermann T, Grever M, Rowe JM, Peterson LC. Minimal residual disease in patients with hairy cell leukemia in complete remission treated with 2-chlorodeoxyadenosine or 2-deoxycoformycin and prediction of early relapse. Clin Cancer Res. 1999 Jul; 5(7):1665-70.
     View PubMed
418. Maguire-Boston EK, Suman V, Jacobsen SJ, Moore SB, Habermann TM, Cerhan JR, Folsom AR. Blood transfusion and risk of non-Hodgkin's lymphoma. Am J Epidemiol. 1999 Jun 15; 149(12):1113-8.
     View PubMed
419. Ansell SM, Grant CS, Habermann TM. Primary thyroid lymphoma. Semin Oncol. 1999 Jun; 26 (3):316-23
     View PubMed
420. Habermann TM, Ryu JH, Inwards DJ, Kurtin PJ. Primary pulmonary lymphoma. Semin Oncol. 1999 Jun; 26(3):307-15.
     View PubMed
421. Habermann TM. State-of-the-art treatments in non-Hodgkin's lymphoma. Cancer Research, Therapy & Control. 1999; 9(3-4):303-14.
     
422. Gordon L, Young M, Weller E, Habermann T, Winter J, Glick J, Ghosh C, Flynn P, Cassileth P. A phase II trial of 200% ProMACE-CytaBOM in patients with previously untreated aggressive lymphomas: analysis of response, toxicity, and dose intensity. Blood. 1999; 94(10):3307-14.
     
423. Strickler JG, Donohue JH, Porter LE, Habermann TM. Laparoscopic biopsy for suspected abdominal lymphoma. Mod Pathol. 1998 Sep; 11(9):831-6.
     View PubMed
424. Witzig TE, Camoriano JK, Schroeder G, Kurtin PJ, Habermann TM. A phase I trial of high dose ProMACE-CytaBOM with granulocyte colony stimulating factor for patients with non-Hodgkin's lymphoma. Leuk Lymphoma. 1998 Jan; 28 (3-4):307-14
     View PubMed
425. Ansell SM, Habermann TM, Hoyer JD, Strickler JG, Chen MG, McDonald TJ. Primary laryngeal lymphoma. Laryngoscope. 1997 Nov; 107 (11 Pt 1):1502-6
     View PubMed
426. Levy NT, Young WF Jr, Habermann TM, Strickler JG, Carney JA, Stanson AW. Adrenal insufficiency as a manifestation of disseminated non-Hodgkin's lymphoma. Mayo Clin Proc. 1997 Sep; 72 (9):818-22
     View PubMed
427. Hartmann LC, Tschetter LK, Habermann TM, Ebbert LP, Johnson PS, Mailliard JA, Levitt R, Suman VJ, Witzig TE, Wieand HS, Miller LL, Moertel CG. Granulocyte colony-stimulating factor in severe chemotherapy-induced afebrile neutropenia. N Engl J Med. 1997 Jun 19; 336(25):1776-80.
     View PubMed
428. Ansell SM, Habermann TM, Kurtin PJ, Witzig TE, Chen MG, Li CY, Inwards DJ, Colgan JP. Predictive capacity of the International Prognostic Factor Index in patients with peripheral T-cell lymphoma. J Clin Oncol. 1997 Jun; 15: (6)2296-301.
     View PubMed
429. Ryu JH, Habermann TM. Pulmonary lymphoma - primary and systemic disease. Seminars in Respiratory and Critical Care Medicine. 1997; 18(4):341-352.
     
430. Badley AD, Portela DF, Patel R, Kyle RA, Habermann TM, Strickler JG, Ilstrup DM, Wiesner RH, de Groen P, de Groen P, Walker RC, Paya CV. Development of monoclonal gammopathy precedes the development of Epstein-Barr virus-induced posttransplant lymphoproliferative disorder. Liver Transpl Surg. 1996 Sep; 2 (5):375-82
     View PubMed
431. Gordon LI, Anderson J, Habermann TM, Winter JN, Glick J, Schilder RJ, Cassileth P. Phase I trial of dose escalation with growth factor support in patients with previously untreated diffuse aggressive lymphomas: determination of the maximum-tolerated dose of ProMACE-CytaBOM. J Clin Oncol. 1996 Apr; 14(4):1275-81.
     View PubMed
432. Menke DM, Tiemann M, Camoriano JK, Chang SF, Madan A, Chow M, Habermann TM, Parwaresch R. Diagnosis of Castleman's disease by identification of an immunophenotypically aberrant population of mantle zone B lymphocytes in paraffin-embedded lymph node biopsies. Am J Clin Pathol. 1996 Mar; 105 (3):268-76
     View PubMed
433. Salamao DR, Nascimento AG, Lloyd RV, Chen MG, Habermann TM, Strickler JG. Lymphoma in soft tissue: a clinicopathologic study of 19 cases. Hum Pathol. 1996 Mar; 27 (3):253-7
     View PubMed
434. Davison SP, Habermann TM, Strickler JG, DeRemee RA, Earle JD, McDonald TJ. Nasal and nasopharyngeal angiocentric T-cell lymphomas. Laryngoscope. 1996 Feb; 106 (2 Pt 1):139-43
     View PubMed
435. Witzig TE, Habermann TM, Kurtin PJ, Schroeder G, Stenson MJ, Greipp PR. S-phase fraction by the labeling index as a predictive factor for progression and survival in low grade non-Hodgkin's lymphoma. Cancer. 1995 Sep 15; 76 (6):1059-64
     View PubMed
436. Walker RC, Marshall WF, Strickler JG, Wiesner RH, Velosa JA, Habermann TM, McGregor CG, Paya CV. Pretransplantation assessment of the risk of lymphoproliferative disorder. Clin Infect Dis. 1995 May; 20 (5):1346-53
     View PubMed
437. Grever M, Kopecky K, Foucar MK, Head D, Bennett JM, Hutchison RE, Corbett WE, Cassileth PA, Habermann T, Golomb H. Randomized comparison of pentostatin versus interferon alfa-2a in previously untreated patients with hairy cell leukemia: an intergroup study. J Clin Oncol. 1995 Apr; 13(4):974-82.
     View PubMed
438. Walker RC, Paya CV, Marshall WF, Strickler JG, Wiesner RH, Velosa JA, Habermann TM, Daly RC, McGregor CG. Pretransplantation seronegative Epstein-Barr virus status is the primary risk factor for posttransplantation lymphoproliferative disorder in adult heart, lung, and other solid organ transplantations. J Heart Lung Transplant. 1995 Mar-Apr; 14 (2):214-21
     View PubMed
439. O'Neill BP, Dinapoli RP, Kurtin PJ, Habermann TM. Occult systemic non-Hodgkin's lymphoma (NHL) in patients initially diagnosed as primary central nervous system lymphoma (PCNSL): how much staging is enough? J Neurooncol. 1995; 25 (1):67-71
     View PubMed
440. Durr ED, Bonner JA, Strickler JG, Martenson JA, Chen MG, Habermann TM, Donohue JH, Earle JD, Grill JP. Management of stage IE primary gastric lymphoma. Acta Haematol. 1995; 94 (2):59-68
     View PubMed
441. Tallman M, Hakimian D, Wheaton S, Kopecky K, Wollins E, Foucar K, Cassileth P, Habermann TM, Grever M, Peterson LC. Minimal residual disease in patients with hairy cell leukemia in complete remission: comparison of 2-chlorodeoxyadenosine with 2-deoxycoformycin and prediction of early relapse. Blood Suppl 1 ,. 1995; 86: 1390a.
     
442. Kurtin PJ, DiCaudo DJ, Habermann TM, Chen MG, Su WP, Su WP. Primary cutaneous large cell lymphomas. Morphologic, immunophenotypic, and clinical features of 20 cases. Am J Surg Pathol. 1994 Dec; 18 (12):1183-91
     View PubMed
443. Orvidas LJ, McCaffrey TV, Lewis JE, Kurtin PJ, Habermann TM. Lymphoma involving the esophagus. Ann Otol Rhinol Laryngol. 1994 Nov; 103: (11)843-8.
     View PubMed
444. Colgan JP, Andersen J, Habermann TM, Earle JD, O'Connell MJ, Neiman RS, Mann RB, Glick JH. Long-term follow-up of a CHOP-based regimen with maintenance therapy and central nervous system prophylaxis in lymphoblastic non-Hodgkin's lymphoma. Leuk Lymphoma. 1994 Oct; 15 (3-4):291-6
     View PubMed
445. Kaufman DK, Habermann TM, Kurtin PJ, O'Neill BP. Neurological complications of peripheral and cutaneous T-cell lymphomas. Ann Neurol. 1994 Oct; 36 (4):625-9
     View PubMed
446. Strickler JG, Meneses MF, Habermann TM, Ilstrup DM, Earle JD, McDonald TJ, Chang KL, Weiss LM. Polymorphic reticulosis: a reappraisal. Hum Pathol. 1994 Jul; 25 (7):659-65
     View PubMed
447. Call TG, Noel P, Noel P, Habermann TM, Beard CM, O'Fallon WM, Kurland LT. Incidence of leukemia in Olmsted County, Minnesota, 1975 through 1989. Mayo Clin Proc. 1994 Apr; 69 (4):315-22
     View PubMed
448. Call TG, Phyliky RL, Noel P, Noel P, Habermann TM, Beard CM, O'Fallon WM, Kurland LT. Incidence of chronic lymphocytic leukemia in Olmsted County, Minnesota, 1935 through 1989, with emphasis on changes in initial stage at diagnosis. Mayo Clin Proc. 1994 Apr; 69 (4):323-8
     View PubMed
449. Fairbanks RK, Bonner JA, Inwards CY, Strickler JG, Habermann TM, Unni KK, Su J. Treatment of stage IE primary lymphoma of bone. Int J Radiat Oncol Biol Phys. 1994 Jan 15; 28 (2):363-72
     View PubMed
450. Donohue JH, Habermann TM. The management of gastric lymphoma. Surg Oncol Clin N Am. 1993; 2:213-232.
     
451. Kurtin PJ, Gaffey TA, Habermann TM. Peripheral T-cell lymphoma involving the placenta. Cancer. 1992 Dec 15; 70 (12):2963-8
     View PubMed
452. Habermann TM. A follow-up of the Mayo Clinic experience in the management of mediastinal masses in Hodgkin's disease and a review of the literature. Sangre (Barc). 1992 Nov-Dec; 37: 482-3.
     
453. Habermann TM. The synchronous presentation of Hodgkin's disease and pregnancy. Sangre (Barc). 1992 Nov-Dec; 37: 486-7.
     
454. Pyke CM, Grant CS, Habermann TM, Kurtin PJ, van Heerden JA, Bergstralh EJ, Kunselman A, Hay ID. Non-Hodgkin's lymphoma of the thyroid: is more than biopsy necessary? World J Surg. 1992 Jul-Aug; 16 (4):604-9; discussion 609-10
     View PubMed
455. Habermann TM. Clinical application of the automated hematologic profiles. The Practice of Internal Medicine-1992. 1992 May 11-15; 215-6.
     
456. Habermann TM, Andersen JW, Cassileth PA, Bennett JM, Oken MM. Sequential administration of recombinant interferon alpha and deoxycoformycin in the treatment of hairy cell leukaemia. Br J Haematol. 1992 Apr; 80 (4):466-71
     View PubMed
457. Letendre L, Hoagland HC, Moore SB, Chen MG, Gastineau DA, Gertz MA, Habermann TM, Litzow MR, Noel P, Noel P, Solberg LA Jr. Mayo Clinic experience with allogeneic and syngeneic bone marrow transplantation, 1982 through 1990. Mayo Clin Proc. 1992 Feb; 67 (2):109-16
     View PubMed
458. Inwards DJ, Piepgras DG, Lie JT, O'Neill BP, Scheithauer BW, Habermann TM. Granulomatous angiitis of the spinal cord associated with Hodgkin's disease. Cancer. 1991 Sep 15; 68 (6):1318-22
     View PubMed
459. Beauregard P, Witzig TE, Kurtin PJ, Greipp PR, Stenson MJ, Katzmann JA, Habermann TM, Wieand HS. Models of S-phase determination in lymphomas from flow cytometric DNA content histograms: comparison with the bromodeoxyuridine labeling index. Hematol Pathol. 1991; 5(4):177-83.
     View PubMed
460. Hildebrand FL Jr, Rosenow EC 3rd, Habermann TM, Tazelaar HD. Pulmonary complications of leukemia. Chest. 1990 Nov; 98 (5):1233-9
     View PubMed
461. Inwards DJ, Habermann TM, Banks PM, Colgan JP, Dewald GW. Cytogenetic findings in 21 cases of peripheral T-cell lymphoma. Am J Hematol. 1990 Oct; 35 (2):88-95
     View PubMed
462. Witzig TE, Banks PM, Stenson MJ, Griepp PR, Katzmann JA, Habermann TM, Colgan JP, Gonchoroff NJ. Rapid immunotyping of B-cell non-Hodgkin's lymphomas by flow cytometry. A comparison with the standard frozen-section method. Am J Clin Pathol. 1990 Sep; 94 (3):280-6
     View PubMed
463. Habermann TM. Alpha interferon: progress and perspectives in the biotherapy of chronic myelogenous leukemia. Oncol Nurs Forum. 1989 Nov-Dec; 16(6 Suppl):8-11.
     View PubMed
464. O'Neill BP, Habermann TM, Banks PM, O'Fallon JR, Earle JD. Primary central nervous system lymphoma as a variant of Richter's syndrome in two patients with chronic lymphocytic leukemia. Cancer. 1989 Sep 15; 64 (6):1296-300
     View PubMed
465. Gastineau DA, Habermann TM, Hermann RC. Severe neuropathy associated with low-dose recombinant interferon-alpha. Am J Med. 1989 Jul; 87 (1):116
     View PubMed
466. Witzig TE, Gonchoroff NJ, Greipp PR, Katzmann JA, Stenson MJ, Habermann TM, Colgan JP, Therneau TM, Banks PM. Rapid S-phase determination of non-Hodgkin's lymphomas with the use of an immunofluorescence bromodeoxyuridine labeling index procedure. Am J Clin Pathol. 1989 Mar; 91 (3):298-301
     View PubMed
467. Diez-Martin JL, Habermann TM, Gastineau DA, Solberg LA Jr, Letendre L. Nonbacterial thrombotic endocarditis in autologous bone marrow transplantation. Am J Med. 1988 Nov; 85 (5):742-4
     View PubMed
468. Greipp PR, Witzig TE, Gonchoroff NJ, Habermann TM, Katzmann JA, O'Fallon WM, Kyle RA. Immunofluorescence labeling indices in myeloma and related monoclonal gammopathies. Mayo Clin Proc. 1987 Nov; 62 (11):969-77
     View PubMed
469. Cox CJ, Habermann TM, Payne BA, Klee GG, Pierre RV. Evaluation of the Coulter Counter model S-Plus IV. Am J Clin Pathol. 1985 Sep; 84(3):297-306.
     View PubMed
470. Witzig TE, Greipp PR, Gonchoroff N, Habermann TM, Katzmann JA, Kyle RA. A new immunofluorescence method using a monoclonal antibody (BU-1) for rapid plasma cell labeling indices. Proc Annu Meet Am Soc Clin Oncol. 1985 Mar; 4:10.
     
471. Ackerman SJ, Kephart GM, Habermann TM, Greipp PR, Gleich GJ. Localization of eosinophil granule major basic protein in human basophils. J Exp Med. 1983 Sep 1; 158(3):946-61.
     View PubMed